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Pathogenesis of Neurodegenerative Diseases via Templated Recruitment
Abstract
A common feature of many neurodegenerative diseases is the deposition of filamentous protein
aggregates in the central nervous system (CNS), including neurofibrillary tangles (NFTs) composed of tau,
and Lewy bodies (LBs) consisting of α-synuclein (α-syn), which are the hallmark lesions of Alzheimer's
disease (AD) and Parkinson's disease (PD) respectively. What causes the conversion of normally soluble
proteins into insoluble fibrils has always been enigmatic, and cell models that recapitulate the abnormal
accumulation of tau into NFT-like aggregates were lacking due to high solubility of tau. Enlightened by in
vitro studies showing nucleation-dependent fibrillization of tau, we tested the hypothesis that preformed
tau fibrils (tau pffs) assembled from recombinant protein may act as seeds to nucleate the fibrillization of
soluble tau in cultured cells. Indeed, we found that minute quantities of tau pffs internalized into cells
over-expressing tau can rapidly recruit large amounts of endogenous tau into detergent-insoluble
filamentous inclusions with properties very similar to NFTs. Moreover, the spontaneous uptake of tau pffs
was shown to be mediated by endocytosis. Together with similar studies on tau and other diseaseassociated proteins, our study implicates cell-to-cell transmission of misfolded proteins through
templated recruitment as a plausible mechanism for the onset and progression of CNS amyloidosis.
Another mysterious phenomenon of neurodegenerative diseases is the frequent co-occurrence of
different protein aggregates, such as NFTs and LBs. To test whether fibrillar α-syn can directly cross-seed
tau into pathological aggregates, we utilized our recently developed synucleinopathy models in primary
neurons and transgenic mice involving delivery of α-syn pffs. Intriguingly, we discovered two distinct
strains of α-syn fibrils demonstrating striking difference in the efficiency of cross-seeding tau pathology
both in neurons and transgenic mice. Biochemical analyses indicated conformational differences
between the two strains, thereby revealing the ability of a single molecule to assemble into more than one
misfolded conformers. We speculate that the existence of conformationally diverse strains may be
another shared feature of amyloid aggregates, accounting for the tremendous heterogeneity of
neurodegenerative diseases with differential extent of concomitant pathologies and highly variable but
sometimes overlapping clinical symptoms.
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ABSTRACT
PATHOGENESIS OF NEURODEGENERATIVE DISEASES VIA
TEMPLATED RECRUITMENT
Jing Guo
Virginia M.Y. Lee
A common feature of many neurodegenerative diseases is the deposition of filamentous protein
aggregates in the central nervous system (CNS), including neurofibrillary tangles (NFTs)
composed of tau, and Lewy bodies (LBs) consisting of α-synuclein (α-syn), which are the
hallmark lesions of Alzheimer’s disease (AD) and Parkinson’s disease (PD) respectively. What
causes the conversion of normally soluble proteins into insoluble fibrils has always been
enigmatic, and cell models that recapitulate the abnormal accumulation of tau into NFT-like
aggregates were lacking due to high solubility of tau. Enlightened by in vitro studies showing
nucleation-dependent fibrillization of tau, we tested the hypothesis that preformed tau fibrils (tau
pffs) assembled from recombinant protein may act as seeds to nucleate the fibrillization of soluble
tau in cultured cells. Indeed, we found that minute quantities of tau pffs internalized into cells
over-expressing tau can rapidly recruit large amounts of endogenous tau into detergent-insoluble
filamentous inclusions with properties very similar to NFTs. Moreover, the spontaneous uptake of
tau pffs was shown to be mediated by endocytosis. Together with similar studies on tau and other
disease-associated proteins, our study implicates cell-to-cell transmission of misfolded proteins
through templated recruitment as a plausible mechanism for the onset and progression of CNS
amyloidosis. Another mysterious phenomenon of neurodegenerative diseases is the frequent cooccurrence of different protein aggregates, such as NFTs and LBs. To test whether fibrillar α-syn
can directly cross-seed tau into pathological aggregates, we utilized our recently developed
synucleinopathy models in primary neurons and transgenic mice involving delivery of α-syn pffs.
Intriguingly, we discovered two distinct strains of α-syn fibrils demonstrating striking difference in
the efficiency of cross-seeding tau pathology both in neurons and transgenic mice. Biochemical
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analyses indicated conformational differences between the two strains, thereby revealing the
ability of a single molecule to assemble into more than one misfolded conformers. We speculate
that the existence of conformationally diverse strains may be another shared feature of amyloid
aggregates, accounting for the tremendous heterogeneity of neurodegenerative diseases with
differential extent of concomitant pathologies and highly variable but sometimes overlapping
clinical symptoms.
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CHAPTER 1: GENERAL INTRODUCTION
1.1 Overview of Neurodegenerative diseases
Neurodegenerative diseases refer to a wide variety of pathological conditions caused by
progressive dysfunction and deterioration of the nervous system, including Alzheimer’s disease
(AD), the most common type of dementia (Alzheimer's Association, 2012), and Parkinson’s
disease (PD), the most common neurodegenerative movement disorder (de Lau and Breteler,
2006). The greatest risk factor for these devastating diseases is advancing age. As the average
life expectancy of humans rapidly increases, an escalating number of the world population is now
suffering from various types of neurodegeneration. It was estimated that in 2010, about 35.6
millions of people worldwide were afflicted with dementia, and this number is expected to double
every 20 years (Alzheimer's Disease International, 2009). In United States alone, around 5.4
millions of people are living with AD (Alzheimer's Association, 2012). Unfortunately, to date,
almost all neurodegenerative disorders are considered terminal illnesses with no cure. All
currently approved treatments merely alleviate disease-associated symptoms without reversing or
slowing down disease course (Alzheimer's Disease International, 2009; Melnikova, 2007).
Therefore, there is a pressing need for the discovery of disease-modifying drugs, which
necessitates more advanced understanding of biological processes underlying the pathogenesis
and progression of neurodegenerative diseases.
Despite tremendous diversity in clinical phenotypes, the majority of neurodegenerative
diseases share a common feature, which is the accumulation of disease-specific proteins into
insoluble aggregates, including senile plaques consisting of β-amyloid (Aβ) and neurofibrillary
tangles (NFT) consisting of tau in AD (Glenner and Wong, 1984; Lee et al., 1991), Lewy bodies
(LB) and Lewy neurites (LN) composed of α-synuclein (α-syn) in PD (Spillantini et al., 1997),
TDP-43 aggregates in Amyotrophic Lateral Sclerosis (Neumann et al., 2006), and polyglutamine
inclusions in Huntington’s disease (DiFiglia et al., 1997), and prion protein aggregates in
Creutzfeldt-Jakob disease (Bolton et al., 1982). Most of these protein aggregates are
characterized by enriched β–pleated sheet structures and are shown to consist of 8-20 nm wide
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filaments by electron microscopy (reviewed by Forman et al., 2004; Goedert, 1999). What triggers
the conversion of normally soluble proteins into filamentous polymers remains a topic of active
research and also forms the basis of my thesis study. Importantly, the identification of pathogenic
mutations in the genes coding for various disease-associated proteins provides the strongest
argument that these proteins are causally linked to the pathogenesis of neurodegenerative
diseases instead of merely serving as pathological markers.
However, there is an ongoing debate on the exact toxic species along the aggregation
pathway, whether it is oligomers, proto-fibrils, or mature fibrils. Traditionally, mature filamentous
aggregates are believed to be detrimental to cells since they are consistently found in regions
undergoing neurodegeneration. It is easily conceivable that thick bundles of intracellular fibrils
may create physical obstacles for important cellular processes, such as protein trafficking and
axonal transport, and due to their inherent stickiness, they could also sequester critical
cytoplasmic proteins including their soluble counterparts, resulting in loss-of-function toxicity
(reviewed by Ballatore et al., 2007; Forman et al., 2004). More recently, multiple lines of evidence
suggested that pre-fibrillar protein species could be harmful to cells as well. For example, soluble
Aβ oligomers were demonstrated to be toxic to cultured neurons (Dahlgren et al., 2002; Lambert
et al., 1998) and impair long-term potentiation both in cultured hippocampal slices and in vivo
(Walsh et al., 2002; Wang et al., 2002); α-syn was shown to form annular or pore-like proto-fibrils
which can potentially disrupt membrane structures (Ding et al., 2002; Lashuel et al., 2002); in
animal models over-expressing tau, neuronal dysfunction or death sometimes precedes NFT
formation or occurs independent of NFTs (Santacruz et al., 2005; Wittmann et al., 2001;
Yoshiyama et al., 2007). These studies led to the provocative hypothesis that soluble oligomers
rather than insoluble fibrillar aggregates may be the real culprit of neuronal demise, and formation
of the latter may actually represent a protective cellular mechanism to sequester diffusible toxic
oligomers (reviewed by Caughey and Lansbury, 2003; Haass and Selkoe, 2007). Nevertheless,
none of these studies has truly refuted the toxicity of mature aggregates, and the pathological
relevance of soluble oligomers, on the other hand, remains to be established since only a limited
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number of studies have reported the existence of such species in the disease brains (Maeda et
al., 2007; Patterson et al., 2011).
The following two sections will discuss in greater detail about tau and α-syn, the two
proteins that are the focus of my thesis study.
1.2 Tau and tauopathies
Tau is a microtubule (MT)-associated protein predominantly expressed in the neurons
with a primary cellular function of stabilizing MTs and promoting their assembly (Cleveland et al.,
1977b; Drechsel et al., 1992; Witman et al., 1976). In the adult brain, there are 6 isoforms of tau,
which arise from alternative splicing of the MAPT gene and differ in the number of MT-binding
repeats as well as the number of N-terminal inserts (Andreadis et al., 1992; Goedert et al., 1989).
There can be 3 or 4 MT-binding repeats (referred to as 3R or 4R tau) that bind to the inner
surface of the MTs, and 0-2 of the highly acidic N-terminal inserts (referred to as 0N, 1N or 2N
tau) that project away from MTs. It has been shown that 4R tau binds MTs more avidly than 3R
tau (Butner and Kirschner, 1991; Gustke et al., 1994). In addition, the MT-binding property of tau
is regulated by post-translational modifications, particularly serine/threonine phosphorylation,
which reduces binding affinity of tau for MTs presumably due to electrostatic repulsion between
negatively charged phosphate groups and tubulin residues (Biernat et al., 1993; Bramblett et al.,
1993; Drechsel et al., 1992). Both the isoform composition and phosphorylation of tau are
developmentally regulated, whereby only the shortest 3R isoform is expressed in fetal brains and
fetal tau is more phosphorylated than adult tau (Goedert et al., 1993; Goedert et al., 1989;
Kanemaru et al., 1992), giving rise to more dynamic MT structures in developing brains (Panda et
al., 2003).
Physiologically, tau is a highly soluble protein due to abundant charged residues, such as
lysines that are particularly enriched in the MT-binding repeats (Jones et al., 2012; Mandelkow et
al., 2007). Biophysical studies demonstrated that tau is a natively unfolded protein without welldefined secondary or tertiary structures (Cleveland et al., 1977a; Schweers et al., 1994).
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Interestingly, recent studies suggested that tau actually has a more compact structure than an
ideal random coil, owing to at least transiently existing long-range intramolecular interactions
among the different domains (N-terminus, proline-rich region, MT-binding repeats, C-terminus),
but it is controversial whether such interactions promote or inhibit pathological aggregation
(Elbaum-Garfinkle and Rhoades, 2012; Jeganathan et al., 2006; Mukrasch et al., 2009).
In AD brains, the normally soluble tau protein accumulates into insoluble β-sheet-rich
paired helical filaments as well as straight filaments both in neuronal somas (pathology termed as
NFTs) and processes (pathology termed as neuropil threads) (Berriman et al., 2003; Kidd, 1963;
Wischik et al., 1985), whereby neuropil threads account for >95% of total tau pathology (Mitchell
et al., 2000). Tau aggregates are also found extracellularly as “ghost tangles”, which presumably
come from dead neurons (Bondareff et al., 1994; Braak et al., 1994). For a long time, tau
aggregation was thought to be merely a downstream consequence of extracellular Aβ deposition,
since all mutations identified in familial AD are linked to Aβ but not tau (Duff and Hardy, 1995;
Masters and Beyreuther, 1998). However, a significant correlation between total NFT burden and
cognitive deficits of patients (Arriagada et al., 1992; Wilcock and Esiri, 1982), and a correlation
between the abundance of ghost tangles and the extent of neuron loss (Cras et al., 1995),
suggest that tau aggregation may be a critical player in the disease mechanism. Moreover, the
discovery of a heterogeneous subgroup of frontotemporal dementia (FTD) characterized by tau
inclusions in the absence of Aβ plaques (now collectively termed as tauopathies together with
AD) and, most importantly, the identification of >30 autosomal dominant mutations of the MAPT
gene encoding tau in FTD with parkinsonism linked to chromosome 17 (FTDP-17) strongly
suggest that abnormality in tau alone is sufficient to cause neurodegeneration (Goedert and
Jakes, 2005; Hutton et al., 1998; Rizzu et al., 1999). Interestingly, the majority of mutations are
clustered around the MT-binding repeats. While most missense mutations compromise the ability
of tau in promoting MT assembly (Dayanandan et al., 1999; Hong et al., 1998) and/or increase its
propensity to fibrillize in vitro (Goedert et al., 1999; Nacharaju et al., 1999; von Bergen et al.,
2001), mutations in intron 10 and a number of mutations in the nearby coding regions alter the
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ratio of 4R to 3R isoforms (Hutton et al., 1998). Given that all pathogenic tau mutations alter
either physiological/pathological properties of tau or the isoform composition of tau, and that
NFTs are found in both sporadic and familial FTDP-17 cases, tau must be causally involved in the
pathogenesis of tauopathies.
Since the discovery of tau as the integral building blocks of NFTs (Kosik et al., 1986; Lee
et al., 1991), a large number of studies have been dedicated to investigating in vitro fibrillization of
tau. Although the earliest studies managed to show self-assembly of tau into NFT-like filaments,
the efficiency of fibrillization was very low, despite extremely high concentration of tau and nonphysiological conditions used (Crowther et al., 1992; Crowther et al., 1994; Wille et al., 1992).
Truncated tau consisting of the MT-binding repeats alone shows higher tendency to fibrillize than
full-length tau, consistent with the observation that the repeat region forms the core of NFTs
(Wischik et al., 1988). A breakthrough in the field was achieved when a series of studies
demonstrated that polyanionic cofactors, such as RNA, heparin and arachidonic acid,
dramatically promote fibrillization of tau (Chirita et al., 2003; Goedert et al., 1996; Kampers et al.,
1996). Among them, arachidonic acid is the most potent facilitating cofactor, which can induce
physiological concentrations of tau (low μM range) to form fibrils within hours. The exact
mechanism by which polyanionic cofactors stimulate tau fibrillization is not well understood, but it
is proposed that negative charges carried by these molecules likely neutralize excess positive
charges in the MT-binding domains and flanking regions of tau, thereby enabling intermolecular
interactions of tau through these regions or stabilizing aggregation-prone structures of tau (Sibille
et al., 2006). In addition, micelles formed by arachidonic acid may attract positively charged tau to
their surface so as to increase local concentration of tau (Chirita et al., 2003). However, it remains
unresolved whether any of these inducers of tau fibrillization in vitro is truly involved in the
genesis of NFTs in human brains. RNA is usually highly complexed in the cytoplasm without free
access to tau; heparan sulfate, which is structurally related to heparin, is largely on the
extracellular side of the cell membranes; anionic fatty acids can be found on the cytoplasmic side
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of the cell membranes, but their normal levels inside cells are insufficient to trigger tau fibrillization
(Chirita et al., 2003).
Post-translational modifications on tau itself may play important roles in the onset and
progression of tauopathies. Since phosphorylation inhibits tau-MT interactions and tau is found to
be always hyperphosphorylated in NFTs, it is proposed that upregulated phosphorylation and/or
downregulated dephosphorylation of tau may promote disengagement of tau from the MTs,
resulting in elevated levels of free tau in the cytoplasm, which in turn enhances the chance of tautau interactions (reviewed by Ballatore et al., 2007). Indeed, a study on adult human brain
biopsies demonstrated downregulation of phosphatase in AD brains as compared to control
brains (Matsuo et al., 1994). However, it is still debatable whether hyperphosphorylation precedes
tau aggregation or occurs post-aggregation, and the effect of phosphorylation on the fibrillization
propensity of tau is controversial (Alonso et al., 2001; Schneider et al., 1999). Tau acetylation, a
recently discovered modification of tau on lysine residues, not only serves as a reliable
pathological marker of tauopathies, but was also found to both impair the physiological function of
tau in promoting MT assembly and enhance the pathological aggregation of tau in vitro (Cohen et
al., 2011; Irwin et al., 2012). Importantly, potential acetylation sites mostly lie within the MTbinding repeats which are embedded in the core of NFTs, making acetylation unlikely to occur
after NFT formation. Future studies are required to confirm the pathogenic role of tau acetylation
in tauopathy brains.
1.3 α-syn and synucleinopathies
α-syn is a 140-amino acid cytoplasmic protein abundantly expressed in neurons (Iwai et
al., 1995a; Jakes et al., 1994). Its subcellular localization is developmentally regulated, such that
it only becomes highly concentrated in the synaptic terminals when neurons are mature (Murphy
et al., 2000). The exact physiological functions of α-syn are not clearly defined. Its physical
location in the synapses and close association with synaptic vesicles (Iwai et al., 1995a) suggest
it may play a role in synaptic functions. Indeed, downregulation of α-syn, both in primary neurons
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by antisense oligonucleotide and in mice by genetic knock-out (KO), led to reduced distal pool of
synaptic vesicles (Cabin et al., 2002; Murphy et al., 2000), providing evidence for a possible
regulatory function of α-syn in synaptic transmission. On the other hand, the functional deficits of
dopaminergic neurons in α-syn KO mice occur in the absence of morphological or structural
abnormalities (Abeliovich et al., 2000), suggesting α-syn is not essential for the formation of
synapses per se. Additionally, α-syn was shown to be neuroprotective by acting as a cochaperone together with cysteine-string protein-alpha to protect nerve terminals against stress or
injury (Chandra et al., 2005). More recently, the non-classical chaperone function of α-syn was
demonstrated to be important for maintaining continuous assembly of presynaptic SNARE
complex, which in turn is required by repetitive neurotransmitter release (Burre et al., 2010).
Similar to tau, α-syn is a heat-stable, highly soluble protein, belonging to the family of
natively unfolded protein (Eliezer et al., 2001; Weinreb et al., 1996). However, unlike tau,
recombinant α-syn readily assembles into β-sheet-rich fibrils in vitro under physiological
conditions without any cofactors (Conway et al., 1998; Giasson et al., 1999), although fatty acids
and anionic detergents were shown to further accelerate fibrillization (Necula et al., 2003). The
first 60 amino acids of α-syn on the N-terminus are homologous to a lipid-binding domain of
apolipoproteins (George et al., 1995), and assume α-helical structure upon binding to acidic
phospho-lipids (Davidson et al., 1998; Eliezer et al., 2001). The hydrophobic central domain
(amino acids 61-95), known as non-amyloid component (NAC) of the amyloid precursor protein
due to its initial co-purification with Aβ plaques from AD brains (Weinreb et al., 1996), is both
necessary and sufficient for fibril assembly of α-syn (Giasson et al., 2001; Han et al., 1995),
analogous to the MT-binding domain of tau. The amyloidogenic property of the NAC domain is
also supported by fibrillization incompetency of β-syn, which shares extensive sequence
homology with α-syn but lacks the NAC domain (Giasson et al., 2001). The C-terminus of α-syn,
highly acidic due to enriched glutamate residues, is the most unstructured region of the whole
molecule (Eliezer et al., 2001; Maroteaux et al., 1988). Deletion of C-terminus greatly promotes
the fibrillization rate of α-syn (Crowther et al., 1998; Murray et al., 2003), and since C-terminal
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truncated α-syn was found in PD brains (Baba et al., 1998; Campbell et al., 2001; Li et al., 2005),
proteolytic cleavage has been proposed to be an important pathogenic event in LB diseases.
In PD and other synucleinopathies, such as dementia with Lewy Bodies (DLB),
filamentous α-syn aggregates deposit as LBs and LNs within neuronal somas and processes in a
variety of subcortical and neocortical regions (Spillantini et al., 1998a). Classical LBs found in the
substantia nigra of PD brains are characterized by a dense core surrounded by a halo of radiating
filaments (Forno, 1996), while cortical LBs are morphologically less defined and lack a halo
(Goedert et al., 2012). Biochemical identification of α-syn as the major component of LBs was
only accomplished (Spillantini et al., 1997) after the discovery of an autosomal dominant
pathogenic mutation in α-syn causing early-onset PD (Polymeropoulos et al., 1997). Two
additional mutations were identified later, providing important insight into the pathogenesis of PD
(Kruger et al., 1998; Zarranz et al., 2004). A53T mutation greatly accelerates fibrillization of α-syn
in vitro, whereas A30P mutation promotes oligomerization but not fibrillization of α-syn,
supporting the hypothesis that enhanced formation of pre-fibrillar oligomers may be the shared
toxic mechanism of both mutations (Conway et al., 2000b). However, this hypothesis was
challenged by E46K mutant α-syn, which fibrillizes faster than wt α-syn (Greenbaum et al., 2005)
but forms pore-like proto-fibrils less readily than wt α-syn (Fredenburg et al., 2007). On the other
hand, A30P mutation was shown to significantly reduce the lipid-binding affinity of α-syn (Jensen
et al., 1998), suggesting that the primary toxicity of A30P mutation may be a loss of physiological
functions, rather than gains-of-function toxicity exhibited by A53T and E46K mutations. Together
with disease-causing gene amplification of α-syn (Chartier-Harlin et al., 2004; Singleton et al.,
2003), these genetic studies highlight the key roles of α-syn in the onset and progression of
synucleinopathies.
Phosphorylation of α-syn at serine 129 is a widely accepted pathological marker specific
for LBs (Anderson et al., 2006) and was shown to promote aggregation and toxicity of overexpressed α-syn in rodents (Lee et al., 2011; Sato et al., 2011), but it remains controversial if
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phosphorylation at this residue occurs prior to LB formation. A cell culture study showed that this
modification is not required for the formation of α-syn inclusions, suggesting that it may represent
a post-aggregation event in LB diseases (Luk et al., 2009). In addition, nitrated α-syn has been
identified extensively and specifically in α-syn aggregates in a wide variety of synucleinopathies
(Duda et al., 2000; Giasson et al., 2000a), pointing to a possible role of oxidative stress in the
pathogenesis of these diseases.
1.4 Existing models of tauopathies and synucleinopathies
To date, a large number of animal models have been generated, predominantly using
transgene over-expression systems, in an attempt to recapitulate the cardinal features of various
tauopathies and synucleinopathies. The earliest tau transgenic mouse models over-expressed wt
tau of either the longest isoform (4R2N) or the shortest isoform (3R0N) (Gotz et al., 1995;
Ishihara et al., 1999; Probst et al., 2000; Spittaels et al., 1999). The 4R2N tau-expressing mice
only develop pre-tangle structures in the form of somatodendritic accumulations of
hyperphosphorylated tau or axonal deposits of tau-immunoreactive spheroids. Axonopathy that is
commonly observed in these mice is most likely due to excessive binding of over-expressed tau
to the MTs (Terwel et al., 2005). Such an over-expression artifact in the absence of NFT-like
pathology deviates this model from real disease conditions, whereby the sequestration of soluble
tau into NFTs is expected to compromise MT stability. The 3R0N tau-expressing mice do form
insoluble tau filaments at 18 months of age, but apart from the long incubation period, NFT-like
aggregates are much more abundant in the spinal cord than in the cortex, rendering it another
unsatisfactory model of tauopathies. After the discovery of tau mutations causing FTDP-17,
numerous mouse models expressing mutant tau (P301L, P301S, R406W) succeeded in
generating filamentous tangle-like pathology in relatively young mice (~3-5 month-old) (Allen et
al., 2002; Gotz et al., 2001a; Lewis et al., 2000; Yoshiyama et al., 2007; Zhang et al., 2004).
Moreover, unlike Aβ-oriented AD mouse models which show minimal neurodegeneration in the
presence of abundant plaques (Irizarry et al., 1997a; Irizarry et al., 1997b), the formation of tau
tangles is frequently accompanied by neuron loss, consistent with the correlation of cognitive
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impairment with NFT burden but not plaque load in AD patients (Arriagada et al., 1992). In
addition, tau aggregation was found to result in reduced MT density (Brunden et al., 2010;
Ishihara et al., 1999), demonstrating the loss-of-function toxicity associated with tangle formation.
However, there is no evidence suggesting upregulation of tau levels is a cause of human
tauopathies, thus over-expression animal models may not be suitable for studying the etiology of
tauopathies. Furthermore, as demonstrated by in vitro and cell culture studies, high concentration
of tau can compete with MT motor proteins and result in cellular trafficking defects (Dixit et al.,
2008; Ebneth et al., 1998; Stamer et al., 2002). Therefore, early deficits observed in tau
transgenic mouse models before the appearance of NFTs could be partly due to over-saturation
of MT-binding sites by tau and/or over-stabilization of the MTs, and hyperphosphorylation of tau,
which is observed in all tau over-expressing models, may actually represent a protective strategy
of cells to reduce excessive MT binding by tau (Stamer et al., 2002).
The causal link between genetic amplification of α-syn and familial PD legitimates the use
of α-syn over-expression to model PD and related synucleinopathies. While transgenic mice overexpressing wt α-syn do not form any α-syn inclusions, mice over-expressing A53T or E46K
mutant α-syn age-dependently develop widespread filamentous α-syn aggregates accompanied
by motor phenotypes (Emmer et al., 2011; Giasson et al., 2002). Curiously, and unsatisfactorily,
in these mouse models, α-syn inclusions are abundantly found in regions that are normally not
affected in PD, such as spinal cord and cerebellum, whereas brain structures that are most
vulnerable to α-syn pathology in human, such as substantia nigra and olfactory bulbs, are spared
of inclusions. Therefore, these models do not accurately reproduce human synucleinopathies in
animals. Aggregation of α-syn in the substantia nigra was later achieved by over-expression of
aggregation-prone C-terminal truncated α-syn under the tyrosine hydroxylase promoter which
restricts expression to dopaminergic neurons (Tofaris et al., 2006), and by direct injection of
adeno-associated virus or lentivirus carrying α-syn-expressing vectors into the substantia nigra
(Kirik et al., 2002; Lo Bianco et al., 2002). However, these new approaches still fail to address the
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apparent contradictions of brain region-specific vulnerability to α-syn pathology in rodent brains
vs. human brains.
While animal models provide significant in vivo evidence for the pathogenicity of protein
aggregation, the relatively long incubation periods and lack of amenability for experimental
manipulations limit their usefulness in mechanistic studies and therapeutic investigations
involving high-throughput screening. Therefore, cellular models would be an invaluable
complementary tool to conduct studies that cannot be readily accomplished in animal models.
Unfortunately, due to the high solubility of tau and α-syn, they do not spontaneously aggregate in
cells within the time window of cell culture experiments (days, in contrast to months for animal
experiments) even with massive over-expression. One additional obstacle in generating tau cell
models is that high levels of tau expression are not well-tolerated by dividing cells since
excessive MT stabilization by over-expressed tau can arrest cell division (Kanai et al., 1989).
Over the years, a variety of approaches have been employed to enhance tau or α-syn
aggregation in cells, including expression of mutant or truncated molecules that are more prone
to fibrillization than wt full-length protein (Khlistunova et al., 2006; Vogelsberg-Ragaglia et al.,
2000); subjecting cells to elevated oxidative/nitrative/proteolytic stress which induces protein
misfolding (Lee et al., 2002; McLean et al., 2001; Paxinou et al., 2001); addition of amyloidbinding dyes, such as Congo red, to stabilize aggregation-competent conformations
(Bandyopadhyay et al., 2007); creating conditions that promote hyperphosphorylation (Ferrari et
al., 2003; Sato et al., 2002). Apart from the low efficiency of tau or α-syn aggregation induced in
these models, very few of them gave rise to bona fide filamentous aggregates that are both
Congo Red/ThT/ThS-positive and ultrastructurally similar to NFTs or LBs as seen in disease
brains. Moreover, many of the manipulations utilized to promote intracellular protein aggregation
are inherently detrimental to cells, thereby precluding the use of these models to investigate toxic
mechanisms of protein aggregation.
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1.5 New paradigm of neurodegenerative disease modeling and the transmission
hypothesis
Failures of existing cell culture models in recapitulating disease pathologies call for
alternative strategies. Notably, in vitro studies showed that fibrillization of tau and α-syn occurs
via a nucleation-elongation mechanism, whereby the formation of oligomeric species (the
“nucleus”) is the rate-limiting step responsible for the initial lag phase, while the addition of
monomers to the nucleus happens relatively quickly resulting in a rapid elongation phase
(Friedhoff et al., 1998; Wood et al., 1999). Therefore, seeding with preformed fibrils can
effectively speed up fibrillization of tau and α-syn monomers through bypassing the kinetic barrier
of nucleation. Enlightened by these in vitro studies, we hypothesized that the major road block
towards efficient intracellular fibrillization of tau and α-syn may lie in the slow formation of
fibrillization-competent nucleus. Therefore, we set on applying the same strategy of “seeding” on
cultured cells by introducing preformed tau or α-syn fibrils into cells over-expressing tau or α-syn
respectively. Intriguingly, it was shown by my colleagues that exogenously supplied α-syn fibrils
can indeed act as seeds to efficiently recruit endogenous soluble α-syn into insoluble aggregates
that are highly reminiscent of LBs (Luk et al., 2009).
Around the same time, another research group published a study demonstrating that tau
fibrils can spontaneously enter cells and induce endogenous tau to form aggregates (Frost et al.,
2009). However, endogenous tau aggregates shown in this study appear to be exclusively small
puncta which do not exceed the size of internalized exogenous fibrils, thereby indicating limited
recruitment, and also do not bear any resemblance to NFTs. The inefficient recruitment seen in
this study may be partly due to the large GFP tag on endogenous tau which could interfere with
tau fibrillization and/or due to the omission of protein delivery reagent which can facilitate the
internalization of exogenous fibrils. Therefore, while this was an important proof-of-concept study
for intracellular seeding of tau, the data were not robust enough to support the pathological
relevance of templated recruitment in NFT formation. In Chapter 2, I will describe my effort of
developing and optimizing a cellular system to demonstrate convincingly the formation of NFT-
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like tau inclusions seeded by preformed fibrils, and altered MT stability resulted from the
sequestration of soluble tau by aggregates. In addition, I will show that exogenous tau fibrils can
indeed be taken up by cells via endocytosis, as suggested by the previous study. In Chapter 3, I
will present an extension of this effort to primary neurons, cells that are most relevant for
neurodegenerative tauopathies, and provide further evidence that templated recruitment is a
plausible mechanism underlying the pathogenesis of tauopathies.
Remarkably, in the past few years, an escalating number of studies have employed the
seeding paradigm to model the onset and progression of neurodegenerative diseases both in
cultured cells and in living animals. Intracerebral inoculation of lysates containing tau aggregates
from aged transgenic mice expressing mutant tau were shown to induce tau inclusions in wt tauexpressing mice which do not normally develop tau aggregates (Clavaguera et al., 2009). Two
recent studies conducted in our lab further demonstrated that synthetic fibrils assembled from
recombinant tau or α-syn are wholly sufficient to induce the aggregation of respective proteins in
transgenic mice expressing mutant tau or α-syn (Iba et al., 2013; Luk et al., 2012b). Notably, in all
three studies, inoculate-induced pathology not only develops near the injection site, but also
spreads to synaptically connected distant brain regions, consistent with two recent studies
reporting trans-synaptic transfer of aggregated tau and two earlier studies showing possible
spreading of LB pathology from host dopaminergic neurons to embryonic transplants (Kordower
et al., 2008; Li et al., 2008). Furthermore, wt human α-syn fibrils were shown to induce robust LB
and LN-like inclusions even in non-transgenic neurons without over-expression of α-syn
(Volpicelli-Daley et al., 2011), and intracerebral injection of mouse α-syn fibrils into nontransgenic mice were found to efficiently initiate and spread endogenous mouse α-syn pathology
to various brain regions, including the substantia nigra, which is normally spared of α-syn
inclusions in α-syn over-expressing transgenic mice (Luk et al., 2012a). Intriguingly, LB formation
in the substantia nigra of non-transgenic mice leads to progressive loss of dopaminergic neurons,
recapitulating a key feature of PD that is missing in most of pre-existing mouse models.
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The abovementioned studies have presented converging evidence for transcellular and
cell-to-cell transmission of tau and α-syn pathologies, whereby fibrillar protein aggregates
constitute the sufficient transmissible agent. Moreover, studies on other disease-associated
proteins, such as Aβ and polyglutamine repeats, demonstrated very similar phenomenon (Eisele
et al., 2010; Ren et al., 2009; Stohr et al., 2012), thereby implicating a shared property of
amyloidogenic proteins. It is difficult to imagine that only a few years ago, protein aggregates in
neurodegenerative diseases were still thought to develop in a cell-autonomous manner, and
intercellular transmission was believed to be a unique property of infectious prion particles. The
recent paradigm shift in disease modeling has therefore revolutionized the whole field’s
understanding on the mechanism underlying the onset and progression of central nervous system
amyloidosis. This newly evolved hypothesis of protein-only transmission provides a viable
explanation for the stereotypical progression of tau and α-syn pathologies in AD and PD brains
that has long been observed (Braak and Braak, 1991; Braak et al., 2003).
1.6 Convergence and divergence in tauopathies and synucleinopathies
Neurodegenerative diseases are commonly classified according to the predominant
clinical manifestations (e.g. AD is considered as a cognitive disorder, whereas PD is considered
as a movement disorder) or the major protein lesions (e.g. AD is a tauopathy, but PD is a
synucleinopathy). In reality, however, there are substantial overlaps among the various diseases
in terms of both clinical symptoms and neuropathologies (Galpern and Lang, 2006). It has been
increasingly recognized that PD is not simply a movement disorder, but it also involves significant
non-motor symptoms, including cognitive deficits. A population-base study revealed >40% of PD
patients fulfilling the clinical criteria for dementia (Mayeux et al., 1992). Conversely, it has been
reported by longitudinal studies that parkinsonism occurs in 36% of pathologically confirmed AD
patients (Morris et al., 1989). With respect to neuropathological substrates, LBs, the hallmark
lesions of PD and DLB, were found in ~50-60% of both familial and sporadic AD cases – most
frequently in the amygdala (Hamilton, 2000; Jellinger, 2003; Kotzbauer et al., 2001; Lippa et al.,
1998), while 33-43% of PD brains showed sufficient senile plaques and NFTs for a pathological
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diagnosis of AD (Jellinger et al., 2002; Mattila et al., 1998), and as high as 87% of DLB cases
reach the pathological criteria for AD (McKeith et al., 2000). While PD with dementia (PD) and
DLB are arbitrarily divided based on the “1-year rule” (a classification of DLB is made if the onset
of dementia occurs within 1 year of the onset of motor symptoms, otherwise the patient is given a
diagnosis of PDD when dementia sets in), the extensive overlaps among PD, PDD, DLB and AD
suggest that all of these diseases may represent a continuum of disorders along the axis of motor
dysfunction and dementia.
Mechanisms underlying frequent co-occurrence of different protein aggregates in various
neurodegenerative diseases are not fully understood. As proposed by the protein homeostasis
theory, aging, the greatest risk factor for most neurodegenerative diseases, is associated with
increased oxidative stress, deteriorated cellular degradation machinery, and consequently
elevated levels of damaged proteins, which can initiate a “damage cascade” that further impairs
the protein quality control systems and leads to even higher amounts of misfolded proteins (Kikis
et al., 2010). Moreover, proteostatic stress arising from the aggregation of one major protein can
elicit a global effect on the structural stability of many other unrelated proteins, possibly resulting
in their misfolding and aggregation (Gidalevitz et al., 2006). An alternative but not mutually
exclusive hypothesis is that filamentous aggregates consisting of one protein may directly seed
the fibrillization of another aggregation-prone protein. The feasibility of such a heterotypic seeding
mechanism is supported by the generation of conformation-dependent and sequenceindependent antibodies which can recognize fibrillar aggregates composed of different proteins,
implicating a generic conformation shared by amyloid fibrils (Kayed et al., 2007; O'Nuallain and
Wetzel, 2002). In line with this possibility, several histological studies have reported close
physical association of tau and α-syn in pathological inclusions (Duda et al., 2002; Galloway et
al., 1989; Ishizawa et al., 2003). Importantly, an earlier study from our lab directly demonstrated
that α-syn and tau promote the fibrillization of each other in the test tube, whereby α-syn can
substitute for anionic factors that are normally required for tau fibrillization and tau also
accelerates the fibril assembly of α-syn (Giasson et al., 2003). Lastly, genome-wide association
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studies consistently identified the H1 haplotype of tau as one of the two most prominent genetic
risk factors for idiopathic PD, besides polymorphisms in the α-syn-coding gene (Satake et al.,
2009; Simon-Sanchez et al., 2009). Although the exact mechanism for increased susceptibility of
the H1 haplotype is unknown, a study showing enhanced expression level of tau conferred by the
H1 variant (Healy et al., 2004) suggests a mechanistic role of tau in the pathogenesis of
synucleinopathies.
Although there are significant overlaps between diseases that were traditionally thought
to be distinct entities, on the other side of the coin, diseases characterized by aggregates made
from the same protein can be highly divergent (reviewed by Lee et al., 2001). Among tauopathies,
all 6 isoforms of tau with an equal ratio of 3R and 4R are found in AD NFTs (Goedert et al., 1992;
Lee et al., 1991), whereas NFTs in progressive supranuclear palsy (PSP) and corticobasal
degeneration (CBD) predominantly consist of 4R tau (Sergeant et al., 1999), while Pick’s disease
(PiD) primarily shows 3R tau inclusions (Sergeant et al., 1997). While tau inclusions are mostly
located in neurons for AD, abundant glial lesions are a distinguishing feature of PSP and CBD,
including tufted astrocytes in PSP, astrocytic plaques in CBD, and coiled bodies (tau inclusions in
oligodendrocytes) in both diseases (Feany and Dickson, 1995; Komori, 1999; Yamada et al.,
1992). Morphologically, NFTs in AD are usually flame-shaped; Pick’s bodies, the signature lesion
of PiD, are spherical tau inclusions; NFTs in PSP and CBD are mostly globose in appearance but
occasionally flame-shaped in PSP (reviewed by Dickson, 1998; Dickson, 1999). Electron
microscopy examination revealed ultrastructural differences in the tau filaments found in different
tauopathies (Crowther, 1991; Crowther and Wischik, 1985; Ksiezak-Reding et al., 1994; Powell et
al., 1974; Takauchi et al., 1984). Furthermore, unlike NFTs in AD, tau aggregates in PiD, PSP
and CBD are mostly thioflavin S (ThS)-negative or Gallyas-negative, and missing tau epitopes
that are present in late-stage AD (Guillozet-Bongaarts et al., 2007), suggesting tau inclusions in
these diseases may be less mature and conformationally different from those found in the AD
brains. Although subcortical pathology is present in all of these disorders, it is especially
pronounced in PSP, which typically shows profound neuronal loss in the basal ganglia,

16

diencephalon and brainstem (reviewed by Dickson, 1999). In terms of clinical features, AD and
PiD are primarily associated with dementia, whereas the dominant signs of PSP and CBD are
motor dysfunctions (reviewed by Dickson, 1998, 1999; Steele et al., 1964).
Similarly, synucleinopathies are marked by considerable heterogeneity, both clinically
and pathologically. As mentioned previously, α-syn inclusions occur in the neuronal cell bodies
and processes as LBs and LNs respectively in PD an DLB. In contrast, in multiple system atrophy
(MSA), α-syn aggregates are predominantly found as cytoplasmic inclusions in the
oligodendrocytes, which consist of α-syn filaments that are morphologically different from those
found in LBs and LNs (Forno, 1996; Kato and Nakamura, 1990; Tu et al., 1998). Not only do MSA
patients present distinct clinical features from other synucleinopathies, but MSA itself can be
categorized into several subtypes with substantial clinical variability (Halliday et al., 2011). Along
the PDD-DLB continuum, there are also large variations in the relative abundance of concomitant
AD pathologies as well as the time interval between the onset of motor symptoms and the onset
of dementia, which can vary by several decades (Gearing et al., 1999; McKeith, 2006; Tsuboi and
Dickson, 2005). While there is a long-standing controversy over the relative importance of LB
pathology vs. co-morbid AD pathologies to cognitive impairment in DLB patients (Colosimo et al.,
2003; Compta et al., 2011; Hurtig et al., 2000), multiple studies have suggested the presence of
two subgroups of PDD patients, one group with relatively young onset, long motor-dementia
interval and less aggressive disease duration, and the other group with older onset, short motordementia interval and more malignant disease course (Compta et al., 2011; Halliday et al., 2008;
Jellinger et al., 2002). Moreover, the former usually presents mostly pure LB pathologies, but the
latter more frequently shows co-existing AD pathologies.
In Chapter 4, I will describe my project which was aimed to explore the cross-seeding of
tau by α-syn fibrils in cultured neurons. The discovery of different strains of α-syn fibrils with
distinct templating activity in this study may offer a potential explanation for both the convergence
and divergence of neurodegenerative diseases.
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CHAPTER 2: SEEDING OF NORMAL TAU BY PATHOLOGICAL TAU CONFORMERS
DRIVES PATHOGENESIS OF ALZHEIMER-LIKE TANGLES*
*This research was originally published in Journal of Biological Chemistry. Guo, J.L., and Lee,

V.M. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimerlike tangles. The Journal of biological chemistry. 2011; 286:15317-15331. © the American Society
for Biochemistry and Molecular Biology.
2.1 Abstract
Neurofibrillary tangles (NFTs) in Alzheimer’s disease and related tauopathies are
comprised of insoluble hyperphosphorylated tau protein, but the mechanisms underlying the
conversion of highly soluble tau into insoluble NFTs remain elusive. Here we demonstrate that
introduction of minute quantities of misfolded preformed tau fibrils (tau pffs) into tau-expressing
cells rapidly recruit large amounts of soluble tau into filamentous inclusions resembling NFTs with
unprecedented efficiency, suggesting a “seeding”-recruitment process as a highly plausible
mechanism underlying NFT formation in vivo. Consistent with the emerging concept of prion-like
transmissibility of disease-causing amyloidogenic proteins, we found that spontaneous uptake of
tau pffs into cells is likely mediated by endocytosis, suggesting a potential mechanism for the
propagation of tau lesions in tauopathy brains. Furthermore, sequestration of soluble tau by pffinduced tau aggregates attenuates microtubule over-stabilization in tau-expressing cells,
supporting the hypothesis of a tau loss-of-function toxicity in cells harboring NFTs. In summary,
our study establishes a cellular system that robustly develops authentic NFT-like tau aggregates
which provides mechanistic insights into NFT pathogenesis and a potential tool for identifying taubased therapeutics.
2.2 Introduction
Neurodegenerative tauopathies, including Alzheimer’s disease (AD) and frontotemporal
dementias (FTD), are characterized by neurofibrillary tangles (NFTs) composed of intracellular
hyperphosphorylated tau aggregates (Goedert et al., 1988; Kosik et al., 1986; Lee et al., 1991;
Pollock et al., 1986). Predominantly expressed in neurons, tau is a microtubule (MT)-binding
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protein which stabilizes and promotes the assembly of MTs (Drechsel et al., 1992; Witman et al.,
1976), and the tau-MT interactions are negatively regulated by phosphorylation of tau (Biernat et
al., 1993; Bramblett et al., 1993). In adult brains, alternative splicing of the MAPT gene
(Andreadis et al., 1992; Goedert et al., 1989) generates 6 tau isoforms containing either 3 or 4
MT-binding repeats (3R or 4R tau) and 0-2 N-terminal inserts (0N, 1N or 2N tau).
A naturally unfolded soluble protein under normal conditions, tau acquires highly-ordered
β-pleated sheet structures as it assembles into insoluble, hyperphosphorylated, 15-20 nmdiameter paired helical filaments as well as less frequent straight filaments that constitute NFTs in
AD and related tauopathies (Berriman et al., 2003; Kidd, 1963). Mechanisms underlying such
dramatic conversions remain a conundrum. Significant correlations of total NFT burden with
cognitive decline are observed in AD patients (Arriagada et al., 1992; Wilcock and Esiri, 1982)
and, importantly, discoveries of over 30 dominantly inherited mutations in the MAPT gene in FTD
with Parkinsonism linked to chromosome 17 (FTDP-17) (Goedert and Jakes, 2005; Hutton et al.,
1998; Rizzu et al., 1999; Spillantini et al., 1998c) strongly suggest a causal link between tau
abnormality and neuronal dysfunction. Although the exact mechanisms of tau-mediated
neurodegeneration are not well understood, both the loss of the MT-binding function of tau due to
sequestration of soluble tau into tangles and toxic gains of function owing to the sheer physical
occupancy of large intracellular aggregates have been proposed to explain the dire
consequences of tau aggregation (Ballatore et al., 2007; Lee et al., 1994).
A cellular system recapitulating features of tauopathies would provide a useful tool to
study the cause and consequences of tau aggregation. However, because tau is a highly soluble
protein, overexpressed tau resists aggregation despite spontaneous hyperphosphorylation in
most cell lines. Moreover, high expression of tau over-stabilizes MTs and inhibits cell division,
and is therefore not well tolerated by dividing cultured cells (Kanai et al., 1989; VogelsbergRagaglia et al., 2000). Thus, our current understanding of tau fibrillization has relied on studies
using cell-free systems in which the formation of tau amyloid fibrils is greatly enhanced by
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polyanionic factors (Chirita et al., 2003; Goedert et al., 1996; Kampers et al., 1996). It has been
shown that the MT-binding repeats of tau are both necessary and sufficient for in vitro
fibrillization, and the repeat domain alone assembles into fibrils more readily than full-length tau
(Wille et al., 1992). Importantly, tau fibril assembly occurs by a nucleation-dependent mechanism,
whereby the formation of oligomeric intermediates constitutes an initial lag phase followed by a
relatively rapid elongation phase (Friedhoff et al., 1998). Therefore, “seeding” tau fibrillization
reactions with preformed tau fibrils (tau pffs) can bypass the rate-limiting nucleation step and
accelerate fibrillization of monomeric tau. We hypothesized that similar “seeding” strategies could
be employed to promote tau aggregation in cultured cells, and in fact several recent cell culture
studies have demonstrated induction of intracellular aggregates by exogenously derived amyloid
fibrils from several disease proteins involved in neurodegenerative disorders, including tau (Frost
et al., 2009; Luk et al., 2009; Nonaka et al., 2010; Ren et al., 2009). Moreover, two recent studies
on transgenic mice demonstrated the induction of wt tau pathology by injection of brain extracts
containing mutant tau aggregates (Clavaguera et al., 2009) or by expression of truncated tau that
is aggregation-prone (de Calignon et al., 2010), exemplifying the in vivo relevance of seeded
aggregation of tau. However, although two previous studies claimed to have demonstrated the
recruitment of soluble tau into insoluble aggregates in cultured cells (Frost et al., 2009; Nonaka et
al., 2010), it is unclear if these tau aggregates resemble NFTs. Here, we provide unequivocal
evidence for the “seeding” phenomenon in cultured cells by demonstrating high efficiency
recruitment of endogenous tau into authentic NFT-like aggregates. Furthermore, the
establishment of a cellular system with significant number of NFT-like aggregates enables
investigation on the pathological mechanisms of tau tangle formation as well as cellular
transmission of pathological tau which are more difficult to be studied in animal models.
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2.3 Results
Intracellular tangle-like aggregates can be induced by preformed fibrils (pffs)
To explore the capability of tau pffs to seed intracellular fibrillization of soluble tau, QBI293 cells were transiently transfected with wild type T40 (wt-T40), the longest human tau isoform
(2N4R), and transduced with pffs generated from myc-tagged full-length human tau (myc-T40) or

Figure 2-S1. Negative stained transmission electron microscopy of preformed fibrils. Fibrils were
assembled from recombinant myc-T40 (A and B), myc-K18 (C and D), or myc-K18/P301L (E and F).
(A), (C) and (E) show unsonicated fibril preparation; (B), (D) and (F) show sonicated fibrils used for
transduction experiments. Magnification: 100,000x. Scale bar: 200 nm.
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truncated tau containing only the 4 MT-binding repeats (myc-K18) (Fig. 2-S1) using BioPORTER
protein delivery reagent. Unlike wt-T40-expressing cells treated with transduction reagent alone,
in which phosphorylated tau recognized by monoclonal antibody (mAb) PHF-1 (pSer396/404)
was completely soluble and extracted by 1% Triton-X100 during fixation (Figure 2-1A), cells
transduced with either myc-T40 or myc-K18 tau pffs showed accumulations of Triton-insoluble
fibrillar phospho-tau aggregates (Figure 2-1B). These induced aggregates were also detected by
anti-phospho-tau mAb AT8 (pSer202/pThr205) and conformation-dependent mAb MC-1 (Figure
2-1C) which specifically recognizes tau in a pathological conformation (Jicha et al., 1997).
Interestingly, pff-induced aggregates exhibited a variety of morphologies, ranging from widely
distributed short fibrils, skein-like accumulations, to localized dense NFT-like inclusions and
sometimes a mixture of phenotypes (Figure 2-1C).
Significantly, double-labeling immunofluorescence in wt-T40-expressing cells using antimyc antibody to detect myc-K18 and myc-T40 pffs, and PHF-1 to detect phosphorylated T40
showed that anti-myc only labeled a fraction of the fibrils detected by PHF1, thus supporting a
“seeding” and recruitment mechanism of tau aggregate formation (Figure 2-1B). Moreover,
phosphorylated tau was non-existent or rare in non-transfected cells transduced with myc-T40
pffs, suggesting a lack of phosphorylation of internalized full-length fibrils (data not shown).
Furthermore, since epitopes recognized by these three tau specific mAbs (PHF-1, AT8 and MC1) are absent from myc-K18, their immunoreactivities in myc-K18 fibril transduced cells can be
entirely attributed to endogenously expressed wt-T40. Thus, exogenously supplied tau pffs do not
constitute the insoluble phospho-tau species we detect in wt-T40 cells treated with pffs. Finally,
accumulation of insoluble tau aggregates failed to occur when pffs were transduced into cells
expressing fibrillization-incompetent tau with K311D mutation (data not shown), further confirming
the de novo fibrillization of soluble tau in wt-T40-expressing cells.
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Figure 2-1. Tau pffs seed endogenous tau fibrillization in wtT40-transfected QBI-293
Cells. (A). Phosphorylated tau recognized by phospho-tau antibody PHF-1(green) was
completely soluble in wtT40-transfected cells treated with BioPORTER reagent alone. Soluble
proteins were extracted by 1% Triton-X100 during fixing in (b) but not in (a). (B). Intracellular
accumulation of insoluble tau recognized by PHF-1 can be induced by both myc-T40 and
myc-K18 pffs transduced using BioPORTER reagent. Exogenous pffs were immunostained
with polyclonal anti-myc antibody (red). (C). Induced tau aggregates showed a range of
morphologies which can be recognized by phospho-tau antibody AT8 and conformationaldependent antibody MC-1. In (B) and (C), cells were extracted with 1% Triton-X100 during
fixing. In all panels, cell nuclei were stained by DAPI (blue). Magnification: 20x for (A); 40x for
(B) and (C). Scale bars: 100 µm for (A); 10 µm for (B) and (C).
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P301L mutation enhances seeded recruitment of endogenous tau
To assess the efficacy of recruitment by pffs of 4R tau, with or without N-terminal inserts,
as well as disease-associated mutant tau, fibril transduction was performed on QBI-293 cells
transiently transfected with human T43 (0N4R), T40/∆K280 (FTDP-17 mutation in the MT-binding
domain), T40/P301L (FTDP-17 mutation in the MT-binding domain), and T40/R406W (FTDP-17
mutation outside the MT-binding domain). Quantification of the percentage of aggregate-bearing
cells induced by these various combinations revealed a similar extent of aggregation in T43- and
T40-transfected cells upon myc-K18 fibril transduction (about 8% of cells had aggregates with
either treatment), suggesting the number of N-terminal inserts does not affect fibrillization (Table
2-1). Among the dominantly inherited tau mutations in FTDP-17 studied here, T40 with the P301L
mutation demonstrated the highest propensity of pff-induced aggregation. Specifically,
transduction of myc-K18 pffs and myc-K18 pffs with P301L mutation (myc-K18/P301L fibrils) led
to about 20% and 35% of cells bearing aggregates, respectively (Table 2-1), corresponding to
~40% and ~70% of the transfected cells assuming 50% transfection efficiency (Figure 2-2A).
Although myc-K18/P301L fibrils appeared to be better “seeds” for T40/P301L recruitment as
monitored by number of aggregate-bearing cells, they were comparable to, or even slightly less
efficient than, myc-K18 fibrils in nucleating the fibrillization of wt-T40 (Table 2-1). Enhanced
aggregation of T40/P301L as compared to wt-T40 corresponded to significantly more
accumulation of Triton-insoluble tau as shown on immunoblots (compare Figure 2-2B with Fig. 2S2B). The induced tau aggregates were also Sarkosyl-insoluble, with the immunoblot of Sarkosyl
extraction indistinguishable from that of Triton extraction (Fig. 2-S3).
Quantification by tau sandwich ELISA indicated that myc-K18/P301L pffs always resulted
in higher amounts of Triton-insoluble T40/P301L tau than myc-K18 pffs, confirming a more
efficient recruitment of soluble tau with the combination of myc-K18/P301L pffs and T40/P301Lexpressing cells (Figure 2-2C). Interestingly, both myc-K18 and myc-K18/P301L pff transduction
on T40/P301L-expressing cells invariably led to a reduction of Triton-soluble tau when compared
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Figure 2-2. P301L mutation enhances pff-induced aggregation. (A). QBI-293 cells were
transiently transfected with T40 with P301L mutation (T40/P301L) and transduced with mycK18 fibrils (a) or myc-K18/P301L fibrils (b) using BioPORTER reagent. Abundant tau
aggregates were detected using mAb PHF-1 (green) after simultaneous 1% Triton-X100
extraction during fixation to remove soluble proteins. (B). Sequential extraction was
performed on T40/P301L-transfected cells treated with Bioporter reagent alone (control), or
with myc-K18 fibrils (K18 fib) or myc-K18/P301L fibrils (K18/PL fib). T: cellular fraction
recovered in 1% Triton-X100 lysis buffer. S: Triton-insoluble fraction solubilized in 1% SDS
lysis buffer. Equal proportions of Triton and SDS fractions were loaded on SDS-PAGE gels.
Immunobloting with polyclonal tau Ab 17025 and PHF-1 revealed accumulation of abundant
Triton-insoluble tau in fibril transduced cells. GAPDH served as a loading control. (C).
Sandwich tau ELISA on cell lysates from 4 independent experiments confirmed induction of
significant amount of Triton-insoluble tau with fibril transduction which was always
accompanied by a reduction in soluble tau. Magnification: 40x. Scale bar: 50 µm.
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Figure 2-S2. Comparison of myc-K18 and mycK18/P301L pff transduction on wtT40expressing cells. (A). Triton-insoluble tau aggregates in wtT40-transfected cells with mycK18 (a) or myc-K18/P301L (b) fibril transduction. Green: PHF-1 staining with soluble proteins
removed by 1% Triton-X100 during fixing. (B). Small amount of Triton-insoluble tau could be
detected on western blot with both myc-K18 and myc-K18/P301L pff transduction (K18 fib and
K18/PL fib respectively). T: cellular fraction recovered in 1% Triton-X lysis buffer. S: Tritoninsoluble fraction solubilized in 1% SDS lysis buffer. Equal proportions of Triton and SDS
fractions were loaded on SDS-PAGE gels. Magnification: 40x. Scale bar: 50 µm.

Figure 2-S3. Immunoblots of Sarkosyl extraction are indistinguishable from that of
Triton-X100 extraction. Cells transfected with T40/P301L and treated with transduction
reagent alone (control) or transduced with myc-K18 or myc-K18/P301L fibrils (K18 fib and
K18/PL fib respectively) with reagent were sequentially extracted with 1% Sarkosyl lysis
buffer (S) followed by 1% SDS lysis buffer (D). Immunoblotting using polyclonal tau Ab 17025
and mAb phospho-tau Ab PHF-1 showed abundant Sarkosyl-insoluble tau induced by pff
transduction. Equal proportions of Sarkosyl and SDS fractions were loaded on SDS-PAGE
gels.
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with non-transduced cells, further supporting that the accumulation of insoluble tau is through
sequestration/recruitment of soluble tau.
Intriguingly, live immunostaining followed by immunofluorescence after fixation and
permeabilization (two-stage staining) revealed that the majority of pffs associated with cells were
merely membrane-associated despite extensive trypsinization before replating cells to coverslips,
while only a small amount of pffs were truly internalized (Figure 2-3A). Moreover, double labeling
using anti-myc antibody and PHF-1 in cells extracted with 1% Triton X-100 showed that less than
half of the induced aggregates contained detectable colocalizing pffs (Figure 2-3B), suggesting
that small amounts of pff seeds are sufficient to induce robust endogenous tau fibrillization.
Pff-induced tau aggregates are comprised of filamentous NFT-like amyloid structures.
Immuno-EM using PHF-1 revealed abundant cytoplasmic filaments in pff-transduced
cells (Figure 2-4) but not in those treated with transduction reagent alone. Moreover, diverse
organelles, including mitochondria, lysosomes and other vesicular structures, were detected
within and adjacent to PHF-1 positive filamentous structures (Figures 2-4A (a),(b)). The lack of
diffuse PHF-1 staining in the cytoplasm outside of the PHF inclusions further supports the
concept of “seeding” and recruitment of soluble tau to form NFT-like structures in pff-transduced
cells.
To examine the progression of pff-induced endogenous tau aggregation, we fixed cells at
different time points after the addition of pff/reagent complex. At t = 1 hr, there was little
accumulation of Triton-insoluble tau, except for a few rare cells showing focal PHF-1
immunoreactivities with small but intensely labeled inclusions surrounded by slender, discrete
fibrillar structures (Fig. 2-S4A). At t = 3 hr, focal inclusions became more frequent and a small
population of cells developed skein-like accumulations throughout the cytoplasm (Figure 2-5A). It
is noteworthy that the earliest focal accumulations were almost always colocalized with myc
immunoreactivities, suggesting that aggregation first begins in cells containing more abundant
fibril seeds which rapidly initiate the conversion of endogenous tau into insoluble aggregates
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Figure 2-3. Internalization of small quantities of tau pffs is sufficient to induce robust
tau aggregation. QBI-293 cells were transiently transfected with mutant T40/P301L tau and
transduced with myc-K18/P301L pffs using BioPORTER reagent. (A). Incubation of fibril
transduced cells with polyclonal anti-myc antibody before fixing (live, red) followed by staining
of fixed and permeabilized cells with anti-myc mAb 9E10 (fixed, green) showed extensive
colocalization, suggesting the majority of the pffs detected were merely extracellularly
associated with cell membranes. Arrows point to truly internalized fibrils which were only
recognized by 9E10 applied to fixed and permeabilized cells but not polyclonal anti-myc
antibody used on live cells. (B). Double-labeling of phospho-aggregates by PHF-1 (green)
and exogenous pffs by polyclonal anti-myc (red) showed very little colocalization. Arrows
point to aggregates with colocalizing pff seeds. Aggregates without arrows do not contain
obvious pff seeds. Magnification: 20x. Scale bar: 100 µm.
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Figure 2-4. Pff-induced tau aggregates consist of filamentous structures. T40/P301Ltransfected QBI-293 cells were transduced with myc-K18/P301L fibrils using BioPORTER
reagent. (A). Immuno-EM using mAb PHF-1 showed abundant filamentous tau aggregates in
the cytoplasm. Arrows indicate mitochondria and/or vesicular structures in close association
with tau fibrils. (B). Routine EM showing tau fibrils. Magnification: 12,000x for (A) (a); 30,000x
for (A) (b); 50,000 for (B). Scale bars: 2 µm for (A) (a); 500 nm for (A) (b) and (B).

Figure 2-S4. Pff-induced tau aggregates at early time points. (A). One hour after the
addition of myc-K18/P301L fibril/BioPORTER reagent complex to T40/P301L-transfected
cells, a few rare cells showed local accumulation of insoluble tau (PHF-1) colocalizing with
exogenous pffs (myc). (B). Up to t = 3 hr after fibril addition, ThS staining entirely overlapped
with pff staining (myc). 1% Triton-X100 was added during fixing to remove soluble proteins.
Magnification: 40x for (A); 20x for (B). Scale bar: 10 µm in (A); 100 µm in (B).
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Figure 2-5. Time-dependent development of insoluble tau aggregates. QBI-293 cells
transfected with T40/P301L mutant tau were transduced with myc-K18/P301L fibrils using
BioPORTER reagent. (A). At t = 3 hr after the addition of fibril/reagent complex, a small
percentage of cells started showing accumulations of insoluble tau (PHF-1) with focal
inclusions colocalizing with pff staining (myc). (B). At t = 6 hr, more cells developed
aggregates, most of which are skein-like and diffusely distributed throughout the cytoplasm. A
small population of cells showed ThS-positive large aggregates. (C). Large aggregates
recognized by ThS were more frequently seen at t = 24 hr after fibril addition. Soluble proteins
were extracted by 1% Triton-X100 during fixing for all. Magnification: 40x. Scale bar: 50 µm.

through physical recruitment. At t = 6 hr, insoluble tau was found in about 4% of total cells;
although diffuse fibrillar accumulations remained the most common phenotype at this stage,
some aggregates started showing signs of coalescence, and large compact inclusions appeared
in a small subset of cells (Figure 2-5B). Twenty-four hr after fibril transduction, about 25% of total
cells were replete with Triton-insoluble tau, with a significant portion of cells bearing large,
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densely packed aggregates (Figure 2-5C). Thioflavin S (ThS) was used to determine if pffinduced tau aggregates form amyloid fibrils. Up to t = 3 hr, ThS staining completely overlapped
with myc immunoreactivities, indicating exclusive recognition of β-pleated sheet in mycK18/P301L pffs (Fig. 2-S4B). ThS staining that colocalized with PHF-1 positive endogenous tau
aggregates first emerged at t = 6 hr, and became more abundant at t = 24 hr (Figure 2-5B,C).
Interestingly, only the large compact aggregates, but not diffuse skein-like inclusions, were
recognized by ThS. We speculate that dispersed fibrillar aggregates probably represent early fibril
species which eventually coalesce and mature into β sheet-rich inclusions.
Newly synthesized tau is recruited rapidly into insoluble tau fibrils
To directly monitor the recruitment of newly synthesized tau into insoluble aggregates, we
performed pulse-chase experiments on myc-K18/P301L pff-transduced T40/P301L-expressing
cells. In cells treated with transduction reagent alone, [35S]-radiolabeled tau remained soluble
over a 6 hr chase period despite a time-dependent electrophoretic mobility shift indicative of
phosphorylation of the newly synthesized tau. In contrast, an increasing proportion of
radiolabeled T40/P301L tau emerged in the Triton-insoluble fraction of fibril-transduced cells,
accompanied by more rapid reduction of soluble tau than in the control cells, demonstrating
active recruitment of newly synthesized tau into an insoluble pool (Figure 2-6). After 1 hr chase,
an appreciable amount of T40/P301L tau was already detected in the insoluble fraction,
highlighting the rapid solubility change of tau in the presence of misfolded seeds. Moreover, the
detection of slower migrating insoluble radiolabeled tau suggests continuous recruitment of
soluble tau that is being modified by phosphorylation over time.
Reduced MT stability is associated with tau aggregation
Consistent with previous studies in other cell lines, overexpression of tau in QBI-293 cells
led to the formation of thick MT bundles due to excessive stabilization of MTs (Kanai et al., 1989;
Matsumura et al., 1999). We hypothesized that seeded recruitment of tau into insoluble fibrils
may attenuate the over-stabilization of MTs by sequestering the soluble pool of tau. As expected,
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Figure 2-6. Newly synthesized tau is rapidly recruited into insoluble aggregates. One
day after myc-K18/P301L fibril transduction on QBI-293 cells transiently transfected with
T40/P301L, cells were pulsed with [35S]-methionine for 20 min and chased for different
durations (0 to 6 hr). Cell lysates were sequentially extracted using 1% Triton-X100 followed
by 1% SDS lysis buffer, and tau was immunoprecipitated from both fractions with mAbs T46
and Tau 5. Equal proportions of Triton (T) and SDS (S) fractions were loaded on SDS-PAGE
for autoradiography. (A). Autoradiograph indicating that newly synthesized tau remained
soluble in cells treated with reagent alone (Rg control) but rapidly turned insoluble in fibriltransduced cells (Fib Td). (B). Quantification from 2 independent experiments showing the
distribution of radiolabeld tau in the soluble and insoluble fractions over time (Error bar:
standard error).

T40/P301L-expressing cells that were transduced with myc-K18 or myc-K18/P301L pffs showed
significantly less MT bundling revealed by immunostaining of acetylated-tubulin (Ac-tub), a
marker of stable MTs, as compared to those treated with transduction reagent alone (~40% and
~60% reduction in the percentage of cells with MT bundles by myc-K18 and myc-K18/P301L pff
transduction respectively) (Figure 2-7A,C). The majority of cells with aggregates showed an
absence of MT bundles and cells that retained bundles typically showed diffuse tau staining
(Figure 2-7B). Reduced Ac-tub levels associated with pff-induced aggregation was further
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confirmed using an Ac-tub sandwich ELISA (Figure 2-7D). In addition, there was a significant
correlation between Ac-tub level and soluble tau, but not insoluble tau, suggesting that the loss of
soluble tau rather then aggregation per se was responsible for the reduced MT stability (Figure 27E,F). This observation likely accounts for the occasional MT bundles observed in cells carrying
aggregates (data not shown).
Spontaneous fibril uptake is mediated by endocytosis
To determine if tau pffs can be taken up spontaneously in the absence of protein delivery
reagent, we incubated T40/P301L-transfected cells with myc-K18/P301L pffs for 30 hr, followed
by trypsinization and incubation for an additional 18 hr. Aggregation of endogenous tau was
detected in about 10% of total cells, accompanied by appreciable accumulation of Triton-insoluble
tau detected on immunoblots (Figure 2-8A(a),B). Interestingly, exogenous pffs were barely visible
by immunostaining (Figure 2-8E), suggesting that internalization of minute quantities of pffs
without transduction reagent is sufficient to induce recruitment of endogenous tau into fibrils. To
investigate whether this uptake of tau pffs occurs by endocytosis, we incubated T40/P301Lexpressing cells with myc-K18/P301L pffs for 4 hr at either 37°C or 4°C; the latter temperature
blocks endocytosis. Since the amount of pff internalized by cells is too low to be easily detected
by either immunostaining or immunoblotting (Figure 2-8E,F), we quantified Triton-insoluble
endogenous tau aggregates as an indirect readout of pff entry. Pff incubation at 37°C for 4 hr
prior to trypsinization and an additional 44 hr incubation resulted in ~ 3% of total cells with tau
inclusions, whereas 4 hr pff incubation at 4°C followed by exactly the same treatments resulted in
a dramatic and significant reduction in the percentage of tau aggregate-bearing cells (Figure 28A,C,D), suggesting pff uptake is a temperature-dependent process. The small number of cells
with tau aggregates (~0.5% of total cells) detected after 4°C pff incubation could be due to the
internalization of residual membrane-associated fibrils following trypsinization and additional
incubation. Moreover, the difference in the extent of aggregation induced by 4 hr versus 30 hr
incubation of pffs (~3% vs. ~10% aggregate-bearing cells) indicated a time-dependent
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Figure 2-7. Tau aggregation results in reduced MT stability. (A). QBI-293 cells transfected with
T40/P301L and transduced with Myc-K18 (K18 fib) or myc-K18/P301L (K18/PL fib) pffs showed
significant reductions in MT-bundling compared to control cells treated with BioPORTER transduction
reagent alone (control), as revealed by acetylated-tubulin (Ac-tub) staining. (B). Double-staining of PHF1 and Ac-tub showed that cells with MT bundles usually showed diffuse tau immunostaining (arrows),
whereas those with tau aggregates often lacked bundling (arrow heads). (C). Quantification from 3
independent experiments demonstrated statistically significant reduction in the percentage of cells with
MT bundles in the presence of fibril transduction (Error bar: standard error; *: p < 0.05). (D). Ac-tub
sandwich ELISA on samples from 4 independent experiments showed significant decrease in Ac-tub
levels associated with fibril transduction (Error bar: standard error; *: p < 0.05). (E,F). Ac-tub and tau
sandwich ELISA revealed highly significant correlation of Ac-tub levels with Triton-soluble tau (E: p <
0.0005), but not with Triton-insoluble tau (F: p > 0.05), across control and fibril transduced samples from
4 independent experiments. Magnification: 20x for (A); 40x for (B). Scale bar: 100 µm for (A); 50 µm for
(B).
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Figure 2-8. Spontaneous uptake of pffs without transduction reagent also induces intracellular
tau aggregation. (A). T40/P301L aggregation induced by myc-K18/P301L pffs alone after 30 hr
incubation at 37°C (a) or 4 hr incubation at 37°C (b). Minimal aggregation was observed with 4 hr
incubation at 4°C (c). For all conditions, cells were trypsinized and replated after the designated
incubation period and fixed 48 hr after the initial addition of fibrils. Soluble proteins were extracted with
1% Triton-X100 during fixing. White: PHF-1. (B). 48 hr incubation with myc-K18/P301L pffs at 37°C led
to significant accumulation of Triton-insoluble T40/P301L detected on immunoblots. Control cells were
transfected with T40/P301L without fibril transduction. (C). 4 hr incubation with myc-K18/P301L fibrils at
37°C but not at 4°C resulted in detectable T40/P301L Triton-insoluble aggregates. (D). Quantification
from 4 independent experiments showed significant reduction in aggregate-bearing cells when a 4 hr
fibril incubation was performed at 4°C instead of 37°C (Error bar: standard error; *: p < 0.05 compared to
4 hr incubation at 37°C). Thirty-hour incubation with tau pffs at 37°C resulted in the highest incidence of
aggregates (n = 3; Error bar: standard error; **: p < 0.01 compared to 4 hr incubation at 37°C). (E). Myctagged pffs were barely visible in cells transduced with fibrils alone without BioPORTER reagent. White:
anti-myc Ab. (F). Exogenous myc-tagged tau pffs were non-detectable with anti-myc mAb 9E10 via
immunoblot under various transduction paradigms: transduction of pffs with BioPORTER reagent (fib Td
with Rg), 30 hr incubation with pffs alone (30hr fib alone), or 4 hr incubation with fibrils alone (4hr fib
alone). Cells were trypsinized and replated to new wells after the designated incubation time so that the
majority of extracelluarly associated pffs were removed. Total fib input: the amount of tau pffs used for
transduction was added to cells immediately before lysing. *: non-specific bands. For (B), (C) and (F), T:
1% Triton-X100 fraction; S: 1% SDS fraction. Equal proportions of Triton and SDS fractions were loaded
on SDS-PAGE gels. Magnification: 20x. Scale bar: 100 µm.
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internalization of fibrils (Figure 2-8D). These results suggest spontaneous uptake of pffs probably
occurs by endocytosis.
Adsorptive endocytosis enhances tau pff uptake
To further explore potential mechanisms of endocytosis-mediated pff entry, we incubated
cells with pffs in the presence of WGA, a plant lectin that has high affinity for N-acetyl
glucosamine (GlcNAc) and sialic acid on the plasma membrane and is readily internalized by
cells via adsorptive endocytosis (Broadwell et al., 1988; Gonatas and Avrameas, 1973). Apart
from being a substrate of the endocytic pathway, WGA was also shown to potentiate the uptake
of other proteins mediated by the same endocytic pathway (Banks et al., 1998; Banks et al.,
1997). Interestingly, we found that WGA increased the prevalence of tau aggregate-bearing cells
(Figure 2-9A,B) and the amount of Triton-insoluble tau in fibril transduced cells (Figure 2-9C) in a
dose-dependent manner, which paralleled increased cellular association with pffs (Figure 2-9D).
Without WGA treatment, there was minimal fibril staining even without trypsinization. Increasing
the dose of WGA not only led to progressively more abundant cell-associated pffs, but two-stage
staining revealed that a substantial percentage of these fibrils were indeed intracellular (Figure 29E). Furthermore, the effects of WGA on pff uptake and tau aggregation were significantly
attenuated by adding 0.1 M GlcNAc to the medium, which reduces WGA-plasma membrane
interactions through competition with GlcNAc on the plasma membrane (Gonatas and Avrameas,
1973), suggesting that WGA-mediated induction of adsorptive endocytosis is necessary for
increased pff uptake and augmented tau aggregation (Fig. 2-S5B and Figure 2-9F,G). On the
other hand, up to 15 µg/ml of WGA does not increase the expression level of tau, nor does it
induce accumulation of insoluble tau in the absence of pffs (Fig. 2-S5A). Therefore, increased
intracellular tau aggregate formation by WGA treatment is primarily due to enhanced
internalization of pffs. Taken together, spontaneous pff entry seems to occur at least in part
through adsorptive endocytosis which can be potentiated by WGA.
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Figure 2-9. Wheat germ agglutinin (WGA) promotes pff-induced tau aggregation by
enhancing spontaneous pff uptake. (A). T40/P301L-transfected cells were incubated with
myc-K18/P301L pffs in the presence of 0, 5, 10 and15 µg/ml of WGA (0, 5, 10, 15) without
BioPORTER reagent. Increasing dose of WGA resulted in more frequent phospho-tau
aggregates. Green: PHF-1 with 1% Triton-X100 added during fixing. (B). Quantification from 3
independent experiments indicated that WGA dose-dependently increased the percentage of
cells with aggregation (Error bar: standard error; *: p < 0.05; **: p < 0.01). (C). WGA treatment
increased accumulation of Triton-insoluble tau shown on immunoblots. T: 1% Triton-X fraction;
S: 1% SDS fraction. Equal proportions of Triton and SDS fractions were loaded on SDS-PAGE.
(D). WGA also dose-dependently (0, 5, 10 and15 µg/ml) increased the amount of cell-associated
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pffs revealed by myc immunoreactivities (red). (E). Two-stage immunostaining (see method
section) performed on cells treated with 15 µg/ml of WGA showed frequent occurrence of truly
internalized pffs that were only labeled by 9E10 (green, fixed) applied to fixed and permeabilized
cells but not polyclonal anti-myc antibody incubated with live cells (red, live). Arrows point to
examples of truly intracellular pffs. (F). N-acetyl glucosamine (GlcNAc), which inhibits binding of
WGA to plasma membrane, dramatically attenuated the aggregation-enhancing effects of WGA.
(G). Quantification from 3 independent experiments showed significant reduction of tau
aggregation in WGA-treated fibril transduced cells in the presence of GlcNAc (Error bar:
standard error; *: p < 0.05). Magnification: 20x in (A) and (F); 40x in (D) and (E). Scale bars: 100
µm in (A) and (F); 50 µm in (D) and (E).

Figure 2-S5. WGA promotes pff association with cells without changing tau expression
levels. (A). Cells transiently transfected with T40/P301L mutant tau were treated with
different doses of WGA. WGA did not dose-dependently increase the expression level of tau
and there was no accumulation of Triton-insoluble tau without fibril transduction. T: 1% TritonX fraction; S: 1% SDS fraction. Equal proportions of Triton and SDS fractions were loaded on
SDS-PAGE. (B). Enhanced cellular association with pffs induced by WGA was blocked by
GlcNAc treatment. Red: Pffs recognized by polyclonal anti-myc Ab. Magnification: 40x. Scale
bar: 50 µm.
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2.4 Discussion
Our study convincingly demonstrates that exogenously supplied tau pff seeds can recruit
soluble endogenous tau into insoluble fibrillar aggregates which highly resemble NFTs based on
a variety of criteria, including immunofluorescence, amyloid dye binding, immuno-EM and
biochemical analysis. Interestingly, a small quantity of internalized tau pffs appears sufficient to
recruit and sequester large amounts of endogenous tau into filamentous tau inclusions.
Sequestration of soluble tau by pff-induced aggregation significantly attenuates MT overstabilization resulting from tau overexpression, supporting the concept that there is a reduction of
soluble tau in neurodegenerative tauopathies. Intriguingly, substantial aggregation of soluble tau
can also be induced by the spontaneous uptake of pffs, which seems to occur via adsorptive
endocytosis that is potentiated by the plant lectin WGA, demonstrating a cellular transmissibility
of tau pathology.
Although the uptake and “seeding” capacity of preformed tau fibrils in cultured cells was
reported recently (Frost et al., 2009; Nonaka et al., 2010), the induction and formation of
intracellular aggregates in our current study are fundamentally different from those previous
studies in several ways. First, the intracellular aggregates induced in our model are
morphologically different from previous studies. The inclusions we observed are clearly fibrillar in
nature and mature into β-pleated sheet rich fibrils recognized by ThS. Second, similar to tau
tangles detected in AD and other tauopathies, the intracellular aggregates exhibit a diversity of
morphologies, ranging from spatially distributed skein-like accumulations to large and densely
packed aggregates, which probably represent different stages of aggregation. Third, unlike
previous reports, detectable pff seeds rarely coincide with the intracellular inclusions in our
system; instead, the majority of aggregates that are composed of recruited, phosphorylated
endogenous tau greatly exceed the physical size of the seeds. Fourth, our use of protein delivery
reagent to augment introduction of pffs into cells provides better efficiency of tau pff entry as
compared to previous reports. Finally, unlike previous studies that expressed endogenous tau
tagged with a fluorescent protein, our system employs untagged tau which facilitates recruitment
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since the large fluorescent protein tag may interfere with the conformational change required for
efficient tau fibril assembly.
For the past 20 years, significant efforts have been devoted to produce cell-based
models that develop tau aggregates similar to those observed in tauopathies but with little
success. This is because tau is a highly soluble and naturally unfolded protein, and therefore it
has been notoriously difficult to make it aggregate in cultured cells. Strategies have been used in
the past with minimal success to produce tau tangles in cells, including overexpression of
aggregation-prone tau mutants (Vogelsberg-Ragaglia et al., 2000), overexpression of truncated
tau that fibrillizes more readily than full-length tau (Khlistunova et al., 2006; Wang et al., 2007),
addition of pre-aggregated amyloid-beta fibrils (Ferrari et al., 2003), treatment conditions that
promote tau phosphorylation (Sato et al., 2002), and the addition of aromatic dyes such as Congo
red to overcome the kinetic barrier of fibrillization (Bandyopadhyay et al., 2007). In our optimized
system, however, tau aggregation could be rapidly induced within hours after the introduction of
small quantities of misfolded tau pffs and result in the accumulation of large amounts of insoluble
tau fibrils. Thus, such robust induction of authentic NFT-like accumulations suggests that a
seeding-recruitment process is a highly plausible mechanism underlying NFT formation in vivo in
the absence of tau overexpression. Conceivably, pff-induced aggregation that occurs within
hours/days in tau-overexpressing cultured cells could be prolonged into a pathological event that
happens over years or even decades under physiological conditions, i.e. in human brains.
Although our time-course experiments which reveal close association of pff seeds with
endogenous phosphorylated tau aggregates at early time points suggest a direct physical
recruitment of soluble endogenous tau by exogenous pffs to account for the solubility change of
the former, we do not rule out possible conformational changes of soluble tau templated by
misfolded seeds before it elongates onto the existing intracellular fibrils.
Our studies also demonstrate that the formation of intracellular tau tangles can be
accelerated by FTDP-17 genetic mutations that were shown previously to increase the
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fibrillization propensity and/or reduce the MT-binding affinity of tau (Hasegawa et al., 1998; Hong
et al., 1998; Nacharaju et al., 1999; von Bergen et al., 2001). Among the FTDP-17 associated
mutations (∆K280, P301L and R406W) tested in our model, only P301L, the most aggressive
disease causing mutation found in FTDP-17 patients, dramatically promoted aggregation. This
correlates well with the rapid clinical onset and progression observed in FTDP-17 patients (Mirra
et al., 1999; Spillantini et al., 1998b; van Swieten et al., 1999) and transgenic mice harboring
P301L mutant tau (Gotz et al., 2001a; Lee et al., 2005; Lewis et al., 2000). However, unlike a
previous study that was unable to demonstrate recombinant P301L mutant tau seeding wt tau in
a cell-free system (Aoyagi et al., 2007), we found that wt and P301L mutant tau can cross-seed
each other readily, although fibril seeds composed of P301L mutant are slightly less efficient in
recruiting wt-T40 than wt seeds. In addition, the difference in aggregation propensity between wt
tau and P301L tau observed in our cellular model may be further magnified in a physiological
setting where tau is not over-expressed. This may explain the absence of insoluble wt tau
deposition in FTDP-17 patients with P301L mutation (Miyasaka et al., 2001), where the
overwhelmingly higher fibrillization propensity of P301L mutant tau could mask the much slower
aggregation of wt tau that may not occur to an appreciable extent during a short disease course.
Despite lower MT-binding affinity of T40/P301L compared with wt-T40, QBI-293 cells
transiently over-expressing T40/P301L mutant tau are still capable of MT bundling. Interestingly,
pff-induced aggregation resulted in significant attenuation of this phenotype. Reduced stable MTs
is a well-established feature of tauopathy brains (Boutte et al., 2005; Hempen and Brion, 1996;
Paula-Barbosa et al., 1987), but studies exploring the relationship between compromised MT
stability and tau aggregation were based on postmortem brain examination and therefore are only
correlative. Our study demonstrates a direct causal link between tau aggregation and reduced MT
stability, although we showed earlier that MT stability is reduced following phosphatase inhibitor
treatment of cultured neurons which increases tau phosphorylation (Merrick et al., 1997). Thus,
both tau aggregation and hyperphosphorylation could act synergistically to reduce MT stability.
Significantly, we observed a strong correlation between MT stability and the amount of soluble

41

tau, but not insoluble tau, suggesting depletion of soluble tau into fibrillar aggregates rather than
aggregates themselves are responsible for a diminution of stable MTs. Although our observations
were made in an artificial cell system with overexpression of tau, it is highly plausible that tangle
formation in human brains, where the majority of tau is normally bound to MTs for maintaining
their stability, could impair the integrity of MTs by a similar mechanism of soluble tau
sequestration. Given the critical role of MTs in axonal transport and consequently neuronal
survival, our study supports the loss-of-function hypothesis of NFT toxicity. Consistent with this
interpretation are studies demonstrating the beneficial effects of MT-stabilizing drugs in mouse
models of tauopathy without direct modulation of tau aggregation (Brunden et al., 2010; Zhang et
al., 2005).
Although our study did not address the origination of misfolded seeds in vivo, we
discovered that the amount of internalized pffs required for robust aggregation to occur was
surprisingly small and barely detectable in our system. This finding holds important implications
for tauopathies: it is conceivable that a small amount of misfolded seeds of tau slowly
accumulated over decades in post-mitotic neurons can eventually initiate a full-blown cascade of
massive aggregation of soluble tau, rendering tangle formation a self-perpetuating event once
initiated. The sonicated pffs we introduced into cells contain a heterogeneous mixture of fibrillar
species with varying dimensions, and intracellular aggregates that formed without coincident
detectable pffs were likely seeded by species that were too small to be visualized by light
microscopy. Further studies are required to characterize the exact biophysical properties of the
seeding species and to explore possible mechanisms underlying the formation of recruitmentcompetent aggregation seeds in vivo.
Consistent with recent studies pointing to the possible transmissibility of diseaseassociated amyloidogenic proteins (Aguzzi and Rajendran, 2009; Goedert et al., 2010), we found
that tau pffs alone can also induce formation of tangle-like accumulations in a substantial
population of cells, albeit to a lower extent than in the presence of protein delivery reagent. Our
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study thus complements an earlier in vivo study on the transmission of tau pathology in mouse
brains (Clavaguera et al., 2009) by implicating tau fibrils present in the brain extracts as the entity
solely responsible for the induction and spreading of tau pathology. Moreover, faster induction of
tau aggregation and easier manipulation of our cell culture model than animal models allow us to
conduct mechanistic studies that cannot be accomplished in vivo. In fact, we discovered from our
cellular system that spontaneous uptake of tau fibrils appears to occur via endocytic pathways
that are temperature- and time-dependent, and the potentiation of tau aggregate formation by
WGA treatment suggests that fibril entry is probably mediated, at least partly, by adsorptive
endocytosis. This indicates a potential mechanism through which aggregated tau released from
dying/dead neurons or from extracellular ‘ghost tangles’ may gain access into surrounding
healthy neurons where it nucleates fibrillization of soluble tau. Taken together, our study provides
further evidence for the “prion-like” properties of tau, and offers plausible explanation for the
stereotypical propagation of tau pathology in AD brains (Braak and Braak, 1991) and the
successful application of immunotherapy in ameliorating tau pathology in a mouse model (Asuni
et al., 2007). Further studies are needed to investigate whether misfolded tau can also be
routinely secreted into the extracellular space, which would provide additional insight into the
transmission cycle of tau lesions.
In summary, we have established a simple, and yet highly reproducible and robust,
cellular system of tau aggregation recapitulating key features of tauopathies. We have employed
this system to gain important insights into the onset and progression of tau pathology. Our cellbased tauopathy model not only provides an invaluable tool for studying the pathogenesis of tau
aggregation, but also offers a potential system for identifying therapeutic strategies against
neurodegenerative tauopathies, such as small molecules inhibiting fibrillization of tau or
antibodies blocking the spontaneous cellular uptake of fibril seeds.
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Table 2-1. % of aggregate-bearing cells with specific combinations of endogenous tau
transfection (Tf) and fibril transduction.
wtT40
(2N4R)

T43 (0N4R) T40/P301L T40/∆K280 T40/R406W

5’myc-K18

~8%

~8%

~20%

~5%

~6%

5’mycK18/P301L

~5%

NTa

~35%

NTa

NTa

Tf
Fibrils

a: not tested
2.5 Materials and Methods
Reagents and antibodies
BioPORTER® Quikease™ Protein Delivery Kit for fibril transduction, wheat germ
agglutinin (WGA) and N-acetyl glucosamine (GlcNAc) were purchased from Sigma. Antibodies
used in this study are listed and described in Table 2-S1.
Recombinant tau purification and in vitro fibrillization
The cDNAs coding for (1) the longest isoform of tau (2N4R) with a myc tag at the 3’ end
(3’myc-T40), (2) truncated tau containing only 4 MT-binding repeats with a myc tag at the 5’ end
(5’myc-K18) and (3) 5’myc-K18 containing P301L mutation (5’myc-K18/P301L) were cloned into
NdeI/EcoRI sites in pRK172 bacterial expression vector. Each protein was expressed in BL21
(DE3) RIL cells and purified by cationic exchange using a Fast Protein Liquid Chromatography
(FPLC) column as previously described (34). In vitro fibrillization was conducted by mixing 40 µM
recombinant tau with 40 µM low-molecular-weight heparin and 2 mM DTT in 100 mM sodium
acetate buffer (pH 7.0). Except 3’myc-T40 which was agitated at 1,000 rpm for 5 days, the other
proteins were incubated at 37°C without shaking for 2-3 days. Successful fibrillization was
confirmed using ThT fluorescence assay, sedimentation test and negative stain electron
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microscopy (Fig. 2-S1) as previously described (Li and Lee, 2006). Before being used for
transduction on cells, fibrillization mixture was centrifuged at 100,000g for 30 min at 4°C. The
resulted pellet was resuspended in equal volume of 100 mM sodium acetate buffer (pH 7.0)
without heparin and DTT, and frozen as single-use aliquots at -80°C.
Cell culture and fibril transduction
QBI-293 cells (QBiogene) were grown in full media (DMEM, 10% FBS) supplemented
with penicillin/streptomycin and L-glutamine. For fibril transduction, cells were plated at 400K/well
in a 6-well tissue culture plate one day before transient transfection with WT or mutant tau in
pcDNA5/TO or pcDNA3.1 (+) using FuGENE® 6 (Roche) as per manufacturer’s instructions at 2
µg DNA per well. About 16 hr after transfection, resuspended fibril aliquots were diluted into 10
µM using 100 mM sodium acetate buffer (pH 7.0) and sonicated with 20-30 pulses, 80 µL of
which was added to one tube of BioPORTER reagent, gently vortexed for 5 sec and allowed to
stand at room temperature (RT) for 5-10 min. During the formation of pffs/reagent complex, cells
were washed once with 2 mL OptiMEM (Invitrogen) and placed on 500 µL OptiMEM before the
fibril-reagent complex was diluted with 420 µL OptiMEM and added to cells. For experiments
performed on cells plated on 12-well plates, all reagents were reduced by half. Six to seven hr
after the addition of fibrils, cells were placed on starvation medium (DMEM, 0.5% FBS,
penicillin/streptomycin, L-glutamine) to reduce cell division, 24 hr after which they were washed
once with versene/EDTA, incubated with 0.05% trypsin/EDTA for 10 min at 37°C to remove the
majority of membrane-associated fibrils and replated to poly-D-lysine-coated glass coverslips for
immunostaining. Fixing was performed one night after replating.
For fibril-alone transduction without BioPORTER reagent, cells were placed on starvation
medium right before the addition of fibrils. Fibrils were processed in exactly the same way and the
same amount was used as in reagent-mediated transduction. Cells were trypsinized and replated
either 4 hr or 30 hr after the initial addition of fibrils. For experiments using WGA, different doses
of WGA were added to starvation medium together with pffs. To inhibit endocytosis of WGA, 0.1
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M GlcNAc was incubated with medium containing pffs and 10 µg/ml WGA for 1 hr at 37°C before
being added to cells which were pre-incubated in 0.1M GlcNAc-containing medium for 1 hr. Cells
were placed on WGA-free starvation medium 5-6 hr after fibril addition and fixed after overnight
incubation to minimize possible toxicity resulted from WGA treatment.
No replating was done for biochemical analysis except for experiments attempting to
quantify cell-associated pffs (Figure 7F) and 4 hr fibril-alone transduction experiments (Figure 7C)
in which cells were transferred to new 6-well plates after the incubation period.
Immunocytochemistry
Immunocytochemistry was performed 48 hr after the initial addition of fibrils unless
indicated otherwise. Cells were fixed in 4% paraformaldehyde (PFA) for 10 min and
permeabilized with 0.1% Triton-X100 for 15 min, or fixed with 4% PFA containing 1% Triton-X100
for 15 min to remove soluble proteins. For visualization of microtubules, cells were fixed with
0.3% glutaraldehyde in PEM buffer (80 mM PIPES, pH6.8, 5 mM EGTA, 1 mM MgCl2) for 10 min,
extracted with 1% Triton-X100 for 15 min before being quenched with 10 mg/ml sodium
borohydride for 7 min followed by 0.1 M glycine for 20 min. After blocking with 3% BSA and 3%
FBS for at least 1 hr at RT, cells were incubated with specific primary antibodies (see Table 2-S1)
for 2 hr at RT or overnight at 4°C followed by staining with appropriate Alexa fluor 594 or 488conjugated secondary antibodies (goat anti-mouse/rabbit/mouse IgG1/mouse IgG2b) for 1-3 hr at
RT. DAPI was added to PBS wash to label cell nuclei. For ThS staining, cells were incubated with
0.005% ThS for 8 min and differentiated with 70% ethanol 4 times, 5 min each.
Two-stage immunostaining was employed to distinguish between membrane-associated
and truly internalized pffs. Live cells were incubated with rabbit polycloncal anti-myc Ab diluted in
medium containing 25 mM HEPES for 1 hr at 4°C. After 3 washes with cold medium, cells were
fixed with 4% PFA and permeabilized with 0.1% Triton-X100. Following blocking, cells were
incubated with monoclonal anti-myc Ab 9E10 for 1-2 hr at RT. Rabbit myc Ab is expected to bind
to cell membrane-associated pffs only, where 9E10 would bind to both membrane-associated and
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intracellular pffs, therefore truly internalized pffs should only be recognized by 9E10 but not rabbit
myc Ab.
Epifluorescence images were acquired using Olympus BX 51 microscope (B&B
Microscopes) equipped with a digital camera DP71 (Olympus) and DP manager (Olympus).
Sequential extraction and western blot
Cells were washed once with PBS before being scraped into Triton lysis buffer (1%
TritonX-100 in 50 mM Tris, 150 mM NaCl, pH 7.6) or Sarkosyl lysis buffer (1% Sarkosyl in 50 mM
Tris, 150 mM NaCl, pH 7.6) containing protease and phosphatase inhibitors and incubated on ice
for 10-15 min. For Sarkosyl extraction, lysates were rotated at room temperature for 1 hr before
the next step. Following sonication, lysates were centrifuged at 100,000g for 30 min at 4°C.
Supernatants were kept as “Triton/Sarkosyl fraction”, while pellets were washed once in
Triton/Sarkosyl lysis buffer, resuspended and sonicated in SDS lysis buffer (1% SDS in 50 mM
Tris, 150 mM NaCl, pH 7.6). After centrifugation at 100,000g for 30 min at 22°C, supernatants
were saved as “SDS fraction”. Equal proportions of Triton/Sarkosyl and SDS fractions were
resolved on 10% SDS polyacrylamide gels, transferred to nitrocellulose membranes, and blocked
in 5% milk in TBS before probing with specific Abs (see Table 2-S1). Protein-Free block
(ThermoFisher) was used for PHF-1 blots.
Pulse chase
Reagent-mediated transduction was performed as described above. One day after
transduction, cells were placed on methionine-free medium for 15 min and then pulsed with
methionine-free medium containing [35S]-methionine (150 µCi for each well on 12-well plate) for
20 min, following which cells were switched into complete medium containing 5 mM cold
methionine and chased for different durations. During harvest, cells were washed once in HBSS
and sequentially extracted using 1% Triton-X followed by 1% SDS lysis buffer. Tau was
immunoprecipitated from cell lysates diluted in RIPA using a combination of mAbs T46 and Tau
5.
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Electron microscopy (EM)
To visualize pffs made in vitro, 6 μL unsonicated or sonicated fibrils was placed on 300
meshed Formvar/carbon film-coated copper grids (Electron Microscopy Sciences) for 3 min,
washed twice with 50 mM Tris buffer (pH 7.6) for 5 min each, stained with 10-15 drops of 2%
uranyl acetate, and visualized with Jeol 1010 transmission electron microscope (Peabody).
Immuno-EM of reagent alone treated cells and fibril transduced cells were performed as
described previously (Luk et al., 2009) using PHF-1 as the primary antibody.
Sandwich ELISA for quantifying Ac-tub and tau in cell lysates
Levels of acetylated tubulin (Ac-tub) and tau in cell lysates were quantified using
sandwich ELISA in 384-well plate format. For Ac-tub ELISA, tubulin mAb 12G10 was used as the
capture antibody, and horseradish peroxidase (HRP)-conjugated Ac-tub mAb was used as the
reporting antibody. Standard curves were generated using serially diluted brain lysates from wt
mouse. 18 μg of cell lysates diluted in EC buffer (0.02 M sodium phosphate buffer pH7.0, 2mM
EDTA, 0.4M NaCl, 0.2% BSA, 0.05% CHAPS, 0.4% Blockace, 0.05% NaN3) was loaded to each
well and incubated overnight at 4°C. On the following day, after 4 hr incubation with reporting
antibody at room temperature, trimethy benzidine (TMB) peroxidase substrate solution was
added and the plate was read using SpectraMax at 450 nm absorbance. For quantifying tau in
Triton and SDS fractions, cell lysates from sequential extraction were diluted 1,000 times in EC
buffer. Serially diluted recombinant human T40 was used to generate standard curves. 30 μL of
diluted samples were loaded into each well of the plate coated with capture antibody Tau 5. After
overnight incubation at 4°C, captured proteins were reported using biotin-labeled BT2 and HT7
which were left to incubate overnight at 4°C. On the next day, following 1 hr incubation with HRPconjugated streptavidin at 25°C, the plate was developed using TMB peroxidase substrate
solution.
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Quantifications and statistical analysis
For quantifying % of cells developing tau aggregates with different combinations of
endogenous tau and pffs, 10-20 random-field images were taken at 40x magnification for each
combination and at least two independent experiments were performed. For quantification of MTbundling and pff alone-induced tau aggregation under various conditions (i.e. different
temperatures, with or without WGA/GlcNAc), 10 random-field images were taken at 20x
magnification for each condition in each experiment and 3-4 independent experiments were
performed. Two-tailed paired student’s t-test was used for all the comparisons in the study and
differences with p values less than 0.05 were considered significant.
2.6 Supplementary Materials
Table 2-S1. Antibodies used in Chapter 2.
Antibody

Specificity

Host species

Dilution

Source

17025

Human
recombinant tau

rabbit
polyclonal

1:1000 (WB, ICC)

(Ishihara et al.,
1999)

PHF-1

p-Tau
(phosphorylated
at Ser 396 and
404)

mouse
monoclonal

1:1000 (WB,
immuno-EM); 1:2000
(ICC)

(Otvos et al.,
1994)

AT8

p-Tau
(phosphorylated
at Ser 202)

mouse
monoclonal

1:500 (ICC)

Innogenetics

MC-1

Tau in the
pathological
conformation

mouse
monoclonal

1:500 (ICC)

Gift from Dr. Peter
Davies Lab

Gift from Dr.
Lester Binder Lab

Pierce (Thermo
Scientific)

Tau 5

Tau (210230aa)

mouse
monoclonal

5ug/ml as capture
antibody in tau
ELISA; 6ug for
immunoprecipitating
tau from ~100ug
protein

biotinylated
BT2

Tau (194198aa)

mouse
monoclonal

125ng/ml as
reporting antibody in
tau ELISA together
with HT7
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biotinylated
HT7

Tau (159163aa)

mouse
monoclonal

125ng/ml as
reporting antibody in
tau ELISA together
with BT2

Pierce (Thermo
Scientific)

T46

Tau (404441aa)

mouse
monoclonal

11ug for
immunoprecipitating
tau from ~100ug
protein

(Kosik et al.,
1988)

myc 9E10

myc tag

mouse
monoclonal

1:1000 (WB, ICC)

Developmental
Studies
Hybridoma Bank
(DSHB)

Anti-c-myc

c-myc tag

rabbit
polyclonal

1:5000 (regular ICC);
1:1000 (live staining)

Sigma

GAPDH
(6C5)

Glyceraldehyde3-phosphate
dehydrogenase

mouse
monoclonal

1:3000 (WB)

Advanced
Immunochemical

12G10

tubulin

mouse
monoclonal

10ug/ml as capture
antibody in Ace-tub
ELISA

DSHB

Acetylated
tubulin (6-11
B-1)

Acetylatedtubulin

mouse
monoclonal

1:4000 (ELISA);
1:1000 (ICC)

Sigma
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CHAPTER 3: NEUROFIBRILLARY TANGLE-LIKE TAU PATHOLOGY INDUCED BY
SYNTHETIC TAU FIBRILS IN PRIMARY NEURONS OVER-EXPRESSING MUTANT
TAU*
*This study was originally published in FEBS letters. Guo, J.L., and Lee, V.M. Neurofibrillary
tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing
mutant tau. FEBS letters. doi: 10.1016/j.febslet.2013.01.051. © Elsevier
3.1 Abstract
Increasing evidence demonstrates the transmissibility of fibrillar species of tau protein,
but this has never been directly tested in neurons, the cell type most affected by formation of tau
inclusions in neurodegenerative tauopathies. Here we show that synthetic tau fibrils made from
recombinant protein not only time-dependently recruit normal tau into neurofibrillary tangle-like
insoluble aggregates in primary hippocampal neurons over-expressing human tau, but also
induce neuritic tau pathology in non-transgenic neurons. This study provides highly compelling
support for the protein-only hypothesis of pathological tau transmission in primary neurons and
describes a useful neuronal model for studying the pathogenesis of tauopathies.
3.2 Introduction
Tau, a microtubule-binding protein enriched in axons, accumulates into intracellular
hyperphosphorylated aggregates known as neurofibrillary tangles (NFT) in a wide variety of
neurodegenerative diseases, including Alzheimer’s disease, frontotemporal dementia with
Parkinsonism linked to chromosome 17, progressive supranuclear palsy, corticobasal
degeneration and Pick’s disease, which are collectively termed neurodegenerative tauopathies
(Ballatore et al., 2007). It has always been enigmatic what initiates the conversion of tau from a
highly soluble protein without defined secondary structure into insoluble beta-sheet rich fibrils.
Recently, numerous studies have shown that exogenously supplied pathological tau, including
synthetic tau fibrils, can drive soluble tau into tangle-like inclusions in both cell culture systems
and mouse models (Clavaguera et al., 2009; Frost et al., 2009; Guo and Lee, 2011; Iba et al.,
2013; Nonaka et al., 2010), implicating a seeding-recruitment process as well as cell-to-cell
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transmission of pathology as possible underlying mechanisms for the initiation and progression of
tauopathies. Similar results have been demonstrated for other amyloidogenic proteins, such as βamyloid and α-synuclein (α-syn) (Eisele et al., 2010; Luk et al., 2012a; Luk et al., 2012b; Stohr et
al., 2012; Volpicelli-Daley et al., 2011), therefore suggesting a unifying pathogenic mechanism for
neurodegenerative diseases involving protein aggregation.
We previously found that synthetic tau fibrils can spontaneously enter non-neuronal cells
and recruit normal tau into pathological accumulations (Guo and Lee, 2011), but it was unclear
whether this phenomenon could also happen in post-mitotic neurons, which are the more relevant
cell type for studying tauopathies. While a recent study from our lab showed that intracerebral
inoculation of preformed tau fibrils (tau pffs) into transgenic (Tg) mice overexpressing human
mutant P301S tau (PS19) dramatically accelerated development of tau pathology (Iba et al.,
2013) thereby providing in vivo evidence for transmissibility of synthetic tau fibrils, a study in
cultured neurons would provide an in vitro system more amenable for mechanistic interrogations
and investigation of novel therapies. Here, we demonstrate that synthetic tau fibrils made from
recombinant protein triggered robust aggregation of otherwise soluble endogenous tau into NFTlike inclusions in primary neurons dissociated from embryonic mouse hippocampus.
3.3 Results
Despite the over-expression of human tau harboring P301S mutation, primary
hippocampal neurons dissociated from PS19 mouse embryos showed phosphorylated tau
recognized by AT8 that remained Triton X-100 soluble up to 24 d

in vitro (Figure 3-1A).

Remarkably, addition of tau pffs consisting of only the MT-binding domain with P301L mutation
(myc-K18/P301L) to neuron medium at 6 d in vitro , without any transduction reagent, led to
robust accumulation of phosphorylated tau throughout soma and neurites that resisted detergent
extraction at 18 d post-transduction (24 d in vitro) (Figure 3-1A). In addition, perikaryal
aggregates in pff-treated neurons were intensely labeled by disease-specific conformational
antibody MC-1 (Jicha et al., 1997), indicating pathological conformation acquired by pff-induced
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aggregates. Higher magnification images revealed AT8 and MC-1 labeled inclusions as bundles
of aggregates highly reminiscent of NFTs filling up the soma of a subset of neurons (Figure 31B). Since both AT8 and MC-1 recognize epitopes absent from myc-K18/P301L pffs and pfftransduced tau knock-out neurons displayed no immunoreactivity for any tau antibodies tested
(Figure 3-S1 and Figure 3-3C), the observed tau aggregates in PS19 neurons must represent
fibrillization of endogenous full-length tau seeded by exogenous pffs that spontaneously entered
neurons. Furthermore, K18/P301L pffs without a myc tag also induced widespread accumulation
of pathological tau within the same time frame, ruling out non-specific effects associated with the
tag (Figure 3-S2).
Pff-induced solubility change of endogenous tau was further assessed by sequentially
extracting pff-transduced neurons as well as PBS-treated control neurons into Triton X-100 lysis
buffer followed by SDS lysis buffer and immunoblotting with different tau antibodies. Prominent
Triton-soluble tau was present in PBS- and pff treated cultures but SDS-soluble tau was
recovered only in pff-transduced neurons (Figure 3-1C).
Ultrastructural analysis using routine transmission EM revealed cytoplasmic filaments in
neurons treated with pffs (Figure

3-2A) but not in PBS-treated control neurons (data not

shown). Immuno-EM with both HRP-labeling and nanogold-amplification demonstrated MC-1
immunoreactivity of pff-induced fibrillar accumulations, further supporting the recruitment of
endogenous full-length tau into NFT-like filamentous aggregates (Figure 3-2B and C).
A time-course analysis demonstrated that the prevalence of aggregate-bearing cells
increased over time, from sparse distribution at 6 d post-pff addition to about 20% of neurons
carrying perikaryal aggregates at 18 d post-transduction (Figure 3-3A). Moreover, diffuse tau
accumulations seen as punctate AT8 and MC-1 immunoreactivity at 6 d turned into densely
packed aggregates at 12 d (Figure 3-3B), while NFT-like aggregate bundles described earlier
were only observed at 18 d post-transduction (Figure 3-1C). The progressive augmentation in
insoluble tau aggregates was also evident on immunoblots of sequentially extracted neuron
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lysates at different time points with about 33% of total human tau sequestered into Tritoninsoluble fraction at 18 d post-transduction (Figure 3-3C).

Figure 3-1. Insoluble tau accumulated in PS19 primary hippocampal neurons after
incubation with myc-K18/P301L pffs. (A) PS19 neurons treated with PBS (PBS control) or
myc-K18/P301L fibrils (pff Td) were immunostained with phospho-tau mAb AT8 and
conformational mAb MC-1 with or without 1% Triton-X100 extraction during fixing (ext, no ext,
respectively). DAPI staining was used to visualize nuclei (blue). Scale bar: 100 µm. (B)
Perikaryal tau aggregates recognized by AT8 and MC-1. Scale bar: 50 µm. (C) Neurons treated
with PBS or myc-K18/P301L fibrils (pff) were sequentially extracted with 1% Triton-X100 lysis
buffer (T) followed by 1% SDS lysis buffer (S) and immunoblotted with AT8, polyclonal antibody
against total tau (17025), and mAb against human tau (T14). GAPDH served as loading control.
Results from two independent sets of neurons were shown.
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Figure 3-S1. Primary hippocampal neurons from tau knock-out mice transduced with tau
pffs showed no immunoreactivity for various tau antibodies. Cell nuclei were visualized
using DAPI staining (blue). 1% Triton-X was added to 4% PFA during fixing to remove soluble
proteins. Scale bar: 50µm.

Figure 3-S2. Non-tagged K18/P301L fibrils also induced extensive tau aggregation
throughout cell bodies and neurites of PS19 neurons. Soluble proteins were removed by 1%
Triton-X during fixing and neurons were double-labeled with polyclonal antibody for total tau
(17025) and antibody specific for neuronal nuclei (NeuN). Scale bar: 50µm.
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Figure 3-2. Ultrastructural analysis of tau pff-induced aggregates by EM and immuno-EM.
Routine EM (A) revealed filamentous structures in the cytoplasm of tau pff transduced neurons,
which were recognized by MC-1 in immuno-EM using both HRP-labeling (B) and nanogoldamplification (C) detecting methods. Scale bar: 500 nm.

Interestingly, early inclusions did not contain endogenous mouse tau recognized by mAb
T49, which appeared at 12 d post-pff transduction and became more abundant after 18 d
incubation in aggregates co-labeled with polyclonal tau antibody 17025 that preferentially
recognizes human tau on immunostaining (Figure 3-3D). Therefore, mouse tau can be recruited
into pff-seeded aggregates although the process occurred more slowly compared to over-
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expressed human tau. Unlike immunostaining by human tau specific mAb T14 which completely
overlapped with 17025 staining (Figure 3-S3), mouse tau immunoreactivity only partially
colocalized with that of 17025 even at 18 d post-transduction (Figure 3-3D), suggesting not all
inclusions contained misfolded mouse tau. The time-dependent emergence of insoluble mouse
tau was also detected on immunoblot, although the insoluble pool only constituted a very small
fraction of total mouse tau (Figure 3-3C).
The differential seeding capacity of wt versus mutant and truncated versus full-length tau
pffs was compared in PS19 neurons. Full-length tau pffs carrying P301S mutation (mycT40/P301S pffs) were similarly efficient as myc-K18/P301L pffs (Figure 3-4A and B). In contrast,
wt tau pffs, both full-length and truncated (myc-T40 and myc-K18), demonstrated significantly
lower seeding efficiency with especially pronounced reduction in neuritic pathology than mutant
pffs, although myc-T40 pffs appeared to be slightly more potent than myc-K18 pffs (Figure 3-4A
and B).
Myc-K18 and myc-K18/P301L pffs were also tested in non-Tg primary neurons for their
capability to seed endogenous mouse tau fibrillization without over-expressed human mutant tau.
Interestingly, wt myc-K18 pffs, but not mutant myc-K18/P301L pffs, were able to induce punctate
accumulations of insoluble mouse tau in the neurites of non-Tg neurons after 18 d incubation
(Figure 3-4C). Notably, the amount of tau inclusions induced in non-Tg neurons was highly
limited as compared to that observed in PS19 neurons, most likely owing to lack of tau overexpression and mutation. In addition, unlike pff-induced tau pathology that were throughout the
soma and processes of PS19 neurons, mouse tau aggregation was never found in the soma of
pff-transduced non-Tg neurons, likely due to predominant expression of endogenous tau in the
axons.
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Figure 3-3. Time-dependent increase in pff-induced tau pathology and recruitment of mouse tau into
aggregates. (A) Increasing population of cells developed tau pathology from 6 d to 18 d incubation after pff
addition. Green: AT8. Blue: DAPI. Scale bar: 100 µm. (B) Morphological difference between 6 d and 12 d
post-transduction aggregates immunostained with AT8 and MC-1. Scale bar: 50 µm. (C) Sequentially
extracted PS19 neuron lysates at different time points after pff addition (6 d, 12 d, 18 d) or at 18 d after PBS
treatment (PBS) and tau knock-out neuron lysates (tau KO) at 18 d post-addition of PBS or pffs were
immunoblotted with AT8, 17025, T14 as well as mAb specific for mouse tau (T49). (D) Double-labeling of
aggregates by T49 and 17025 at different time points after pff addition. Scale bar: 50 µm. For (A), (B) and
(D), soluble proteins were removed by 1% Triton-X100 during fixing.
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Figure 3-S3. Double-labeling of insoluble tau aggregates. Triton-insoluble tau aggregates
induced by tau pffs were double labeled with total tau antibody (17025) and human tau specific
antibody (T14). Scale bar: 50µm.
3.4 Discussion
The current study demonstrated induction of robust tau aggregation inside primary
neurons by the simple addition of synthetic tau fibrils to neuronal culture medium without any
transduction reagent, suggesting that the previously described phenomenon of spontaneous
uptake of fibrillar tau and templated conversion of normal tau into pathological aggregates (Frost
et al., 2009; Guo and Lee, 2011; Nonaka et al., 2010) is also applicable to neurons, the cell type
most relevant for neurodegenerative tauopathies. Importantly, pff-induced tau aggregation also
occurred in non-Tg neurons in the absence of over-expression, albeit to a much less extent than
in PS19 neurons which over-express mutant tau, suggesting that the seeding-recruitment process
can indeed take place at physiological conditions and underlie the etiology of NFT formation in
tauopathies.
As a highly soluble protein, tau resists aggregation under normal conditions. It was
therefore a breakthrough in the field when polyanionic cofactors, such as heparin, RNA, and fatty
acids, were found to greatly promote in vitro fibrillization of tau (Chirita et al., 2003; Goedert et al.,
1996; Kampers et al., 1996). Even though preformed tau fibrils can dramatically accelerate the
kinetics of in vitro fibril assembly by acting as seeds, efficient seeding reaction still requires the
presence of cofactors (Friedhoff et al., 1998). Curiously, tau pffs alone are sufficient to drive
aggregation of soluble tau inside the cells without the addition of any cofactor, especially
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Figure 3-4. Differential seeding capacity of distinct forms of tau pffs on PS19 and non-Tg
primary neurons. (A) Tau pathology (green: AT8) induced in PS19 neurons by myc-K18, mycK18/P301L (myc-K18/PL), myc-T40 and myc-T40/P301S (myc-T40/PS) fibrils. Scale bar: 100
µm. (B) Quantification of percentage area occupied by AT8-positive pathology induced by the
different pffs (mean + SEM). Number of independent sets of PS19 neurons tested: n = 2 for mycK18, n = 3 for the other three. *: < 0.05. **: < 0.005. (C) Transduction of myc-K18 but not mycK18/P301L pffs on non-Tg neurons resulted in neuritic tau pathology (green: AT8). Scale bar: 50
µm. For both (A) and (C), soluble proteins were removed by 1% Triton-X100 during fixing.
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considering the fact that pffs we added to neurons were re-suspended in heparin-free buffer.
Therefore, intracellular environment appears to be more permissive for seeded fibrillization than a
cell-free system. Consequently, while polyanionic cofactors may catalyze the initial formation of
misfoded tau seeds in human brains, their involvement in NFT genesis may not be obligatory,
since seeded fibrillization of tau is a self-perpetuating process in cells once pathological
conformers are generated.
Although mutant tau pffs resulted in dramatically more abundant pathology than wt tau
pffs in PS19 neurons overexpressing mutant tau, they showed even lower seeding capacity than
wt pffs in non-Tg neurons expressing wt mouse tau. The asymmetrical seeding between wt and
P301L mutant tau was also observed in our previous non-neuronal model albeit less dramatically
(Guo and Lee, 2011). Together with the finding that NFTs in human patients harboring P301L
mutation are nearly exclusively composed of mutant tau (Miyasaka et al., 2001), these studies
point to possible conformational disparities between wt and mutant tau fibrils. Since we have
never detected obvious differences in the morphologies of the two types of fibrils at EM level, we
speculate any structural differences are likely more subtle as suggested by a previous study
(Aoyagi et al., 2007).
Interestingly, full-length wt tau (myc-T40) pffs showed a tendency to seed better than
truncated wt (myc-K18) pffs despite equal mass thus a lower molarity of the former being added
to PS19 neurons. In our previous study when transduction reagent was used to facilitate pff
uptake in non-neuronal cells (Guo and Lee, 2011), wt T40 pffs actually demonstrated less
efficient seeding than wt K18 pffs (unpublished data), therefore the observed difference between
full-length and truncated tau pffs in primary neurons is probably not due to differential recruiting
capacity per se, but possibly due to more efficient uptake of full-length pffs. With the N-terminus
of tau was shown to be critical for extracellular secretion (Kim et al., 2010), it would be interesting
to explore whether the same domain is playing a role in the uptake of fibrillar tau into neurons.
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Unlike the recently developed neuronal model of synucleinopathy in which robust Lewy
body- and Lewy neurite-like accumulations composed of mouse α-syn can be induced in non-Tg
neurons by α-syn pffs (Volpicelli-Daley et al., 2011), low abundance of tau aggregates form upon
wt tau pff transduction on non-Tg neurons. The difference could be attributed to several reasons.
First, non-Tg mice naturally express α-syn of the A53T variant which is a pathogenic mutation in
human. Not only does A53T mutation greatly enhance fibrillization of α-syn (Conway et al.,
2000a), but mouse α-syn even fibrillizes much more readily than human α-syn carrying the A53T
mutation (unpublished data). Lack of such a “natural” mutation in mouse tau limits the extent of
tau pathology that can develop within our experimental time window. Second, α-syn is highly
concentrated at presynaptic terminals in mature neurons (Murphy et al., 2000) and the local high
concentration probably facilitates efficient recruitment by internalized pff seeds. In contrast, tau is
more diffusely located throughout axons in non-Tg neurons. Third, the adult isoform of tau with
four repeats (4R) only constitutes a small fraction of total tau in developing neurons (Dotti et al.,
1987; Ferreira et al., 1997), while the predominantly expressed 3R-tau has lower propensity to
aggregate than 4R-tau (Zhong et al., 2012) in addition to a seeding barrier between 3R- and 4Rtau as previously reported (Dinkel et al., 2011). Nonetheless, seeding endogenous mouse tau in
non-Tg neurons provides a more physiological system for studying tau aggregation and pathology
spreading.
In summary, our study directly demonstrates the transmissibility of fibrillar tau in neurons,
thereby presenting a neuronal model suitable for both mechanistic studies on the pathogenesis of
NFTs and therapeutic investigation to identify drugs that can reverse or prevent tau pathology.
3.5 Materials and Methods
Recombinant Tau Purification and in Vitro Fibrillization Assays
The cDNAs coding for (1) the longest isoform of wildtype (wt) human tau with a myc tag
at the 3’ end (myc-T40), (2) truncated human tau containing four MT-binding repeats with a myc
tag at the 5’ end (myc-K18), (3) 3’myc-T40 with P301S mutation (myc-T40/P301S), (4) 5’myc-
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K18 containing P301L mutation (myc-K18/P301L) were cloned into pRK172 bacterial expression
vector. Each protein was expressed in BL21 (DE3) RIL cells and purified by cationic exchange
using a Fast Protein Liquid Chromatography (FPLC) as previously described (Li and Lee, 2006).
For in vitro fibrillization, 40 µM recombinant tau was incubated with 40 µM low-molecularweight heparin and 2 mM DTT in 100 mM sodium acetate buffer (pH 7.0) at 37°C. Myc-T40 and
myc-T40/P301S were agitated at 1000 rpm for 5 to 7 d and 1 d respectively, but myc-K18 and
myc-K18/P301L were incubated without agitation for 2-3 d. Before they were used for
transduction in neurons, fibrillization mixtures were centrifuged at 100,000 g for 30 min at 22°C,
and the resulted pellet was re-suspended in equal volume of 100 mM sodium acetate buffer (pH
7.0) without heparin and DTT. Successful fibrillization was verified by sedimentation test, ThT
test and negative stain EM.
Primary Neuron Cultures and Fibril Transduction
Primary neuron cultures were prepared from E15-E17 embryos from het/het or homo/het
crosses of PS19 mice (Yoshiyama et al., 2007), non-Tg CD1 mice (Charles River, Wilmington,
MA) and tau knock-out mice (Dawson et al., 2001). Dissociated hippocampal neurons were
plated onto poly-D-lysine coated 13 mm coverslips or 6-well plates. Pff transduction was
performed at 6 d in vitro, whereby tau pffs were diluted in PBS and sonicated with 60 pulses
before being added to neuron medium. Neurons on each coverslip received 1.5 µg of tau pffs
and those on the 6-well plate received 6 µg of pffs per well. Transduced neurons were
harvested for immunocytochemistry or sequential extraction at 18 d post-pff transduction unless
otherwise indicated.
Immunocytochemistry
Neurons were fixed in 4% paraformaldehyde (PFA) containing 2% sucrose for 15 min
and permeabilized with 0.1% Triton-X100 for 15 min, or fixed with 4% PFA containing 2%
sucrose and 1% Triton-X100 for 15 min to remove soluble proteins. After blocking with 3% BSA
and 3% FBS for at least one hour at RT, neurons were incubated with specific primary
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antibodies (Supplementary Table 1) overnight at 4°C followed by staining with appropriate Alexa
fluor 594 or 488-conjugated secondary antibodies (Invitrogen; Carlsbad, CA) for 2 hr at RT.
DAPI was added to PBS wash after secondary antibody incubation to label cell nuclei.
Quantification for area occupied by pff-induced pathology was performed on 20x images using
Image J (National Institute of Health).
Sequential Extraction and Western Blot Analysis
Neurons were scraped into Triton lysis buffer (1% TritonX-100 in 50 mM Tris, 150 mM
NaCl, pH 7.6) containing phosphatase and protease inhibitor cocktail, sonicated, and
centrifuged at 100,000 g for 30 min at 4°C. Pellets were washed once in Triton lysis buffer, resuspended into SDS lysis buffer (1% SDS in 50 mM Tris, 150 mM NaCl, pH7.6) at a volume that
is ¼ of the Triton lysis buffer and centrifuged at 100,000 g for 30 min at 22°C. Supernatants from
Triton and SDS extractions were resolved on SDS-PAGE, transferred to nitrocellulose
membranes, and blocked in 5% milk or 7.5% BSA in TBS before immunoblotted with specific
antibodies (Supplementary Table 1). 10 µg of proteins from Triton fractions and equal volume of
corresponding SDS fractions were loaded per lane.
Electron Microscopy (EM)
Negative stain transmission EM (TEM) of tau pffs, TEM and immuno-EM of pff
transduced primary hippocampal neurons were performed as previously described (Guo and Lee,
2011; Volpicelli-Daley et al., 2011). Monoclonal antibody (mAb) MC-1 was used in the immunoEM of neurons.
Table 3-S1. Antibodies used in Chapter 3.
Antibody

17025

Specificity

Host species

Dilution

Source or
Reference

Human recombinant tau

rabbit
polyclonal

1:1000 (WB),
1:5000 of
affinity purified
(ICC)

(Ishihara et al.,
1999)
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AT8

p-Tau (phosphorylated at
Ser 202 and Thr 205)

mouse
monoclonal

1:1000 (WB),
1:500 (ICC)

Innogenetics

MC-1

Tau in the pathological
conformation

mouse
monoclonal

1:500 (ICC)

Gift from Dr.
Peter Davies
Lab

GAPDH
(6C5)

Glyceraldehyde-3phosphate
dehydrogenase

mouse
monoclonal

1:3000 (WB)

Advanced
Immunochemical

T14

Human tau

mouse
monoclonal

1:1000 (WB,
ICC)

(Kosik et al.,
1988)

T49

Mouse tau

mouse
monoclonal

1:1000 (WB,
ICC)

(Ishihara et al.,
2001)
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CHAPTER 4: Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in
Neurons*
*This study was submitted on Jan 28, 2013. Guo, J.L., Covell, D., Daniels, J., Iba, M., Stieber, A.,
Zhang, B., Trojanowski, J.Q., and Lee, V.M. Distinct α-Synuclein strains differentially promote tau
inclusions in neurons.
4.1 Abstract
Many neurodegenerative diseases are characterized by the accumulation of insoluble
protein aggregates, including neurofibrillary tangles composed of tau in Alzheimer’s disease and
Lewy bodies composed of α-synuclein in Parkinson’s disease. Moreover, different pathological
proteins frequently co-deposit in the same degenerating brains. To test whether pathological αsynuclein can

directly cross-seed tau fibrillization, we employed recently developed

synucleinopathy models in primary neurons and transgenic mice based on the administration of
preformed α-synuclein fibrils assembled from recombinant protein to induce disease pathology.
Remarkably, we discovered two distinct strains of synthetic α-synuclein fibrils which
demonstrated striking differences in the efficiency of cross-seeding tau aggregation, both in
neuron cultures and in vivo. Proteinase K digestion and further biochemical analyses revealed
conformational differences between the two strains, which were generated through repetitive
seeded fibrillization in vitro. We speculate that different strains of pathological α-synuclein likely
exist in nature and may underlie the tremendous heterogeneity of synucleinopathies.
4.2 Introduction
A common feature of many neurodegenerative diseases is the accumulation of normally
soluble proteins into filamentous insoluble aggregates, including neurofibrillary tangles (NFTs)
composed of tau in Alzheimer’s disease (AD) and frontotemporal degeneration (Goedert et al.,
1988; Lee et al., 1991; Lee et al., 2001), and Lewy bodies (LB) composed of α-synuclein (α-syn)
in Parkinson’s disease (PD) and dementia with LB (DLB) (Baba et al., 1998; Spillantini et al.,
1997). Both tau and α-syn are natively unfolded proteins without well-defined secondary or
tertiary structures (Cleveland et al., 1977a; Eliezer et al., 2001; Schweers et al., 1994; Weinreb et
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al., 1996). While tau is a microtubule-binding protein which stabilizes and promotes microtubule
assembly in the axon (Drechsel et al., 1992; Witman et al., 1976), α-syn is a phospholipid-binding
protein highly concentrated in the presynaptic terminals where it is shown to promote SNARE
complex formation and modulate synaptic functions (Burre et al., 2010; Cabin et al., 2002; Iwai et
al., 1995a; Murphy et al., 2000). Although the exact mechanisms whereby tau and α-syn
aggregates induce neurodegeneration are not fully understood, they are thought to contribute to
neuronal dysfunction and death through loss of normal functions and/or toxic gains of functions
(Ballatore et al., 2007; Goedert, 2001).
How normally soluble proteins undergo conformational changes to become insoluble and
form aggregates is a long-standing mystery. However, there is increasing evidence that robust
aggregation of disease-associated proteins, including tau and α-syn, can be induced by
exogenously supplied preformed fibrils (pffs) in cultured cells, as well as in living animals (Frost et
al., 2009; Guo and Lee, 2011; Iba et al., 2013; Luk et al., 2012a; Luk et al., 2012b; Luk et al.,
2009; Volpicelli-Daley et al., 2011). These studies suggest that small amounts of misfolded
protein can act as seeds to initiate templated recruitment of their soluble counterparts into fibrillar
structures. Moreover, cell-to-cell transmission of these amyloid protein aggregates are strongly
implicated as an underlying mechanism for the stereotypical spatiotemporal progression of both
AD and PD pathologies (Braak and Braak, 1991; Braak et al., 2002; Braak et al., 2003).
Another recurrent theme of neurodegenerative diseases is the frequent co-occurrence of
different disease protein aggregates in the same patient as exemplified by the fact that >50% of
AD cases show LB pathologies (Hamilton, 2000; Jellinger, 2003; Kotzbauer et al., 2001; Lippa et
al., 1998), while co-morbid AD pathologies, including Aβ plaques and NFTs, are also commonly
found in PD and DLB cases (Gomez-Tortosa et al., 2000; Ince et al., 1991; McKeith et al., 1996).
This phenomenon could be explained by global dysregulation of protein homeostasis in disease
brains, whereby misfolding of one major protein overwhelms the proteostatic machinery and
compromises the folding of other aggregation-prone proteins (Gidalevitz et al., 2006; Kikis et al.,
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2010). Alternatively or additionally, filamentous aggregates composed of one protein may directly
cross-seed other amyloidogenic proteins owing to potentially shared structural features of amyloid
fibrils (Kayed et al., 2007; O'Nuallain and Wetzel, 2002). Indeed, we showed earlier that α-syn
and tau synergistically promote the fibrillization of each other in a cell-free system as well as in
transgenic (Tg) mice (Giasson et al., 2003), while more recently α-syn pffs were shown to induce
tau aggregation in cultured non-neuronal cells (Waxman and Giasson, 2011). To confirm this
cross-seeding phenomenon in physiologically more relevant systems, we utilized recently
developed synucleinopathy models in primary neurons and Tg mice, in which exogenously added
α-syn pffs promote the recruitment and aggregation of endogenous α-syn (Luk et al., 2012b;
Volpicelli-Daley et al., 2011). Remarkably, our study led to the discovery of two distinct “strains” of
synthetic α-syn pffs generated in vitro that exhibited striking differences in the efficacy of tau
cross-seeding, which we ascribe to divergent conformations between the two strains of pffs as
revealed by biochemical analyses.
4.3 Results
Generation of different strains of α-syn pffs with differential cross-seeding of tau
To investigate whether α-syn pffs can cross-seed tau in primary neurons, we incubated
hippocampal neurons generated from mouse embryos overexpressing human mutant P301S tau
(PS19) with α-syn pffs assembled de novo from Myc-tagged C-terminal truncated 1-120
monomers (1-120-Myc). At 18 d post transduction, highly abundant LB and Lewy-neurite (LN) like
α-syn inclusions that are resistant to Triton-X100 extraction were observed throughout the
cultured neurons (see Figure 4-1A top panel). However, Triton-insoluble hyperphosphorylated tau
aggregates were only infrequently found in neuronal processes and rarely colocalized with α-syn
pathology, suggesting their formation is likely an indirect consequence of α-syn accumulation
rather than a direct result of cross-seeding by α-syn. In neurons derived from non-Tg mice, no
appreciable tau aggregates were induced (Figure 4-1A, bottom panel).

68

Figure 4-1. Generation of different strains of α-syn pffs with differential cross-seeding of tau in
neurons. (A) Accumulations of insoluble phospho-α-syn (81A) and phospho-tau (AT8) induced by de novo
1-120-Myc pffs (strain A) in primary hippocampal neurons dissociated from PS19 mouse embryos overexpressing human tau with P301S mutation or from non-Tg mouse embryos. (B) Schematic diagram for
procedures of repetitive seeded fibrillization in vitro which resulted in evolution of strain A pffs into strain B
and post-B strains. (C) α-syn and tau pathologies caused by seeded 1-120-Myc pffs (strain B) in PS19 and
non-Tg neurons. (D) Phenotypic changes in α-syn and tau pathologies induced by wt full-length α-syn pffs of
different self-seeding passages. For (A), (C) and (D), neurons were fixed 18 d after the initial addition of pffs
and 1% Triton-X100 was added to 4% PFA during fixing to remove soluble proteins. Scale bar: 50 μm. See
also Figure 4-S1.
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Remarkably, a very different pattern of Triton-insoluble α-syn and tau inclusions was
observed in neurons treated with a preparation of 1-120-Myc pffs generated through repetitive
seeded fibrillization in vitro, whereby 5 or 10% of pffs from each passage were included as seeds
in the fibrillization reaction of the subsequent passage (Figure 4-1B). While α-syn pathology was
somewhat less abundant in the 18 d post-transduction culture as compared to that transduced
with the de novo 1-120-Myc pffs, widespread fibrillar tau aggregates that extensively colocalized
with neuritic α-syn inclusions were observed in both PS19 and non-Tg neurons (Figure 4-1C).
Surprisingly, the extent of endogenous mouse tau pathology induced in non-Tg neurons by these
α-syn pffs dramatically exceeded that induced by synthetic tau pffs as reported recently (Guo and
Lee, 2013). To distinguish the two types of α-syn pffs that exhibit distinct seeding properties in
neurons and hence are reminiscent of prion “strains”, we designate pffs with limited crossseeding ability of tau, which were used in all our previous α-syn transmission studies (Luk et al.,
2012b; Luk et al., 2009; Volpicelli-Daley et al., 2011), as strain A, and the newly discovered pffs
with efficient cross-seeding of tau as strain B (Table 4-S2). The generation of strain B through
repeated self-seeding in vitro was reproduced using several different batches of 1-120-Myc
monomer, as confirmed by a phenotypic transition from a relative paucity of insoluble tau in early
passages to the appearance of robust tau pathology induced by later passages of 1-120-Myc pffs
(Figure 4-S1A).
To test whether wild type (wt) full-length (FL) α-syn can also form strains A and B α-syn
fibrils, non-Tg neurons were incubated for 18 d with FL α-syn pffs generated de novo (P1) or
through repetitive self-seeding in vitro (P2 onwards) (Figure 4-1B). P1 pffs always behaved as
strain A, resulting in profuse α-syn inclusions with minimal tau aggregation (Figure 4-1D). FL αsyn pffs of subsequent passages led to diminishing α-syn pathology with small amounts of
neuritic tau pathology first emerging in neurons transduced with P4 or P5 pffs, followed by full
conversion to strain B that induces abundant tau pathology usually by P6 or P7 (Figure 4-1D).
Such conversion of FL α-syn pffs from strain A towards strain B through repeated self-seeding in
vitro was accomplished using four different batches of FL α-syn monomer, although this process
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did not always give rise to prototypical strain B pffs that are defined by extensive colocalization
between α-syn and tau pathologies in transduced neurons. An intermediate phenotype with
relatively abundant tau pathology accompanied by far more abundant α-syn pathology was

Figure 4-S1. Evolution of strains through repetitive self-seeding in vitro. (A) Phenotypical changes in
insoluble tau aggregates (AT8) induced by different passages of 1-120-Myc pffs in PS19 neurons. (B) An
example of α-syn and tau pathologies induced in non-Tg neurons when repetitive self-seeding led to
incomplete conversion to strain B pffs. (C) Examples of post-B strains which resulted in morphologically
distinct α-syn inclusions (predominantly granular aggregates for 1, prominent cell body accumulations
together with elongated neuritic threads for 2) accompanied by variable extent of tau pathology in non-Tg
neurons. Strain 2 shown here also induced occasional cell body accumulations of tau. For (A) – (C), soluble
proteins were removed from neurons by 1% Triton-X100 in 4% PFA during fixing. Scale bar: 50 μm.
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sometimes observed (Figure 4-S1B), which is likely due to incomplete conversion of strain A to
strain B, resulting in a mixture of the two strains. Notably, continual self-seeding in vitro after full
or partial conversion to strain B led to “strain drift” within a few passages, resulting in what we
refer to as “post-B strains”, which induce a variable amount of tau pathology and morphologically
diverse α-syn inclusions (Figure 4-S1C, Table 4-S2).
Characterization of neurons transduced with different strains of α-syn pffs
A previous study used immuno-electron microscopy (immuno-EM) to show that abundant
phospho-α-syn-positive filaments formed throughout the cell bodies and processes of neurons
transduced with α-syn pffs that are now designated as strain A (Volpicelli-Daley et al., 2011).
Similarly, we found cytoplasmic α-syn filaments in strain B pff-transduced neurons using immunoEM, but mostly confined to neurites (Figure 4-2A and B). Meanwhile, filamentous aggregates that
are immunoreactive for phospho-tau were observed in neurons treated with strain B pffs,
confirming that fibrillization of tau indeed was induced by pathological α-syn (Figure 4-2C and D).
Immunocytochemistry on neurons incubated for different durations with α-syn pffs
generated from either FL or 1-120-Myc α-syn more clearly revealed differences between the two
strains (Figure 4-3 and Figure 4-S3, respectively). While non-Tg neurons transduced with strain A
pffs were replete with α-syn pathology in the absence of any overt tau pathology at 10 d posttransduction, those transduced with strain B pffs showed only sparse α-syn aggregates, but a
small amount of neuritic tau accumulations was already detected (Figure 4-3A and Figure 4-S3A).
However, by 14 d and 18 d post-transduction, the burden of α-syn aggregates increased in strain
B transduced neurons, accompanied by a dramatic surge in the levels of tau aggregates, nearly
all of which colocalized with the α-syn pathology (Figure 4-3A-D, Figure 4-S3A). In contrast, strain
A-induced α-syn pathology appeared to plateau at 14 d post-transduction, but appreciable
neuritic tau pathology never occurred despite higher abundance of α-syn inclusions in these
neurons than in strain B-transduced neurons at all time points tested. The distinct seeding
properties of the two strains of α-syn pffs were confirmed biochemically by immunoblotting
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lysates from neurons that were sequentially extracted with 1% Triton-X100 lysis buffer followed
by 2% SDS lysis buffer. Triton-insoluble tau was only detected in strain B pff-transduced neurons,
being most prominent after 18 d incubation, even though Triton-insoluble α-syn was much more
abundant in neurons treated with strain A pffs (Figure 4-3E and F, Figure 4-S3B).

Figure 4-2. Ultrastructural analysis of strain B α-syn pff-induced cytoplasmic filaments by
immuno-EM. (A) and (B) 81A immunoreactive α-syn filaments observed in strain B α-syn pfftransduced neurons using immuno-EM labeled by nanogold. (C) and (D) AT8-positive tau
filaments detected in these neurons by immuno-EM using nanogold amplification. Scale bar: 500
nm.
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Consistent with our previous study (Volpicelli-Daley et al., 2011), strain A pffs were highly
toxic to neurons as evidenced by visual inspection after 14 d incubation, as well as by
significantly increased Lactate dehydrogenase (LDH) release and reduced metabolic activity
(Figure 4-3G, Figure 4-S3C and D). In stark contrast, strain B pffs had no negative impact on cell
survival even after 18 d incubation. Immunostaining of microtubule-associated protein 2 (MAP2)
and neurofilament light chain (NFL) in 18 d post-transduction neurons showed bundled but intact
neuronal processes in strain B treated neurons, whereas the integrity of both dendrites and axons
was severely compromised in strain A-treated neurons as indicated by a dramatic reduction in the
density of both MAP2 and NFL staining and frequent beading of dendritic MAP2 staining (Figure
4-S3E). The prominent reduction of soluble tau in 18 d strain A-transduced neuron lysates was
most likely a result of extensive cell death as well (Figure 4-3E and F, Figure 4-S3B). As shown
previously (Volpicelli-Daley et al., 2011), strain A pffs per se are not toxic to α-syn knock-out
neurons, thus their toxicity in α-syn-expressing neurons must be due to the massive aggregation
and/or simultaneous depletion of soluble functional α-syn. The lack of toxicity of strain B pffs at
the post-transduction time intervals examined here is therefore most likely due to the reduced
induction of α-syn pathology, but we surmise that toxicity could emerge after longer incubation.
Although strain B pffs caused widespread aggregation of tau as detected by immunostaining, the
actual amount of insoluble tau induced only constituted a very small fraction of total tau as shown
by immunoblotting (Figure 4-3E and F).
Biophysical and biochemical analyses of α-syn pff strains
Since the distinct seeding properties of the two strains of α-syn pffs could reflect
structural differences between them, we tested this hypothesis in a series of biophysical and
biochemical analyses performed on α-syn strain A and B pffs that were verified by neuronal
phenotyping. No convincing difference in the morphology of filaments could be identified between
the two strains using negative staining transmission EM (TEM), which revealed that 1-120-Myc
pffs of both strains are ~9 nm in diameter and FL α-syn pffs are ~10-11 nm in diameter (Figure 44A). Equal concentrations of fibrils of both strains demonstrated a wide range of ThT
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Figure 4-3. Inverse seeding capacity for α-syn and tau pathologies accompanied by differential
cellular toxicity. (A) Immunostaining for insoluble phospho-α-syn (81A) and phospho-tau (AT8) at different
time points (10 d, 14 d, 18 d) after the addition of strain A or strain B FL α-syn pffs into non-Tg neurons. 1%
Triton-X100 was added to 4% PFA during fixing to remove soluble proteins. (B) and (C) Quantification of %
area occupied by 81A- and AT8-labeled pathologies respectively for experiments described in (A) (n = 4
different preparations of strain A and strain B pffs; results shown as mean +/- SEM. *: p < 0.05; **: p < 0.01;
***: p < 0.0005). (D) Calculation of % of α-syn pathology with colocalizing tau pathology (area occupied by
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81A/area occupied by AT8 x 100%) for strain B pff transduced neurons (n = 4 different preparations of strain
B pffs; results shown as mean +/- SEM. ***: p < 0.0005; ****: p < 0.0001). (E) PS19 neurons treated with
PBS, or transduced with strain A or strain B FL α-syn pffs were sequentially extracted with 1% Triton-X100
lysis buffer (T) followed by 2% SDS lysis buffer (S) at different time points. Neuron lysates from T and S
fractions were immunoblotted with 17025 (total tau), T14 (human tau), AT8 (phospho-tau), T49 (mouse tau),
81A (phospho-α-syn), and GAPDH antibody (loading control). (F) Non-Tg neurons at 18 d post-transduction
of strain A or strain B FL α-syn pffs were sequentially extracted and immunoblotted with AT8, T49, mouse αsyn and GAPDH antibodies. (G) LDH assay on non-Tg neurons transduced with strain A or strain B FL αsyn pffs at 14 d and 18 d post-transduction (n = 4 independent batches of neurons; results shown as mean
+/- SEM. *: p < 0.05; ***: p < 0.005). Scale bar: 50 μm. See also Figure 4-S3.

fluorescence signal without clear separation between them (Figure 4-4B). In addition, Fourier
transform infrared spectroscopy (FTIR) and circular dichroism (CD) also failed to show
conspicuous differences between these two strains (Figure 4-4C and D), suggesting that
whatever structural differences exist must be too subtle to be revealed by techniques that only
measure gross structural features.
To test whether α-syn pff strains can be distinguished biochemically using proteinase K
(PK) digestion, as originally demonstrated for human prion strains (Aguzzi et al., 2007; Parchi et
al., 1996), different passages of FL α-syn pffs generated through self-seeding in vitro were
incubated with PK at 37 °C. The digestion products predominantly consist of 5 bands running
between 10 and 15 kDa, with the 5th band being least abundant for de novo P1 pffs that are
strain A (Figure 4-5A). Notably, the 5th band consistently became highly prominent around P5P7, thereby correlating with the neuronal phenotypic transition into strain B. The relative intensity
of the 5th band compared to the 1st band typically shows a decline from P1 to P2, followed by an
upward trend at later passages (Figure 4-5B), suggesting stereotypical conformational changes
generated by repetitive seeded fibrillization.
To directly examine whether the two strains of pffs show distinct PK digestion patterns,
neuronal phenotype-confirmed strain A and strain B pffs were incubated with different
concentrations of PK (Figure 4-5C). No significant difference in overall PK resistance was
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Figure 4-S3. Differential seeding capacity and toxicity of the two strains of α-syn pffs. (A)
Immunostaining for insoluble phospho-α-syn (81A) and phospho-tau (AT8) at different time points (10 d, 14
d, 18 d) after the addition of strain A or strain B 1-120-Myc α-syn pffs into non-Tg neurons. 1% Triton-X100
was added to 4% PFA during fixing to remove soluble proteins. (B) PS19 neurons treated with PBS, or
transduced with strain A or strain B 1-120-Myc pffs were sequentially extracted and immunoblotted with the
same antibodies as in Figure 4-3. (C) LDH assay on non-Tg neurons transduced with strain A or strain B 1120-Myc pffs at 14 d and 18 d post-transduction (n = 4 independent batches of neurons; results shown as
mean +/- SEM. *: p < 0.05; **: p < 0.01; ***: p < 0.005). (D) Alamar blue assay on non-Tg neurons after 18 d
incubation with PBS, strain A or strain B pffs (n = 4 independent batches of neurons; results shown as mean
+/- SEM. *: p < 0.05; ***: p < 0.005). (E) Immunostaining of differently treated non-Tg neurons at 18 d posttransduction using antibodies specific for MAP2 and NFL. Scale bar: 50 μm. Arrows point to examples of
dendritic MAP2 beading.
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observed, such that no loss in the total amount of α-syn proteins was seen after each strain was
treated with PK (Figure 4-S5A). Since the 1st band of the PK digestion products migrates with the
same mobility as FL α-syn on denaturing gels, it presumably represents residual uncleaved FL αsyn pffs in the reaction mixture. Detailed analysis of all 5 bands revealed a significantly higher
ratio of cleaved species (sum of 2nd to 5th bands) to uncleaved α-syn (1st band) for strain B pffs at
all tested PK concentrations (Figure 4-5D), and this difference was predominantly driven by
increased relative abundance of the 3rd and 5th bands in the strain B digestion products, with the
5th band most dramatically differentiating the two strains at 2.5 μg/ml PK (Figure 4-5E and F,
Figure 4-S5B and C).
N-terminal sequencing indicated that both the 2nd and the 4th bands primarily contain αsyn peptides starting around residues 19-21, while the 3rd and the 5th bands both start at residue
31 (Figure 4-5A). Epitope mapping, using a panel of antibodies recognizing different regions of αsyn (see Table 4-S1), confirmed that all cleavage products (2nd to 5th bands) are N-terminal
truncated except for a small fraction of N-terminal intact peptide contained in the 3rd band (Figure
4-5G, SNL-4 and Syn506 immunoblots). As expected, the non-amyloid component (NAC) domain
of α-syn, which makes up the central amyloidogenic core of α-syn fibrils (Giasson et al., 2001), is
preserved in all PK-resistant fragments, including a faint 6th band that is only detected by NAC
domain-specific antibody and only present in PK digested strain B pffs. A C-terminal specific
antibody revealed that the extreme C-terminus (Figure 4-5G, syn102 immunoblot) is largely intact
in the 2nd and 3rd bands but absent in the 4th and 5th bands. Although the exact C-terminal
truncation sites for the 4th and 5th bands were not determined, the cleavage point is likely around
residue 125 based on LB509 and Syn211 recognition (epitopes at amino acids 115-122 and 121125, respectively) of all 5 bands. In summary, both the 3rd and 5th bands, which are more
prominent in PK-digested strain B pffs, consist of peptides N-terminally cleaved after residue 30,
while the 5th band has an additional C-terminal cleavage site around residue 125 (Figure 4-5H).
Increased N- and C-terminal truncation of strain B pffs by PK suggests that the two termini may
be more exposed for PK access in strain B than in strain A pffs. Moreover, the two strains of pffs
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Figure 4-4. Biophysical studies on the two strains of α-syn pffs. (A) Negative staining TEM images of
strain A and strain B α-syn pffs assembled from FL α-syn and 1-120-Myc. Scale bar: 100 nm. (B) ThT
binding assay of strain A and strain B FL α-syn pffs (n = 8; results shown as scatterplot with mean +/SEM). (C) FTIR on the two strains of FL α-syn pffs (results from 3 independent experiments were
superimposed). (D) CD on the two strains of 1-120-Myc pffs (n = 3, results shown as mean +/- SEM).

made from 1-120-Myc, which lacks the C-terminal cleavage site for PK, also can be clearly
distinguished by an elevated amount of PK digestion product starting at residue 31 for strain B
(Figure 4-S5D), further supporting increased PK cleavage at the N-terminus as a biochemical
signature for strain B pffs.
Induction of pathological strains on endogenous α-syn
Although strain B α-syn pffs can efficiently induce endogenous tau aggregation in non-Tg
neurons, this cross-seeding phenomenon failed to occur in α-syn knock-out neurons (data not
shown), thereby indicating that the fibrillization of mouse tau seen in non-Tg neurons must be
mediated via endogenous mouse α-syn. It is conceivable that the internalized α-syn pffs
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Figure 4-5. Conformational differences between the strains revealed by proteinase K (PK) digestion.
(A) Different passages (P1-P7) of self-seeded FL α-syn pffs were incubated with 2.5 μg/ml of PK at 37°C for
30 min, resolved on 12% Bis-Tris gel and stained with Coomassie blue. Results from one representative
series were shown. N-terminal sequencing results for the 2nd to 5th bands were presented in brackets. (B)
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Quantification of the relative intensity of the 5th band to the 1st band for experiments described in (A).
Results from 3 series of self-seeded FL α-syn pffs were shown. (C) Pairs of strains A and B FL α-syn pffs
made from the same batches of monomer were incubated with different concentrations of PK (1, 1.5, 2, 2.5
μg/ml) at 37°C for 30 min. Digestion products from two pairs of pffs were shown here. Untreated pffs were
loaded on the same gels (0 μg/ml). (D) Quantification of the ratio of cleaved species (sum of the 2nd to 5th
bands) to uncleaved molecules (the 1st band) for experiments described in (C) (n = 4 sets of strains A and B
FL α-syn pffs; results shown as mean +/- SEM. **: p < 0.01). (E) Quantification of the ratio of the 3rd band to
the 1st band for the same samples shown in (D) (results shown as mean +/- SEM. *: p < 0.05; **: p < 0.01).
(F) Quantification of the ratio of the 5th band to the 1st band for the same samples shown in (D) (results
shown as mean +/- SEM. **: p < 0.01; ***: p < 0.001). (G) Three pairs of strains A and B FL α-syn pffs were
digested with 2 or 2.5 μg/ml of PK at 37°C for 30 min and immunoblotted with antibodies recognizing
different epitopes of α-syn indicated in brackets. (H) Deduced identities of major products from PK digestion.
(I) 1% Triton-insoluble extracts from strain A or strain B pff transduced neurons were digested with 2 μg/ml
of PK for 30 min at 37°C and immunoblotted with polyclonal antibody specific for mouse α-syn. For nondigested control, neuron extracts loaded were 1/3 of that used for digestion. (J) Quantification of PK
resistant Triton-insoluble endogenous mouse α-syn for experiments described in (H) (n = 4 different sets of
strains A and B FL or 1-120-Myc α-syn pffs; results shown as mean +/- SEM. **: p < 0.005). See also Figure
4-S5.

Figure 4-S5. Biochemical analysis on the two strains of α-syn pffs. (A) Quantification of % PK-resistant
α-syn (sum of 5 bands with PK digestion/non-digested pffs x100%) for experiments described in Figure 45C. (B) Quantification of the ratio of the 2nd band to the 1st band for experiments described in Figure 4-5C.
(C) Quantification of the ratio of the 4th band to the 1st band for experiments described in Figure 4-5C. (D)
An example of strain A and strain B 1-120-Myc pffs digested with 2 μg/ml of PK at 37°C for 30 min, stained
with Coomassie blue, and immunoblotted with different epitope-specific α-syn antibodies. N-terminal
sequencing results were shown in brackets.
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themselves provide an insufficient quantity of nucleating structures to directly trigger tau
fibrillization, presumably due to a less efficient cross-seeding of tau than homotypic seeding of αsyn, whereas endogenous α-syn aggregates templated by internalized pffs create additional αsyn seeding structures that may reach a quantity sufficient to initiate the conversion of soluble tau
into fibrillar aggregates. Such a 2-step templated recruitment mechanism is supported by an
exponential increase in the percentage of α-syn pathology that colocalizes with tau pathology
over time, which is consistent with the interpretation that tau aggregation lags behind that of αsyn (Figure 4-3A and D). It thus follows that endogenous α-syn must have adopted distinct
conformations upon seeding by different exogenous pff strains in order to give rise to the
disproportionate extent of tau pathology. Indeed, Triton-insoluble mouse α-syn extracted from
strain B pff-transduced neurons revealed consistently lower PK resistance than that extracted
from strain A pff-transduced neurons (Figure 4-5I and J), even when higher amounts of lysates
from strain B-transduced neurons were used for PK digestion to adjust for less abundant
insoluble α-syn (data not shown), although no significant differences in the banding patterns were
observed. Taken together, these experiments demonstrate that conformationally different α-syn
aggregates can be generated not just from purified recombinant protein, but also from
intracellularly expressed protein.
The roles of N- and C- termini in strain conformations
Since possible conformational changes of α-syn pffs at the N- and C-termini correlate
with phenotypic conversion from strain A to strain B, we further investigated whether the two
termini play causal roles in strain evolution by testing self-seeded pffs assembled from N- or Cterminal truncated α-syn molecules (Figure 4-6A, results summarized in Table 4-S3).
Interestingly, pffs made from N-terminal truncated α-syn 58-140 and 32-140 almost always
remained incapable of cross-seeding tau up to P10 of self-seeding despite efficient induction of αsyn pathology (Figure 4-6B). One simple explanation for failed cross-seeding could be that the Nterminus of α-syn pffs is required for direct interaction with tau to trigger its misfolding, but this
possibility is unlikely since the experiments described above showed that exogenous strain B pffs
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do not directly induce tau pathology, which implicates endogenous full-length α-syn as the
obligatory mediator of tau aggregation regardless of the pffs that are transduced (Figure 4-6A). A
more plausible alternative explanation is that the N-terminus of α-syn may be necessary for
generating a cross-seeding competent conformation in the exogenous α-syn pffs which can then
be conferred onto endogenous α-syn through templating. Besides the lack of tau cross-seeding,
both 58-140 and 32-140 pffs remained phenotypically stable in terms of α-syn pathology induced
by different passages of pffs in neurons. While 32-140 pffs constantly behaved as strong strain A
pffs, inducing highly abundant LB and LN like α-syn inclusions after 7 d incubation and frequently
resulting in extensive cell death at 18 d post-transduction, 58-140 pffs invariably led to
morphologically distinct α-syn aggregates, consisting of unusually long fibrillar accumulations in
neurites with almost no cell body inclusions (Figure 4-6B). The distinct pattern of α-syn inclusions
induced by 58-140 pffs could be caused by near complete loss of the lipid-binding N-terminus in
58-140, which may potentially alter pff uptake and/or intracellular seeding mechanisms. However,
FL α-syn pffs are also capable of acquiring similar seeding properties in neurons when their in
vitro fibrillization is templated by 58-140 pffs (Figure 4-S6A), thus pointing to a unique
conformation adopted by 58-140 pffs that can be acquired by FL α-syn.
The similar behavior of 1-120-Myc and FL α-syn in strain evolution suggests the extreme
C-terminus may play a minimal role in pff conformation. Surprisingly, 1-120 without a myc tag at
the C-terminus stochastically gave rise to different strains of de novo pffs, i.e., sometimes strain
A, occasionally weak strain B, but most frequently fibrils with phenotypes resembling one of the
post-B strains inducing granular α-syn inclusions, or behaving as 58-140 pffs leading to elongated
fibrillar aggregates of α-syn (Figure 4-S6B). There was also no predictable pattern of strain
conversion through repetitive self-seeding. Therefore, unlike the N-terminus of α-syn which
appears to contribute to conformational diversities of fibrils generated through repeated selfseeding, the C-terminus seems to normally limit or impede the generation of structurally diverse
strains. The much more predictable behavior of 1-120-Myc may be due to the enriched negative
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charges in the Myc tag that is attached after residue 120, which happen to partially mimic the
natural C-terminus of FL α-syn.

Figure 4-6. The roles of N- and C-termini in strain conformations. (A) Schematic diagram for testing the
roles of N- and C-termini in generating or adopting strains A and B conformation. (B) Pathology induced by
de novo or self-seeded (P1-P10) 58-140 or 32-140 pffs in non-Tg neurons. Cells were fixed at 18 d posttransduction for 58-140 pffs but at 7 d post-transduction for 32-140 pffs due to extensive cell death caused
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by the latter at later time points. (C) Insoluble α-syn aggregates resulted from 1-120 or 58-140 pffs that were
initially seeded by strain A pffs. Cells were fixed at 18 d post-transduction. (D) Insoluble α-syn and tau
aggregates induced by FL α-syn, 58-140, 32-140, or 1-120 pffs that were seeded by strain B pffs at 18 d
post-transduction. (E) Quantification of % area occupied by AT8-labeled tau pathology for experiments
described in (D) (number of independent preparations of pffs tested: n = 5 for 10% seed control, n = 4 for
FL, n = 5 for 58-140, n = 8 for 32-140, n = 4 for 1-120; results shown as scatterplot with mean +/- SEM. **: p
< 0.005; ***: p < 0.0005; ****: p < 0.0001). (F) Calculation of % of α-syn pathology with colocalizing tau
pathology for experiments described in (D) (same number of independent pff preparations tested as in (E),
****: p < 0.0001). For (B), (C) and (D), soluble proteins were removed from neurons by 1% Triton-X in 4%
PFA during fixing. Scale bar: 50 μm. See also Figure 4-S6.

To test whether the N- and C-termini are merely facilitating the acquisition of strainspecific conformations by middle regions of α-syn, or instead are an integral part of a particular
conformation, N- or C-terminal truncated α-syn proteins were fibrillized in the presence of 10%
strain A or 10% strain B pffs to test their ability to conform to these respective strains when
seeded (Figure 4-6A, results summarized in Table 4-S3). For strain A-seeded fibrillization, an
additional round of self-seeding was conducted on P2 fibrils to dilute out the original strain A
seeds, which can potentially mask the phenotypes of seeded pffs formed by truncated α-syn.
Unlike the stochastic nature of its spontaneous fibrillization, 1-120 faithfully acquired strain A
phenotype when seeded by strain A pffs (Figure 4-6C). This cannot be accounted for by the
residual 1% strain A seeds present in the fibrillization mixture (Figures 4-S6C), suggesting that
the extreme C-terminus is not an essential part of strain A conformation, although it normally
assists the other regions of α-syn to acquire that conformation. In contrast, strain A-seeded 58140 pffs still predominantly induced elongated α-syn accumulations with infrequent cell body
inclusions (Figure 4-6C), similar to pathology induced by typical 58-140 pffs mixed with 1% strain
A seeds right before transduction to simulate failed strain A conversion (Figures 4-S6C).
Therefore, the absence of residues 1-57 impairs the acquisition of strain A conformation. As
expected from the spontaneous generation of strain A pffs, 32-140 pffs seeded by strain A always
displayed typical strain A phenotypes (data not shown), confirming that residues 1-31 are not an
integral part of strain A core structure. This in turn points to residues 32-57 as an important region
of α-syn needed to adopt the strain A configuration, accounting for the different properties of 32140 and 58-140 pffs.
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Figure 4-S6. Conformational roles of N- and C-termini. (A) FL α-syn fibrillization was seeded by 10% of
58-140 pffs and the resulted P2 pffs were used to seed another round of fibrillization of FL α-syn, leading to
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the formation of P3 pffs. Pathology induced by these P3 pffs initially seeded by 58-140 pffs is
indistinguishable from pathology induced by typical 58-140 pffs, and the extent of pathology significantly
exceeded what could be caused by the residual 1% 58-140 pff seeds. Quantification of % area occupied by
α-syn aggregates: n = 4 for 58-140 seeded FL pffs P3, n = 2 for 1% 58-140 pff control; results shown as
scatterplot with mean +/- SEM; ***: p < 0.0005. (B) Phenotypic variations of de novo 1-120 pffs (P1) shown
in non-Tg neurons. (C) Control experiment for Figure 4-6C: Non-Tg neurons were transduced with 99% 1120 pffs of various strains or 99% 58-140 pffs (1.98 μg per coverslip) mixed with 1% strain A pffs (0.02 μg
per coverslip) right before being added to neurons to simulate failed strain A conversion. The pattern of αsyn pathology induced appeared to be driven predominantly by 1-120 or 58-140 pffs which were added at a
much higher dose. (D) Control experiment for Figure 4-6D: only sparse α-syn and tau pathologies were
induced by 10% strain B seeds alone (0.2 μg per coverslip) in non-Tg neurons. For (A) – (D), soluble
proteins were removed from neurons by 1% Triton-X100 in 4% PFA during fixing. Scale bar: 50 μm.

When seeded by strain B pffs, FL α-syn, 32-140 and 1-120 all reliably acquired the ability
to induce tau aggregation far beyond what could be attributed to the 10% strain B seeds present
in the fibrillization mixture (Figure 4-6D and E, compare with Figure 4-S6D). The extensive
colocalization between endogenous α-syn and tau pathology (Figure 4-6D and F) further supports
the induction of specific endogenous α-syn conformers that are capable of cross-seeding tau.
Therefore, although the initial 31 residues at the extreme N-terminus and the last 20 residues at
the C-terminus may facilitate the spontaneous generation of strain B by FL α-syn through
repetitive self-seeding, they do not constitute the core structure of the strain B conformation.
However, we did notice significantly less abundant aggregation of both α-syn and tau induced by
strain B-seeded 32-140 and 1-120 than by equivalently seeded FL α-syn pffs (Figure 4-6E),
despite similar percentages of α-syn pathology with colocalizing tau pathology. This suggests that
the lack of the extreme N- or C-terminus of α-syn may result in reduced efficiency in strain Btemplated fibrillization, although we cannot rule out the possibility that acquisition of the strain B
conformation somehow compromises the internalization of N- or C-terminal truncated α-syn pffs.
On the other hand, strain B-seeded 58-140 pffs still behaved exactly the same as spontaneously
generated 58-140 pffs, with the vast majority of α-syn aggregates showing no colocalizing tau
pathology and the sparsely distributed tau inclusions being entirely accounted for by the 10%
residual strain B seeds (Figure 4-6D, E and F), thereby indicating a complete failure to adopt the
strain B conformation. The striking difference between 32-140 and 58-140 when seeded by strain
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B further implicates the critical role of residues 32-57 in the generation of the strain B
conformation, as well as the strain A conformation as noted above.
Strain-specific cross-seeding of tau pathology in vivo
To test whether the two strains of α-syn pffs differentially induce tau pathology in vivo, we
performed unilateral inoculation of strain A or B α-syn pffs into the hippocampus of 2-3 month old
PS19 mice, which over-express human P301S mutant tau, prior to the onset of extensive
transgene-induced tau pathology at ~12 months of age (Iba et al., 2013). The induction and
spreading of tau inclusions were examined using immunohistochemistry at different time points
after α-syn pff inoculation (Figure 4-7A). At 3 months post-injection, only a few rare cells showed
abnormal accumulation of hyperphosphorylated tau recognized by mAb AT8 near the injection
site of strain A-inoculated mice, whereas numerous neurons bearing AT8-positive tau inclusions
were observed in strain B-injected mice around the same area (Figure 4-7A and B). Moreover,
phospho-tau aggregates were also found in parts of the hippocampus that are more rostral and
caudal to the injection site, which suggests transmission of cross-seeded tau pathology, and
strain B-injected mice displayed significantly more tau inclusions in these regions as well. For
reasons that are unclear, the caudal hippocampus consistently showed more abundant tau
aggregates than the injection site, regardless of α-syn pff strain injected. The differential induction
of pathological tau aggregates by the two strains of pffs was confirmed using mAb MC1, a
monoclonal antibody (mAb) specific for a pathological conformation of tau (Jicha et al., 1997)
(Figure 4-7C).
At 6 months post-injection, mice inoculated with strain B pffs continued to show
significant tau pathology, although there was only a minor increase in the rostral and caudal
hippocampus and even a slight reduction of pathology around the injection site as compared to
the 3 month post-injection mice. On the other hand, strain A-injected mice demonstrated an
obvious increase in phospho-tau aggregates after 3 and 6 additional months of post-injection
time, but even at 9 months post-injection, the extent of tau pathology in mice receiving strain A
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was far less than that induced by strain B pff injection (Figure 4-7A and B). These results clearly
illustrate the greatly enhanced tau cross-seeding capacity of strain B pffs compared to strain A
pffs in living animals, exactly as observed in cultured neurons.

Figure 4-7. Strain-specific cross-seeding of tau pathology in vivo. (A) AT8-positive tau
aggregates detected in different parts of ipsilateral hippocampus (rostral, near injection site,
caudal) at 3, 6, or 9 months after inoculation of strain A or strain B 1-120-Myc pffs into the
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hippocampus of PS19 mice. (B) Quantification of AT8-positive neurons in different parts of
ipsilateral hippocampus for different experimental groups (n = 4 for 3 months post-injection of
either strain, n = 4 for 6 or 9 months post-injection of strain A, n = 3 for 6 months post-injection of
strain B; results shown as mean +/- SEM. *: p < 0.05. **: p < 0.005. ***: p < 0.0005. ****: p <
0.00001). (C) MC1 immunoreactivity in different parts of ipsilateral hippocampus at 3 months
post-injection. (D) Tau inclusions cross-seeded by strain B pffs were recognized by TG3 and AcK280. All sections were counterstained with hematoxylin to reveal cell nuclei. Scale bar: 100 μm.

Further characterization revealed that tau aggregates cross-seeded by α-syn pffs were
also recognized by TG3, a conformational specific phospho-tau mAb, and Ac-K280, a polyclonal
antibody specific for acetylated tau (Figure 4-7D), thus distinguishing them from spontaneously
developed tau pathology in aged PS19 mice (Iba et al., 2013). However, unlike pathology induced
by tau pff injections, which showed ThS staining as early as 2 weeks post-injection, minimal ThS
binding was found even for strain B α-syn pff-induced tau aggregates at 6 months post-injection
(data not shown), suggesting that tau aggregates induced by α-syn pffs may mature more slowly
into β-sheet rich structures than those induced by tau pffs.
4.4 Discussion
Here we describe for the first time two distinct strains of synthetic α-syn pffs generated in
vitro with dramatically different seeding properties in primary neurons. Strain A is highly
efficacious in recruiting endogenous α-syn into aggregates, resulting in pronounced cellular
toxicity, while strain B induces α-syn pathology at a much slower rate and is therefore benign to
neurons over the post-transduction time intervals studied here. More remarkably, strain A shows
limited capacity to induce tau aggregation, whereas strain B demonstrates surprisingly high
efficiency in cross-seeding tau pathology. The strain-specific cross-seeding efficacy for tau was
also fully recapitulated in tau Tg mice injected with these α-syn pffs, providing in vivo evidence for
distinct pathological properties of the two synthetic strains. Notably, strain B can be derived from
strain A through repetitive self-seeded fibrillization in vitro, the process of which is associated with
progressively enhanced exposure of the N- and C-termini of α-syn in the fibrillized form as
revealed by PK digestion. Therefore, α-syn pff strains represent different conformers of fibrillar αsyn species with distinguishable templating activities in healthy neurons.
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The concept of “strains” originated from the prion field, whereby different strains of prion
are associated with distinct histopathological lesion profiles with varying clinical aggressiveness
and the phenotypic differences are believed to be encoded by conformational differences in the
infectious prion particles (Aguzzi et al., 2007; Bessen et al., 1995; Bessen and Marsh, 1994;
Telling et al., 1996). The different forms of α-syn pffs we describe here closely parallel prion
strains in that they exhibit structural variations, differences in pathological manifestation, and
heritability of phenotypic traits via direct seeding in vitro, except that most known prion strains
originate in vivo from patients afflicted by a prion disease or animal models thereof and synthetic
prions assembled from recombinant proteins generally show low infectivity in the absence of
added cofactors (Colby et al., 2009; Makarava et al., 2010). Besides strain A and strain B, which
are described in great detail here, we also observed several other α-syn strains with distinct
seeding properties in neurons (summarized in Table 4-S2), exemplifying the diversity of synthetic
α-syn strains that can be generated in vitro.
Previous structural studies suggest the fibrillization core of α-syn spans from residues 30
to ~100-110 (Comellas et al., 2011; Miake et al., 2002; Vilar et al., 2008), extending beyond the
NAC domain (residues 61-95) that is both necessary and sufficient for α-syn fibrillization (Giasson
et al., 2001; Iwai et al., 1995b; Luk et al., 2009). Here we showed that 58-140, which has an intact
NAC domain, is fully capable of seeding intracellular fibrillization of endogenous α-syn, but
generates a unique pathological conformer distinct from strain A or B, supporting the structural
role of residues on the N-terminal side of NAC domain in regulating distinct α-syn fibril
conformations. Moreover, in stark contrast to 32-140, 58-140 is deficient in acquiring either strain
A or strain B conformation when seeded (Table 4-S3), suggesting that residues 32-57 constitute
a critical part of the fibrillization core for both strains and the exact folding of this region within
fibrillar α-syn strongly influences its seeding properties in neurons. The malleable nature of this
region is consistent with a high resolution solid-state NMR study showing that the β-strand
consisting of residues 38-49 displays more dynamic structure than other β-strands in the fibril
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core, while residues in the NAC domain demonstrate the most rigid structure (Comellas et al.,
2011).
Experiments on 32-140 and 1-120 (refer to Table 4-S3) revealed that the N- and Ctermini both facilitate the stereotypical conversion of strain A into strain B with continual seeding,
although they themselves are not part of the core structure for either strain. Consistent with
earlier studies (Miake et al., 2002; Murray et al., 2003; Vilar et al., 2008), our PK digestion
experiments indicated that the N- and C-termini are more accessible than the NAC domain in αsyn fibrils. NMR studies also suggest the two termini are structurally more flexible than the fibril
core (Comellas et al., 2011; Vilar et al., 2008). The intriguing correlation between seeding
phenotypes and relative exposure of the two termini in α-syn pffs revealed by PK digestion further
suggests that increased exposure of the two termini may somehow promote rearrangement of the
fibrillization core from strain A conformation towards strain B conformation. Interestingly, while the
N-terminus appears to be required for spontaneous generation of structural diversity within the
fibrillization core, the C-terminus normally restrains the core domain from stochastically evolving
into diverse conformations, which could be related to the inhibitory effects of C-terminus on
fibrillization (Crowther et al., 1998; Murray et al., 2003). On the other hand, since the two extreme
termini lie outside the fibrillization core, PK digestion patterns which merely provide clues about
relative accessibility of the termini can only be considered as a surrogate marker for strains.
Detailed atomic-level analysis, such as high resolution solid-state NMR spectroscopy, would be
required to unveil exact strain-specific folding patterns of fibrillar α-syn.
In this study we demonstrated that a spectrum of α-syn strains can arise from the
simplest reactions in a cell-free system without any cofactors. One can well imagine that in real
human brains with a highly complex cellular and biochemical environment, the likelihood of
forming diverse strains would be far greater. Interestingly, LBs found in midbrain structures such
as the substantia nigra are morphologically different from those found in the cortical regions
(Hurtig et al., 2000; Spillantini et al., 1998a), possibly representing distinct strains of α-syn
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aggregates formed under specific cellular milieus associated with different brain regions.
Moreover, in PD with dementia (PDD) or DLB cases with concomitant AD pathologies, NFTs are
most frequently detected in the limbic and neocortical areas but not in the midbrain, independent
from the density of LBs (Gearing et al., 1999; Gomez-Tortosa et al., 2000). This region-specific
distribution of co-occurring NFTs could be due to selective vulnerability of different brain areas to
tau aggregation, but it could also result from differential cross-seeding capacity of α-syn
aggregates arising in these different regions analogous to synthetic α-syn strains observed in our
study. In fact, close physical association of tau and α-syn deposits have been observed in
synucleinopathies (Duda et al., 2002; Galloway et al., 1989; Ishizawa et al., 2003), supporting
direct cross-seeding between the two types of pathologies.
Besides differing cellular and biochemical factors, other events can also facilitate the
generation of different α-syn strains in vivo. First, C-terminal truncation of α-syn has been
detected in synucleinopathy brains (Baba et al., 1998; Campbell et al., 2001; Li et al., 2005). This
cleavage event not only can accelerate fibrillization of α-syn (Crowther et al., 1998; Murray et al.,
2003), but was also shown to promote stochastic formation of diverse aggregated strains in our
study. Thus, it is plausible that C-terminal truncated fibrils of different conformations can then
serve as seeds to induce fibrillization of FL α-syn into different strains. Second, recent studies
have implicated inter-neuronal transmission of α-syn aggregates as the underlying mechanism for
stereotypical progression of α-syn pathology in PD and DLB (Luk et al., 2012a; Luk et al., 2012b).
Since every transmission event from one neuron to the other can be viewed as a bona fide
seeded fibrillization of α-syn in the recipient neuron and our study showed that continual seeding
in vitro can lead to evolution of α-syn strains, it is possible that transmission of α-syn pathology
along multiple neuronal connections could also give rise to divergent pathological strains. This
hypothesis could potentially account for pathologically different LBs in substantial nigra versus
neocortex, which are brain structures affected in distinct stages in the progression of LB diseases
such as PD and DLB (Braak et al., 2003; Kosaka et al., 1988).
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In addition to brain region-specific emergence of α-syn strains, different strains of α-syn
aggregates could also underlie the tremendous heterogeneity of synucleinopathies among
different individuals (Halliday et al., 2011). While mostly found in the neurites and neuronal cell
bodies for the majority of synucleinopathies, α-syn inclusions are largely confined to
oligodendrocytes in multiple system atrophy (Tu et al., 1998), which could be caused by a unique
strain of pathological α-syn developing predominantly in oligodendrocytes but rarely in neurons.
PDD and DLB, belonging to a continuum of LB diseases, are clinically stratified according to the
interval between the onset of motor symptoms and that of cognitive deficits which can vary by
decades (Ballard et al., 2006; McKeith, 2006; Tsuboi and Dickson, 2005). While co-morbid AD
pathologies are more common in DLB than in PDD, a bimodal distribution of neocortical NFTs
has been found in DLB cases (Gearing et al., 1999). Furthermore, several studies have
suggested the existence of two subgroups of PDD patients, one group with younger onset, long
motor-dementia interval and relatively long disease duration, and the other group with older
onset, short motor-dementia interval and more malignant disease course (Compta et al., 2011;
Halliday et al., 2008; Jellinger et al., 2002). Interestingly, the former usually presents purely LB
pathologies, but the latter most often shows concomitant AD pathologies. Although co-morbid AD
pathologies in PDD and DLB may develop independently from LB pathologies, our study raises
the possibility that AD pathologies, especially NFTs, could be directly but variably induced by
different strains of pathological α-syn, the underlying substrates for the vast clinical variations of
synucleinopathies.
Prior to our study, the ability for a single molecule of the same primary sequence to adopt
multiple fibril structures has been shown for a variety of amyloidogenic proteins other than prion
proten, including Aβ (Kodali et al., 2010; Meinhardt et al., 2009; Petkova et al., 2005), tau
(Furukawa et al., 2011) and huntingtin with polyglutamine expansion (Nekooki-Machida et al.,
2009), although the pathological relevance of amyloid fibril polymorphism other than cellular
toxicity has never been investigated in cells or animals. The recently developed neuronal and
animal models of pathology transmission allowed us to demonstrate distinct pathological seeding
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properties of specific α-syn fibril types generated in vitro and classify them into different strains.
While future studies are required to verify the presence of α-syn strains in synucleinopathy brains,
we speculate that perhaps besides inter-neuronal transmission of aggregated proteins, the
existence of conformationally diverse protein strains underlying disease heterogeneity may be
another common feature of neurodegenerative diseases which was thought to be unique to prion
diseases.
4.5 Materials and Methods
Recombinant α-syn Purification and in Vitro Fibrillization
FL α-syn (1-140), N-terminal or C-terminal truncated α-syn (32-140, 58-140, 1-120) and
1-120 with a C-terminal Myc-tag (1-120-Myc) were expressed in BL21 (DE3) RIL cells and
purified as previously described (Giasson et al., 2001). Fibrillization was conducted by diluting
recombinant α-syn to 5 mg/ml in Dulbecco's PBS (Cellgro, Mediatech Inc; pH adjusted to 7.0) and
incubating at 37 °C with constant agitation at 1,000 rpm for 5-7 d. Successful fibrillization was
verified by sedimentation test and ThT-binding assay (see Extended Experimental Procedures).
Pffs were stored at room temperature to avoid freeze and thaw.
Repetitive self-seeding was carried out by including 5 or 10% of existing pffs (0.25 or 0.5
mg/ml in the final reaction) in a fibrillization reaction containing 95% or 90% of fresh monomers
(4.75 or 4.5 mg/ml in the final reaction) for generating the next passage of pffs and the process
was repeated until passage 10 (de novo pffs considered as P1) (Figure 4-1B). For fibrillization
directly seeded by strain A or strain B pffs, 10% of existing pffs of either strain was added to a
fibrillization reaction containing 90% of fresh monomers. All seeded fibrillization was performed
under the same conditions as de novo fibrillization. For each α-syn construct, at least two
independently prepared monomer batches were tested for each fibrillization paradigm, and at
least two series of self-seeded fibrillization were set up for each monomer batch.
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Biophysical Analyses of α-syn pffs
1-120-Myc α-syn strains A and B pffs were sonicated and diluted to a final concentration
of 5 µM in 10 mM phosphate, 100 mM KF buffer (pH 7.3). CD spectra were collected according to
a procedure adapted from the literature (Greenbaum et al., 2005). FL α-syn strains A and B pffs
were spun at 100,000 g for 15 minutes and resuspended in D2O. This process was repeated two
additional times and then each sample was sonicated 50 times. FTIR spectra were collected
according to a procedure adapted from the literature (Huang et al., 2002). See Extended
Experimental Procedures for details.
PK digestion of α-syn pffs
10 μg of pffs were mixed with 1 to 2.5 μg/ml of PK in Dulbecco's PBS to a final volume of
20 μl and incubated at 37°C for 30 min. Digestion was stopped with 1 mM PMSF. Reaction
samples were boiled with SDS-sample buffer for 5 min and resolved on NuPAGE® Novex 12%
Bis-Tris gels (Invitrogen). To identify the N-terminal sequences of PK-resistant fragments,
samples were transferred from 12% Bis-Tris gel to a sequencing-grade PVDF membrane and
individual bands were submitted to the Keck Biotechnology Resource Laboratory (Yale
University) for N-terminal sequencing analysis. Epitope mapping of the PK digestion products
was performed by immunoblotting samples that were transferred onto nitrocellulose membranes
with epitope-specific antibodies to α-syn (see Table 4-S1).
Primary Neuron Cultures and Fibril Transduction
Primary neuron cultures were prepared from E15-E17 embryos from homo/het crosses of
PS19 mice (Yoshiyama et al., 2007) or non-Tg CD1 mice (Charles River). All procedures were
performed according to the NIH Guide for the Care and Use of Experimental Animals and were
approved by the University of Pennsylvania Institutional Animal Care and Use Committee
(IACUC). Dissociated hippocampal neurons were plated onto poly-D-lysine coated coverslips or
dishes. Pff transduction was performed at 6 d or 7 d in vitro, whereby α-syn pffs were diluted to
0.1 mg/ml in PBS and sonicated with 60 pulses before being added to neuron medium. For each
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13 mm coverslip, 2 µg of pffs were added, and 8 µg of pffs were added per well for 6-well plates.
Transduced neurons were harvested for immunocytochemistry or sequential extraction at time
points indicated in the text.
Immunocytochemistry
Neurons were fixed with 4% paraformaldehyde (PFA) in PBS containing 2% sucrose for
15 min and permeabilized with 0.1% Triton-X100 for 15 min, or fixed with 4% PFA containing 1%
Triton-X100 for 15 min to remove soluble proteins. After blocking with 3% BSA and 3% FBS for at
least 1 hr at room temperature, neurons were incubated with specific primary antibodies (see
Supplementary Table 1) overnight at 4 °C followed by staining with appropriate Alexa fluor 594 or
488-conjugated secondary antibodies (Invitrogen) for 2 hr at room temperature. Quantification for
area occupied by pff-induced pathology was performed on 40x images using Image J (National
Institute of Health).
Sequential Extraction and Immunoblot Analysis on Neuron Lysates
Sequential extraction of neurons and immunoblotting of neuron lysates was performed as
previously described (Guo and Lee, 2013). See Extended Experimental Procedures for details.
For PK digestion of neuron lysates, Triton-insoluble extracts were re-suspended in PBS and
sonicated to clear the pellets before digested with 2 µg/ml of PK for 30 min at 37°C. Digested
lysates were resolved on NuPAGE® Novex 12% Bis-Tris gels, transferred to nitrocellulose
membranes and immunoblotted with polyclonal antibody specific for mouse α-syn (see Table 4S1).
Cell Survival Assays
LDH release assay and alamar blue assay were performed using CytoTox 96® NonRadioactive Cytotoxicity Assay kit (Promega) and alamarBlue® Cell Viability Assay kit
(Invitrogen) respectively according to the manufacturers’ protocols (see Extended Experimental
Procedures).
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TEM and Immuno-EM
Negative staining TEM of α-syn pffs and immuno-EM of transduced primary neurons
were performed as previously described (Guo and Lee, 2011; Volpicelli-Daley et al., 2011). See
Extended Experimental Procedures for details.
Stereotaxic Surgery and Immunohistochemistry
Unilateral inoculation of α-syn pffs into the hippocampus of 2-3 month old PS19 mice
were performed using stereotaxic surgery as previously described (Iba et al., 2013) in accordance
with protocols approved by the IACUC of the University of Pennsylvania. For each mouse, 5 µg of
sonicated pffs were injected at a volume of 2.5 µl to one side of the hippocampus (Bregma -2.5
mm, lateral +2 mm, and depth -1.8 mm). Immunohistochemical analysis of injected mice was
conducted at 3, 6, and 9 months post-injection. Brains from perfused animals were fixed in
formalin or 70% ethanol, embedded in paraffin blocks, cut into 6 µm-thick sections and
immunostained with different antibodies (see Table 4-S1) using a polymer horseradish
peroxidase detection system (Biogenex) and counterstained with hematoxylin. The number of
neurons with cell body AT8 immunoreactivity was quantified using 20x images of coronal sections
from 3 different regions (rostral hippocampus, medial hippocampus close to the injection site,
caudal hippocampus). For each mouse, 2 sections from each of the 3 regions were used for
quantification and the average of the 2 sections was included in the statistical analysis for
individual regions.
Statistical Analysis
Two-tailed unpaired Student's t test was used for all the comparisons in the study, and
differences with p values less than 0.05 were considered significant.
4.6 Supplementary Materials
Table 4-S1. Antibodies used in Chapter 4.
Antibody

Specificity

Host
species
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Dilution

Source or
Reference

81A

p-α-syn
(phosphorylated at Ser
129)

mouse
monoclonal

1:5000 (ICC),
1:1000 (WB),
1:1000 (immunoEM)

(Waxman and
Giasson, 2008)

AT8

p-Tau (phosphorylated
at Ser 202 and Thr
205)

mouse
monoclonal

1:1000 (WB,
immuno-EM), 1:500
(ICC), 1:10000
(IHC)

Innogenetics

MC1

Tau in the pathological
conformation

mouse
monoclonal

1:2000 (IHC)

Gift from Dr. Peter
Davies Lab

17025

Human recombinant
tau

rabbit
polyclonal

1:1000 (WB)

(Ishihara et al.,
1999)

T14

Human tau

mouse
monoclonal

1:1000 (WB)

(Kosik et al., 1988)

T49

Mouse tau

mouse
monoclonal

1:1000 (WB)

(Ishihara et al.,
2001)

GAPDH
(6C5)

Glyceraldehyde-3phosphate
dehydrogenase
Mouse α-syn (amino
acids 115-125)

mouse
monoclonal

1:3000 (WB)

Advanced
Immunochemical

rabbit
polyclonal

1:500 (WB)

(Volpicelli-Daley et
al., 2011)

SNL-4

α-syn (amino acids 211)

rabbit
polyclonal

1:2000 (WB)

(Giasson et al.,
1999)

Syn506

α-syn (amino acids 212)

mouse
monoclonal

1:1000 (WB)

(Waxman et al.,
2008)

NAC

α-syn (amino acids 7591)

rabbit
polyclonal

1:500 (WB)

(Giasson et al.,
2001)

LB509

α-syn (amino acids
115-122)

mouse
monoclonal

1:2000 (WB)

(Jakes et al., 1999)

Syn211

α-syn (amino acids
121-125)

mouse
monoclonal

1:2000 (WB)

(Giasson et al.,
2000b)

Syn102

α-syn (amino acids
131-140)

mouse
monoclonal

1:1000 (WB)

(Tu et al., 1998)

TG3

Conformational specific
p-tau (phosphorylated
at Thr 231)

mouse
monoclonal

1:250 (IHC)

Gift from Dr. Peter
Davies Lab

Ac-K280

Tau acetylated at Lys
280

rabbit
polyclonal

1:2000 (IHC)

(Cohen et al., 2011)

17028

MAP2

rabbit
polyclonal

1:5000 (ICC)

(Volpicelli-Daley et
al., 2011)

NFL

Neurofilament light
chain

rabbit
polyclonal

1:2000 (ICC)

In-house

9E10

c-myc tag

mouse
monoclonal

1:1000 (WB)

Santa Cruz

Mse 40
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Table 4-S2. Summary of seeding phenotypes in non-Tg neurons for different strains of αsyn pffs
Strain Name
Strain A

α-syn pathology
Highly abundant aggregation
in both cell bodies and
neurites. A mixture of short
and long fibrillar
accumulations.

Strain B

Slow progression of
aggregates which are mainly
in the neurites. A mixture of
short and long fibrillar
accumulations.
Predominantly granular
aggregates accompanied by
long neuritic threads.

Post-B strain 1

Post-B strain 2

Prominent cell body inclusions
accompanied by elongated
neuritic accumulations.

58-140 like

Long fibrillar accumulations
along neurites with almost no
cell body inclusions.

Tau pathology
Little to rare neuritic
accumulations. Punctate
immunoreactivity associated
with cell death does not
colocalize with α-syn
aggregates.
Widespread neuritic
accumulations extensively
colocalizing with α-syn
aggregates.
Variably rare to frequent
aggregates which colocalize
with thread-like but not
granular α-syn aggregates.
Variably rare to frequent
neuritic aggregates with
occasional cell body
accumulations.
None

Table 4-S3. Summary of strains generated from different α-syn molecules under different
seeding paradigms

58-140

Repetitive selfseeding
Strain A evolves into
strain B
58-140 like

32-140
1-120

Strain A
Multiple strains

FL α-syn

Seeding by strain A

Seeding by strain B

Strain A

Strain B

Predominantly 58-140
like, with some strain
A phenotype
Strain A
Strain A

58-140 like
Strain B
Strain B

Extended Experimental Procedures
ThT binding assay
1mM ThT diluted 40 fold in 100 mM glycine buffer (pH 8.5) was added to equal volume of
50 fold diluted α-syn pffs and incubated for 5-10 minutes at room temperature. Fluorometric
readings were taken at 450nm excitation and 510nm emission using SpectraMax plate reader.
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Sequential Extraction and Immunoblot Analysis on Neuron Lysates
Neurons were scraped into Triton lysis buffer (1% Triton X-100 in 50 mM Tris, 150 mM
NaCl, pH 7.6) containing phosphatase and protease inhibitor cocktail, sonicated, and centrifuged
at 100,000 g for 30 min at 4°C. Pellets were washed once in Triton lysis buffer, re-suspended into
SDS lysis buffer (2% SDS in 50 mM Tris, 150 mM NaCl, pH7.6) at a volume that is ¼ of the Triton
lysis buffer and centrifuged at 100,000 g for 30 min at 22°C. Supernatants from Triton X-100 and
SDS extractions were resolved on SDS-PAGE, transferred to nitrocellulose membranes, and
blocked in 5% milk or 7.5% BSA in TBS before immunoblotted with specific antibodies (see Table
4-S1). 10 µg of proteins from Triton fractions and equal volume of corresponding SDS fractions
were loaded per lane.

Biophysical Analyses of α-syn pffs
For CD analysis, sonicated and diluted pffs were transferred into a 1-mm quartz cuvette,
and the CD spectra between 190 and 240 nm using 0.5 nm steps and 10 s averaging time were
recorded using an Aviv model 202 spectrophotometer (Lakewood, NJ.). For all reported spectra,
a background of pure buffer was subtracted and the spectra shown are an average of three
samples with at least two fibril preparations measured.
A Nicolet Magna-IR 860 spectrometer was used to collect FTIR spectra using 1 cm-1
resolution. A CaF2 sample cell that was divided into two compartments and a Teflon spacer was
used to allow the separate measurements of the sample and reference (D2O) under identical
conditions. The optical path length of the sample cell was determined to be 52 µm by its
interference fringe obtained from the transmittance signal of the empty cell. Temperature control
with ~0.2 °C precision was obtained by a combination of a water bath (Haake K30) and a
thermostated copper block. For all reported spectra, a background of pure buffer was subtracted
and the spectra shown are an average of three samples with at least two fibril preparations
measured.
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TEM and immuno-EM
For negative staining TEM, 6 μl of 50 fold diluted α-syn pffs was placed on 300 meshed
Formvar/carbon film-coated copper grids (Electron Microscopy Sciences) for 3 min, washed twice
with 50 mm Tris buffer (pH 7.6) for 5 min each, stained with 10–15 drops of 2% uranyl acetate,
and visualized with Jeol 1010 transmission electron microscope (Peabody).
For

immuno-EM,

pff

transduced

neurons

were

fixed

in

periodate-lysine-

paraformaldehyde, permeabilized with 0.05% saponin in PBS with 2% fish gelatin (PBS-FG) and
0.05% thimerosal, incubated with mAb 81A (phospho-α-syn) or AT8 (phospho-tau) followed by
incubation with goat anti-mouse IgG coupled to nanogold (Nanoprobes). The nanogold labeled
neurons were postfixed and gold toned with 0.05% gold chloride.

Cell survival assays
LDH release assay was performed on neuron medium at 14 d and 18 d after pff addition
and medium was changed two days before each time point of test. After 30 min incubation of 50
μl of medium with 50 μl of reconstituted substrate at room temperature, 50 μl of stop solution was
added and absorbance at 490 nm was measured using SpectraMax plate reader. Background
absorbance due to plain neuron medium was subtracted from all the readings.
For alamar blue assay, neurons were plated in 96-well plate for pff transduction. At 18 d
post-transduction, 100 μl of fresh medium together with 10 μl of alamarBlue® reagent was added
to each well of neurons and incubated for 4 hr in the 37°C incubator. Fluorometric readings were
taken at 530nm excitation and 590nm emission using SpectraMax plate reader.
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CHAPTER 5: General Conclusions and Further Discussion
5.1 Templated recruitment as a common mechanism for the pathogenesis of
neurodegenerative diseases
Studies described in chapter 2 and 3 demonstrated in non-neuronal cells as well as
primary neurons that synthetic tau fibrils assembled from recombinant protein are able to
spontaneously enter cells and nucleate the fibrillization of endogenous tau. In particular, the study
in non-neuronal cells showed that a miniscule amount of internalized fibrils is sufficient to initiate
robust aggregation of soluble tau, suggesting that templated recruitment is probably a selfperpetuating process which, once started, will progress relentlessly.
The transmissibility of fibrillar tau was further confirmed in an in vivo study (Iba et al.,
2013), whereby intracerebral injection of tau fibrils into transgenic mice over-expressing human
mutant tau led to rapid induction and spreading of tau pathology to multiple brain regions.
Intriguingly, different injection sites resulted in distinct patterns of pathology progression that
coincide with neuronal projections, providing strong support for the notion that the spreading of
transmissible tau species occurs along neuronal connections. Moreover, tau pathology induced
by inoculated tau fibrils bears remarkable resemblance to NFTs in AD, including strong ThSbinding, intense labeling by antibodies specific for acetylated tau (Ac-K280) and conformationally
altered phospho-tau (TG3), and high PK resistance. These cardinal features of AD NFTs are not
only absent from tau inclusions developed in aged uninjected transgenic mice used in this study,
but are also rarely captured in other existing tau transgenic mice (ThS staining was occasionally
reported but always in low abundance, or found only in the spinal cord but not brain), suggesting
that pff-templated fibrillization via intracerebral injection may provide a more disease-relevant
animal model than mere over-expression.
As mentioned in the General Introduction, the phenomenon of cell-to-cell transmission
has been demonstrated for multiple amyloidogenic proteins and suggested to be a shared
mechanism underlying the pathogenesis of many neurodegenerative diseases. It is now
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increasingly accepted that the initial protein misfolding event, which eventually leads to full-blown
disease with widespread pathology, can start in a limited number of neurons that are most
vulnerable to protein aggregation. Small amounts of misfolded protein in these neurons are
adequate to launch massive recruitment of their soluble counterparts into fibrillar aggregates,
which can be released into extracellular space or synaptic cleft and be taken up by neighboring or
synaptically connected neurons, in which the internalized aggregates participate in a new round
of templated recruitment; as this cycle of events repeats, increasing numbers of neurons would
develop pathology, giving rise to the characteristic pattern of pathology progression as outlined by
the Braak staging scheme for AD, PD and DLB (Braak and Braak, 1991; Braak et al., 2002; Braak
et al., 2003; Kosaka et al., 1988).
Meanwhile, as the study described in Chapter 4 suggests, transmissible fibrillar
aggregates can exist as diverse strains with different conformations and highly variable kinetics in
templated recruitment. Different strains may also display distinct cell tropism, owing to cell typespecific cellular and biochemical environment that could differentially influence the seeding
properties of particular strains. For example, a strain that is highly efficient in nucleating
aggregation in the hippocampal neurons may show very low seeding capacity in the substantia
nigral neurons. In addition, as shown in Chapter 4, the various strains may differ dramatically in
their ability to cross-seed the aggregation of another amyloidogenic protein, causing differential
extent of co-morbid pathologies. Given all these possibilities, conformationally diverse strains can
potentially account for not only the frequent while variable co-deposition of different protein
aggregates, but also the tremendous heterogeneity among disorders with the same major protein
lesions. Moreover, the strain-specific conformation of the initial misfolded seeds may be passed
down through templated recruitment, but new strains could also arise during repeated cell-to-cell
transmission, leading to brain region-specific pathologies within one patient.

105

5.2 Differences between tau and α-syn shown by transmission models
Although synthetic fibrils assembled form both tau and α-syn are able to mediate the
transmission of pathologies, studies in primary neurons and transgenic mice suggest that α-syn
may be more “transmissible” than tau (Guo and Lee, 2013; Iba et al., 2013; Luk et al., 2012b;
Volpicelli-Daley et al., 2011). Robust α-syn pathology can be induced by α-syn pffs in wt neurons,
whereas highly limited tau pathology occurs in wt neurons transduced with tau fibrils. Also,
injection of α-syn pffs into the striatum and overlaying cortex of transgenic mice over-expressing
mutant α-syn led to widespread LB-like pathology throughout the brain, but injection of tau pffs
into exactly the same areas in transgenic mice over-expressing mutant tau resulted in spreading
of NFT-like pathology to much more restricted brain regions. While these differences could be
partly due to the A53T variant of α-syn naturally expressed in wt mouse (A53T mutation
accelerates α-syn fibrillization and is pathogenic in human) and differential transgene expression
in the two lines of transgenic mice used for injection studies, we cannot rule out the possibility
that pathological α-syn is intrinsically more efficient than pathological tau in templating and
propagating aggregation. In fact, this possibility is consistent with the findings that tau pathology
is restricted to the brain in various tauopathies, but α-syn pathology appears to initiate from the
peripheral and enteric nervous systems and spread all the way to the brain in PD (Braak and Del
Tredici, 2009).
Several mechanisms could account for the superior transmissibility of α-syn: (1) α-syn
has a higher propensity to fibrillize than tau as shown by in vitro studies. While α-syn readily
assembles into fibrils without any co-factors, even seeded fibrillization of tau requires co-factors
(Friedhoff et al., 1998). (2) In mature neurons, high local concentration of α-syn in the synaptic
terminals may facilitate efficient templated recruitment. This is supported by experiments showing
that pff-induced α-syn aggregation is first initiated in the axons before spreading to the cell bodies
and dendrites, and the induction of pathology is far more efficient in more mature neuron cultures
when α-syn concentration is higher in the axon terminals (Volpicelli-Daley et al., 2011). (3)
Although the mechanism for cell-to-cell transmission of pathology is unknown, synaptic terminals

106

are probable sites for interneuronal transfer of misfolded proteins. If this is true, the unique
subcellular location α-syn gives it an advantage in transmission.
Another

discrepancy

between

the

transmission

models

of

tauopathies

vs.

synucleinopathies is that α-syn aggregation, but not tau aggregation, is consistently accompanied
by cell death, both in neurons and animal models. Toxicity associated with α-syn aggregation
probably arises from filamentous aggregates themselves, which were shown to impair protein
degradation machinery and block the axonal transport of selective cargoes that are critical for cell
survival (unpublished data). Although the buildup of insoluble α-syn is accompanied by a
concomitant reduction of soluble endogenous α-syn, which may result in loss-of-function toxicity,
the observations that neurons derived from α-syn knock-out mice are perfectly healthy and α-syn
knock-out mice do not show structural abnormalities (Abeliovich et al., 2000) argue against this
possibility.
On the other hand, two major possibilities could explain the lack of toxicity of tau
aggregates in the pff transduction/injection models. First, NFTs per se may be benign to cells, but
in tauopathy brains, reduced MT stability due to loss of soluble tau to the NFTs is harmful for
neurons. This hypothesis is consistent with behavioral deficits observed in aged tau KO mice
despite a compensatory upregulation of MAP1A (Dawson et al., 2010; Harada et al., 1994;
Ikegami et al., 2000; Lei et al., 2012). In the pff-transduced primary neurons derived from tau
over-expressing mice, however, only a very small fraction of endogenous mouse tau gets
recruited into the insoluble aggregates, and the minor loss of soluble endogenous tau can be
easily compensated by over-expressed human tau, thus MT integrity is unlikely compromised in
these cells, similarly in pff-injected transgenic mice. Unless robust aggregation of endogenous
mouse tau can be induced in wt neurons/mice without tau over-expression, it would not be
possible to observe the loss-of-function toxicity resulted from tau aggregation. Second, although
fibrillar tau is able to induce and propagate pathology that is highly reminiscent of AD NFTs, the
truly toxic species of tau may be distinct from the transmissible species. Studies on infectious
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prion particles have suggested a dissociation between infectivity and neurotoxicity (reviewed by
Caughey and Lansbury, 2003; Sandberg et al., 2011), which may hold true for tau as well. It is
possible that tau oligomers, instead of mature NFTs, are more toxic to cells. Tau pffs directly
recruit soluble tau into filamentous aggregates and result in a complete bypassing of the slow
oligomerization phase that normally occurs in uninjected transgenic mice prior to the onset of
overt pathology. This in turn could explain the curious paradox of neuron loss in aged untreated
mice bearing ThS-negative tau inclusions but not in pff-injected mice harboring more mature
tangles.
5.3 Therapeutic efforts and implications of recent studies
Currently available treatments for the major neurodegenerative diseases are mainly
targeting malfunctioning neurotransmitter systems, such as L-DOPA (precursor to dopamine)
administration for boosting dopamine levels in PD patients (Cotzias et al., 1969), use of the
cholinesterase inhibitor donepezil and the N-methyld-aspartate (NMDA)-receptor modulator
memantine for AD patients (reviewed by Lleo et al., 2006). Even though these treatments can
ameliorate disease-associated symptoms, since they are not acting on the root cause of the
diseases, they are unable to reverse disease course or even slow down progression.
In the last decade or so, advanced understanding in the cell and molecular mechanisms
underlying these devastating diseases has led to increasing effort in developing diseasemodifying therapies. Take AD for example. A variety of Aβ or tau-targeted approaches are being
actively explored now, including suppressing Aβ production (γ-secretase or β-secretase
inhibitors, α-secretase activator), reducing tau hyperphosphorylation through kinase inhibition,
inhibiting Aβ/tau fibrillization or promoting dissolution of pre-existing aggregates, stabilizing MTs
to compensate for the loss of tau function, etc. (reviewed by Ballatore et al., 2007; Melnikova,
2007). In addition, due to the central role of Aβ in the pathogenesis of AD and the extracellular
location of Aβ plaques, a large number of studies have focused on Aβ immunotherapy aiming at
lowering plaque load. Despite disappointment from the first clinical trial of active Aβ
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immunotherapy, which was discontinued because of unwanted immune responses (Gilman et al.,
2005), continual effort has been dedicated towards improved immunotherapy that is safer and
cost-effective (Fu et al., 2010).
The interneuronal transmission of protein aggregates demonstrated by recent studies has
opened new avenues for therapeutic interventions. Immunotherapy, which was thought to be not
particularly meaningful for intracellularly located protein aggregates, now becomes an attractive
strategy for a variety of neurodegenerative diseases. Since cell-to-cell transmission likely involves
release and uptake of misfolded proteins, drugs or antibodies that block either process would
conceivably stop the spreading of pathology, thereby halting the disease progression. However, if
diverse pathological strains truly exist, they may create challenges for effective immunotherapy,
because antibodies that exhibit high binding affinity for one strain of protein aggregates may not
be equally efficient in complexing with another strain. Therefore, a conformation-dependent
antibody that recognizes a shared conformational epitope of multiple strains may have a broader
application than antibodies recognizing highly specific epitopes, but the feasibility of this
hypothetical approach awaits empirical testing.
5.4 Unanswered questions and future directions
Mechanisms mediating cell-to-cell transmission of protein inclusions
Recent studies, including my study shown in Chapter 2 (Guo and Lee, 2011), suggest
that the uptake of tau fibrils occurs via endocytosis in a temperature-dependent manner, but the
exact endocytic mechanism that mediates the internalization of fibrils made from tau or other
proteins requires further studies. Adsorptive endocytosis was shown to enhance the uptake of
both tau and α-syn fibrils (Guo and Lee, 2011; Volpicelli-Daley et al., 2011), and fibrillar tau was
found to partially colocalize with dextran, a substrate of the fluid-phase endocytosis (Frost et al.,
2009; Wu et al., 2013). Considering the size of fibrils, receptor-mediated endocytosis, which
requires specific interactions between ligands and cell-surface receptors, is most likely not a
major mode for fibril entry.

109

Similarly, it is unclear how aggregates are released into the extracellular space for
transferring into unaffected cells. A number of cell culture studies have demonstrated secretion of
monomeric or oligomeric α-syn and tau into the cell medium via exosomes (Danzer et al., 2012;
Emmanouilidou et al., 2010; Saman et al., 2012). Moreover, two microdialysis studies in healthy
mice were able to detect appreciable levels of tau and α-syn in the interstitial fluid, suggesting
that these proteins may be routinely secreted out of healthy neurons for unknown reasons
(Emmanouilidou et al., 2011; Yamada et al., 2011). So far, no studies have demonstrated
mechanisms for the release of aggregated proteins. Since inoculation studies in mice
demonstrated spreading of pathology along neuronal connections, it will be interesting to explore
whether neurotransmission at the synapses is exploited by pathological aggregates to exit and/or
enter neurons.
The conundrum about 3R and 4R tau
The differential incorporation of tau isoforms into NFTs in different tauopathies (both 3R
and 4R in AD, predominantly 4R in CBD and PSP, but predominantly 3R in PiD) has been a
mystery in the field. It is well established that genetic mutations which disrupt the balance
between 3R and 4R tau are pathogenic, but the exact mechanism is not clearly understood.
Antibodies that are specific for 3R or 4R tau were used in immunohistochemical studies to
examine the relationships between 3R and 4R tau in NFTs. All three patterns of isoform
composition, i.e. 3R+/4R-, 3R-/4R+ and 3R+/4R+, were observed for NFTs and NTs in AD, and
patterns appear to be consistent within each tangle-bearing neuron (Togo et al., 2004). However,
it is unclear whether 3R and 4R tau form hybrid filaments in the 3R+/4R+ NFTs or 3R and 4R tau
filaments merely lie adjacent to one another in the same inclusions. Curiously, extracellular ghost
tangles are only labeled by 3R tau antibodies, either because 4R tau gets degraded in the
extracellular tangles, or the 4R antibody epitope is embedded (Espinoza et al., 2008). A major
concern with these studies is raised by frequent inconsistencies between staining pattern and
biochemical analysis (de Silva et al., 2003; Espinoza et al., 2008). For example, cases with a
paucity of 4R-immunoreactive NFTs in staining still show equal ratio of 3R and 4R tau on
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immunoblots, same as other cases with more even immunoreactivity of 3R and 4R tau by
immunohistochemistry. Such discrepancies could be explained by conformationally diverse tau
filaments with differential masking of the epitopes recognized by isoform-specific antibodies,
which in turn casts a doubt on the reliability of experiments using these antibodies to study
isoform composition of NFTs.
Some of the questions regarding relationships between 3R and 4R tau in aggregation
can be addressed using the recently developed pff-seeding paradigm both in cells and transgenic
animals. In vitro studies have suggested conformational differences between fibrils assembled
from 3R and 4R tau as well as a seeding barrier between them (Dinkel et al., 2011; Furukawa et
al., 2011). In our unpublished study and a similar study by another group (Nonaka et al., 2010),
inefficient cross-seeding between 3R and 4R tau was observed in cultured cells too. It would be
interesting to test isoform-specific recruitment of tau in transgenic mice expressing both 3R and
4R human tau with injection of either 3R or 4R tau fibrils. While it may be tricky to explain brainwide consistency in NFT composition for specific tauopathies if tau inclusions in different neurons
develop cell-autonomously, the newly evolved transmission hypothesis has made it much easier
to understand, whereby the isoform composition of the initial misfolded seeds likely determines
the composition patterns in subsequently affected neurons – given a seeding barrier between 3R
and 4R tau does exist in vivo. Consequently, the initial seeds for AD must contain both 3R and
4R tau.
Inspired by the study shown in Chapter 4 for α-syn, I am particularly curious to explore
whether conformationally diverse tau fibrils can be similarly generated in vitro and whether
different pathological strains of tau are indeed responsible for the tremendous variability among
tauopathies. Unlike α-syn, the different isoforms of tau and the different polyanionic cofactors that
can be used to promote tau fibrillization are expected to create even greater complexity in
possible conformations. Furthermore, a strain of tau fibrils that could efficiently induce pathology
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in wt neurons would be exceptionally useful for dissecting the toxic mechanism of tau
aggregation.
Relationships between Aβ and tau
The identification of both senile plaques and NFTs in postmortem brain examination is
required for a formal diagnosis of AD. However, the relationships between Aβ and tau are yet to
be fully elucidated. Transgenic mice with abundant Aβ plaques usually have minimal neuron loss,
whereas transgenic mice which develop tau inclusions often show prominent neuron death.
Together with the fact that tau aggregation alone leads to diseases such as frontotemporal
dementia while senile plaques are frequently found in aged but non-demented people, these
converging lines of evidence have led to the hypothesis that tau may be a necessary mediator of
neurodegeneration in AD (reviewed by Lee, 2001). A study showing ameliorated Aβ-induced
behavioral deficits in tau KO mice further implicates tau as a downstream effector of Aβassociated neuronal dysfunction (Roberson et al., 2007). Nevertheless, different from AD,
tauopathies without Aβ plaques usually do not have marked memory deficits but commonly
present personality changes and motor deficits, suggesting that Aβ plaques may have a modifier
effect on the downstream toxicity mediated by tau.
Although plaque accumulation in single transgenic mice over-expressing Aβ precursor
protein (APP) does not lead to tau pathology (Games et al., 1995; Hsiao et al., 1996), double
transgenic mice over-expressing both tau and APP show potentiated tangle development than
single transgenic mice over-expressing tau alone (Lewis et al., 2001), and direct injection of Aβ
fibrils into the hippocampus of tan transgenic mice led to dramatically increased numbers of NFTs
in the amygdala where injected neurons project (Gotz et al., 2001b), suggesting Aβ aggregates
accelerate tau aggregation in vivo. A more recent study from our lab further demonstrated that
tau and APP double transgenic mice develop ThS-positive tangles which are rarely found in
single tau transgenic mice (Hurtado et al., 2010). This study is intriguingly reminiscent of human
diseases, whereby NFTs are ThS-positive in AD, but mostly ThS-negative in tauopathies without

112

Aβ plaques. Therefore, Aβ plaques may not directly trigger tau aggregation, but they appear to
accelerate the formation and maturation of tau tangles that are initiated by tau itself. How
extracellular Aβ accumulation is mechanistically linked to enhanced intracellular tau aggregation
is an interest and important topic to investigate, and the primary neuron model described in
Chapter 3 offers a convenient system to address this question.
5.5 Concluding remarks
Together with other recent studies, my thesis work has provided compelling evidence
suggesting templated recruitment of soluble protein and intercellular transmission of pathological
protein aggregates as plausible mechanisms for the onset and progression of neurodegenerative
diseases. Furthermore, the exact conformation of the template dictates its recruitment properties,
possibly giving rise to enormous heterogeneity among diseases characterized by the same
protein inclusions. I hope our study has laid the foundation for future research on the many
questions that are yet to be answered and eventually lead to cures for these fatal diseases.
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